References

Courtney Gidengil; Matthew Bidwell Goetz; Margaret Maglione; Sydne J. Newberry; Peggy Chen; Kelsey O’Hollaren; Nabeel Qureshi; Keller Scholl; Alicia Ruelaz Maher; Olamigoke Akinniranye; Tim M. Kim; Oluwafemi Jimoh; Lea Xenakis; Weilong (David) Kong; Zichun Xu; Owen Hall; Jody Larkin; Aneesa Motala; Susanne Hempel

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gidengil C, Goetz MB, Maglione M, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. (Comparative Effectiveness Review, No. 244.)

Cover of Safety of Vaccines Used for Routine Immunization in the United States: An Update

Safety of Vaccines Used for Routine Immunization in the United States: An Update [Internet].

Show details

Contents

< Prev Next >

References

1.: Centers for Disease Control Prevention. Ten great public health achievements--United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):241–3. PMID: 10220250. [PubMed: 10220250]
2.: Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization during the vaccines for children program era - United States, 1994–2013. MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352–5. PMID: 24759657. [PMC free article: PMC4584777] [PubMed: 24759657]
3.: Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: A systematic review. Vaccine. 2019 Jan 7;37(2):226–34. doi: 10.1016/j.vaccine.2018.11.056. PMID: 30527660. [PMC free article: PMC6545890] [PubMed: 30527660] [CrossRef]
4.: Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086–96. doi: S0264-410X(07)00385-4 [pii] 10.1016/j.vaccine.2007.03.046. PMID: 17544181. [PubMed: 17544181] [CrossRef]
5.: Centers for Disease Control and Prevention. Clinical Overview: Shingles (Herpes Zoster). National Center for Immunization and Respiratory Diseases, Division of Viral Diseases; 2019. https://www.cdc.gov/shingles/hcp/clinical-overview.html. Accessed on August 5, 2020.
6.: Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; 2019. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm. Accessed on August 5, 2020.
7.: Centers for Disease Control and Prevention. Surveillance and Reporting: Pneumococcal Disease. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases; 2017. https://www.cdc.gov/pneumococcal/surveillance.html. Accessed on August 5, 2020.
8.: Centers for Disease Control and Prevention. Active Bacterial Core Surveillance January 5, 2012. http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf. Accessed on September 16, 2020.
9.: Centers for Disease Control and Prevention. Estimates of Deaths Associated with Seasonal Influenza—United States, 1976–2007. Morbidity and Mortality Weekly Report. 2010;59(33):1057–62. [PubMed: 20798667]
10.: Centers for Disease Control and Prevention. Notifiable Diseases and Mortality Tables. Morbidity and Mortality Weekly Report. 2013(61):ND-719–ND-32.
11.: Centers for Disease Control and Prevention. Viral Hepatitis Surveillance United States. 2010. http://www.cdc.gov/hepatitis/Statistics/2010Surveillance. Accessed on September 16, 2020.
12.: Centers for Disease Control and Prevention. Prevention of Herpes Zoster. Morbidity and Mortality Weekly Report. 2008;57(1–30). [PubMed: 18528318]
13.: Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: A systematic review and meta-analysis. Hum Vaccin Immunother. 2018 Mar 4;14(3):758–66. doi: 10.1080/21645515.2017.1345385. PMID: 28708952. [PMC free article: PMC5861794] [PubMed: 28708952] [CrossRef]
14.: Skoff TH, Blain AE, Watt J, et al. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clin Infect Dis. 2017 Nov 29;65(12):1977–83. doi: 10.1093/cid/cix724. PMID: 29028938. [PMC free article: PMC5754921] [PubMed: 29028938] [CrossRef]
15.: Thompson MG, Kwong JC, Regan AK, et al. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: A multi-country retrospective test negative design study, 2010–2016. Clinical Infectious Diseases. 2019;68(9):1444–53. doi: 10.1093/cid/ciy737. [PubMed: 30307490] [CrossRef]
16.: Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics. 2011 May;127 Suppl 1:S23–30. doi: peds.2010-1722E [pii] 10.1542/peds.2010-1722E. PMID: 21502242. [PubMed: 21502242] [CrossRef]
17.: Salmon DA, Pavia A, Gellin B. Editors’ introduction: Vaccine safety throughout the product life cycle. Pediatrics. 2011 May;127 Suppl 1:S1–4. doi: peds.2010-1722U [pii] 10.1542/peds.2010-1722U. PMID: 21502245. [PubMed: 21502245] [CrossRef]
18.: U.S Food and Drug Administration. Postmarketing Requirements and Commitments: Introduction. 2016. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments. Accessed on August 5, 2020.
19.: Nguyen M, Ball R, Midthun K, et al. The Food and Drug Administration’s Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiology & Drug Safety. 2012 Jan;21 Suppl 1:291–7. doi: 10.1002/pds.2323. PMID: 22262619. [PubMed: 22262619] [CrossRef]
20.: Mini-Sentinel. 2011. http://www.mini-sentinel.org/about_us/. Accessed on June 06, 2013.
21.: U.S Food and Drug Administration. Vaccines. 2020. https://www.fda.gov/vaccines-blood-biologics/vaccines. Accessed on August 5, 2020.
22.: Sentinel. Vaccines, Blood, & Biologics Assessments. https://www.sentinelinitiative.org/assessments/vaccines-blood-biologics-assessments. Accessed on February 21, 2021.
23.: Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). 2019. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Accessed on August 5, 2020.
24.: DeStefano F, Vaccine Safety Datalink Research G. The Vaccine Safety Datalink project. Pharmacoepidemiology & Drug Safety. 2001 Aug-Sep;10(5):403–6. PMID: 11802585. [PubMed: 11802585]
25.: Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. 2020. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Accessed on August 5, 2020.
26.: Williams SE, Klein NP, Halsey N, et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009. Vaccine. 2011 16;29(40):6920–7. PMID: 2011489211 MEDLINE PMID 21801776 (http://www.ncbi.nlm.nih.gov/pubmed/21801776). [PMC free article: PMC5832019] [PubMed: 21801776]
27.: Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of Health and Human Services (HHS). Vaccine Safety. https://www.vaccines.gov/basics/safety. Accessed on September 16, 2020.
28.: Maglione MA, Gidengil C, Das L, et al. Safety of Vaccines Used for Routine Immunization in the United States. Evid Rep Technol Assess (Full Rep). 2014 Jul(215):1–740. doi: 10.23970/AHRQEPCERTA215. PMID: 30257278. [PubMed: 30257278] [CrossRef]
29.: Institute of Medicine I. Adverse effects of vaccines: Evidence and causality. Washington, DC: The National Academy Press. 2011. [PubMed: 24624471]
30.: Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20 influenza season. MMWR Recommendations and Reports. 2019;68(3):1. doi: 10.15585/mmwr.rr6803a1. [PMC free article: PMC6713402] [PubMed: 31441906] [CrossRef]
31.: Centers for Disease Control and Prevention. Evidence to Recommendations for HPV Vaccination of Adults, Ages 27 through 45 years. https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html. Accessed on January 30, 2020.
32.: ACIP. Meningococcal ACIP Vaccine Recommendations. 2015. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html#recs.
33.: Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103–8. doi: 10.15585/mmwr.mm6703a5. PMID: 29370152. [PMC free article: PMC5812314] [PubMed: 29370152] [CrossRef]
34.: Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR. Morbidity and mortality weekly report. 2018;67(15):455–8. doi: 10.15585/mmwr.mm6715a5. [PMC free article: PMC6191098] [PubMed: 29672472] [CrossRef]
35.: Centers for Disease Control and Prevention. Immunization Schedules: Table 1. Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2021. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Accessed on February 16, 2021.
36.: Centers for Disease Control and Prevention. Immunization Schedules: Table 1. Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Accessed on February 16, 2021.
37.: U.S Food and Drug Administration. Vaccines Licensed for Use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Accessed on February 16, 2021.
38.: Meissner HC, Plotkin SA. The Facts About Vaccine Safety. Clinical Infectious Diseases. 2020. doi: 10.1093/cid/ciaa697. [PubMed: 33501966] [CrossRef]
39.: Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD); 2008.
40.: PRISMA. Transparent Reporting of Systematic Reviews and Meta-Analyses. 2015. http://www.prisma-statement.org/. Accessed on August 5, 2020.
41.: Motala A, Hempel S, Gidengil C, et al. Safety of Vaccines Used for Routine Immunization in the United States: An update. PROSPERO 2020 CRD42020180089 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020180089. Accessed on August 10, 2020.
42.: Santaguida P, Raina P. The Development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms. McMaster University. 2012.
43.: Chou R, Aronson N, Atkins D, et al. Assessing harms when comparing medical interventions. In: Agency for Healthcare Research and Quality, ed Methods Guide for Comparative Effectiveness Reviews. Rockville, M; 2008.
44.: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF Agency for Healthcare Research and Quality. Rockville, MD: January 2014. www.effectivehealthcare.ahrq.gov.
45.: National Institute of Health NCIDoCTDD. Common Terminology Criteria for Adverse Events (CTCAE) U.S. Department of Health and Human Services; November 27, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed on January 8, 2020.
46.: Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47.: IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014 Feb 18;14:25. doi: 10.1186/1471-2288-14-25. PMID: 24548571. [PMC free article: PMC4015721] [PubMed: 24548571] [CrossRef]
48.: Jackson D, Law M, Rucker G, et al. The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns? Stat Med. 2017 Nov 10;36(25):3923–34. doi: 10.1002/sim.7411. PMID: 28748567. [PMC free article: PMC5628734] [PubMed: 28748567] [CrossRef]
49.: Rover C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015 Nov 14;15:99. doi: 10.1186/s12874-015-0091-1. PMID: 26573817. [PMC free article: PMC4647507] [PubMed: 26573817] [CrossRef]
50.: Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004 Jun 19;328(7454):1490. doi: 10.1136/bmj.328.7454.1490. PMID: 15205295. [PMC free article: PMC428525] [PubMed: 15205295] [CrossRef]
51.: Abdelnour A, Silas PE, Lamas MRV, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine. 2014;32(8):965–72. doi: 10.1016/j.vaccine.2013.12.034. [PubMed: 24397906] [CrossRef]
52.: Acosta J, Benages C, Díaz MA, et al. Preventing pertussis in the early infant: Development and results of a prenatal vaccination program. Acta Medica International. 2016;3(2):78–81. doi: 10.5530/ami.2016.2.17. [CrossRef]
53.: Alberer M, Burchard G, Jelinek T, et al. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. Journal of travel medicine. 2015;22(1):48–56. doi: 10.1111/jtm.12164. [PubMed: 25308927] [CrossRef]
54.: Alberer M, Burchard G, Jelinek T, et al. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. Journal of travel medicine. 2015;22(2):105–14. doi: 10.1111/jtm.12180. [PubMed: 25483566] [CrossRef]
55.: Amdekar YK, Lalwani SK, Bavdekar A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. The Pediatric infectious disease journal. 2013;32(5):509–16. doi: 10.1097/INF.0b013e31827b478d. [PubMed: 23190777] [CrossRef]
56.: Anez G, Hedrick J, Simon MW, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020 Mar 25:1–7. doi: 10.1080/21645515.2020.1733867. PMID: 32209015. [PMC free article: PMC7482862] [PubMed: 32209015] [CrossRef]
57.: Baccarini CI, Simon MW, Brandon D, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2–9 Years of Age: A Phase III, Randomized Study. Pediatric Infectious Disease Journal. 2020:955–60. doi: 10.1097/INF.0000000000002832. [PMC free article: PMC7497415] [PubMed: 32852352] [CrossRef]
58.: Baker MA, Baer B, Kulldorff M, et al. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLoS medicine. 2019;16(7):e1002844. doi: 10.1371/journal.pmed.1002844. [PMC free article: PMC6605647] [PubMed: 31265459] [CrossRef]
59.: Baker MA, Jankosky C, Yih WK, et al. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Vaccine. 2020 Feb 24;38(9):2166–71. doi: 10.1016/j.vaccine.2020.01.046. PMID: 32019703. [PubMed: 32019703] [CrossRef]
60.: Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Human vaccines & immunotherapeutics. 2016;12(9):2278–88. doi: 10.1080/21645515.2016.1182270. [PMC free article: PMC5027712] [PubMed: 27322354] [CrossRef]
61.: Baxter R, Eaton A, Hansen J, et al. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49years. Vaccine. 2017;35(9):1254–8. doi: 10.1016/j.vaccine.2017.01.062. [PubMed: 28162825] [CrossRef]
62.: Baxter R, Lewis E, Goddard K, et al. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 1;63(11):1456–62. doi: 10.1093/cid/ciw607. PMID: 27585798. [PMC free article: PMC6708556] [PubMed: 27585798] [CrossRef]
63.: Baxter R, Lewis N, Bohrer P, et al. Sudden-Onset Sensorineural Hearing Loss after Immunization: A Case-Centered Analysis. Otolaryngol Head Neck Surg. 2016 Jul;155(1):81–6. doi: 10.1177/0194599816639043. PMID: 27026733. [PMC free article: PMC6708600] [PubMed: 27026733] [CrossRef]
64.: Becerra-Culqui TA, Getahun D, Chiu V, et al. Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. Pediatrics. 2018;142(3). doi: 10.1542/peds.2018-0120. [PubMed: 30104424] [CrossRef]
65.: Becerra-Culqui TA, Getahun D, Chiu V, et al. The Association of Prenatal Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccination With Attention-Deficit/Hyperactivity Disorder. American journal of epidemiology. 2020;189(10):1163–72. doi: 10.1093/aje/kwaa074. [PubMed: 32378703] [CrossRef]
66.: Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infectious Diseases. 2013;13:224. doi: 10.1186/1471-2334-13-224. PMID: 23688546. [PMC free article: PMC3668902] [PubMed: 23688546] [CrossRef]
67.: Berenson AB, Hirth JM, Rahman M, et al. Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. Human vaccines & immunotherapeutics. 2016;12(8):1965–71. [PMC free article: PMC4994720] [PubMed: 27002930]
68.: Black S, Klein NP, Shah J, et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age. Vaccine. 2010 Jan 8;28(3):657–63. PMID: 19895922. [PubMed: 19895922]
69.: Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatric Infectious Disease Journal. 2012 Jul;31(7):745–51. PMID: 22466322. [PubMed: 22466322]
70.: Block SL, Klein NP, Sarpong K, et al. Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. The Pediatric infectious disease journal. 2017;36(2):202–8. doi: 10.1097/INF.0000000000001405. [PubMed: 27846058] [CrossRef]
71.: Block SL, Yi T, Sheldon E, et al. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011 Nov 21;29(50):9391–7. PMID: 21983154. [PubMed: 21983154]
72.: Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. The New England journal of medicine. 2015;372(12):1114–25. doi: 10.1056/NEJMoa1408544. [PubMed: 25785969] [CrossRef]
73.: Briggs-Steinberg C, Aboudi D, Hodson G, et al. Clinical Tolerance of In-Neonatal Intensive Care Unit Administration of Rotavirus Vaccine. American journal of perinatology. 2019. doi: 10.1055/s-0039-1698455. [PubMed: 31739360] [CrossRef]
74.: Burke RM, Tate JE, Dahl RM, et al. Does Rotavirus Vaccination Affect Longer-Term Intussusception Risk in US Infants? J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):257–60. doi: 10.1093/jpids/piz035. PMID: 31197368. [PMC free article: PMC8112885] [PubMed: 31197368] [CrossRef]
75.: Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunization Program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(10):1427–34. doi: 10.1093/cid/cit520. [PubMed: 23964090] [CrossRef]
76.: Caspard H, Steffey A, Mallory RM, et al. Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink. BMJ open. 2018;8(12):e023118. doi: 10.1136/bmjopen-2018-023118. [PMC free article: PMC6292422] [PubMed: 30530581] [CrossRef]
77.: Chang L-J, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults >=65years of age: A phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825–34. doi: 10.1016/j.vaccine.2019.08.016. [PubMed: 31431411] [CrossRef]
78.: Chang LJ, Hedrick J, Christensen S, et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020a. doi: 10.1016/j.vaccine.2020.03.017. [PubMed: 32209248] [CrossRef]
79.: Chang LJ, Hedrick J, Christensen S, et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020b. doi: 10.1016/j.vaccine.2020.03.017. [PubMed: 32209248] [CrossRef]
80.: Chang YC, Chou YJ, Liu JY, et al. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan - A representative population-based comparative study. Journal of Infection. 2012;65:231–8. [PubMed: 22561486]
81.: Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. doi: 10.1371/journal.pone.0051452. PMID: 23251538. [PMC free article: PMC3520842] [PubMed: 23251538] [CrossRef]
82.: Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. The Journal of infectious diseases. 2013;208(12):1953–61. doi: 10.1093/infdis/jit365. [PubMed: 23904292] [CrossRef]
83.: Contopoulos-Ioannidis DG, Halpern MS, Maldonado Y. Trends in Hospitalizations for Intussusception in California in Relationship to the Introduction of New Rotavirus Vaccines, 1985–2010. The Pediatric infectious disease journal. 2015;34(7):712–7. doi: 10.1097/INF.0000000000000653. [PubMed: 26069946] [CrossRef]
84.: Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019. doi: 10.1093/cid/ciz1034. [PMC free article: PMC7289658] [PubMed: 31828291] [CrossRef]
85.: Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. The New England journal of medicine. 2016;375(11):1019–32. doi: 10.1056/NEJMoa1603800. [PubMed: 27626517] [CrossRef]
86.: Cutland CL, Nolan T, Halperin SA, et al. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine. 2018;36(14):1908–16. doi: 10.1016/j.vaccine.2018.02.013. [PubMed: 29503112] [CrossRef]
87.: Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(7):952–62. doi: 10.1093/cid/cit428. [PubMed: 23804191] [CrossRef]
88.: Daley MF, Yih WK, Glanz JM, et al. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. Vaccine. 2014;32(25):3019–24. doi: 10.1016/j.vaccine.2014.03.063. [PubMed: 24699471] [CrossRef]
89.: Deichmann KA, Ferrera G, Tran C, et al. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants. Vaccine. 2015;33(20):2379–86. doi: 10.1016/j.vaccine.2015.02.070. [PubMed: 25765966] [CrossRef]
90.: DeMeo SD, Raman SR, Hornik CP, et al. Adverse Events After Routine Immunization of Extremely Low-Birth-Weight Infants. JAMA Pediatr. 2015 Aug;169(8):740–5. doi: 10.1001/jamapediatrics.2015.0418. PMID: 26030302. [PMC free article: PMC4523398] [PubMed: 26030302] [CrossRef]
91.: DeSilva M, Vazquez-Benitez G, Nordin JD, et al. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017;35(29):3655–60. doi: 10.1016/j.vaccine.2017.05.041. [PMC free article: PMC6506841] [PubMed: 28552511] [CrossRef]
92.: Dhingra MS, Kundu R, Gupta M, et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1–G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014;32 Suppl 1:A117–23. doi: 10.1016/j.vaccine.2014.03.069. [PubMed: 25091664] [CrossRef]
93.: Dhingra MS, Peterson J, Hedrick J, et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study. Vaccine. 2020;38(33):5194–201. doi: 10.1016/j.vaccine.2020.06.013. PMID: 32565344. [PubMed: 32565344] [CrossRef]
94.: Domachowske JB, Pankow-Culot H, Bautista M, et al. A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years. Journal of Infectious Diseases. 2013 Jun;207(12):1878–87. doi: 10.1093/infdis/jit091. PMID: 23470848. [PMC free article: PMC3654742] [PubMed: 23470848] [CrossRef]
95.: Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6). doi: 10.1542/peds.2019-1808. [PMC free article: PMC7780202] [PubMed: 31740498] [CrossRef]
96.: Duffy J, Weintraub E, Hambidge SJ, et al. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics. 2016;138(1):1–10. doi: 10.1542/peds.2016-0320. PMID: 116609674. Language: English. Entry Date: 20160708. Revision Date: 20160714. Publication Type: Article. [PMC free article: PMC6503849] [PubMed: 27273711] [CrossRef]
97.: Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. The New England journal of medicine. 2017;376(25):2427–36. doi: 10.1056/NEJMoa1608862. [PubMed: 28636855] [CrossRef]
98.: Dunkle LM, Izikson R, Patriarca PA, et al. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age. The Journal of infectious diseases. 2017;216(10):1219–26. doi: 10.1093/infdis/jix478. [PubMed: 28968871] [CrossRef]
99.: Dynavax Technologies C. Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine. 2015.
100.: Dynavax Technologies Corporation. Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine. 2006.
101.: Eriksson M, Käyhty H, Saha H, et al. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transplant Infectious Disease. 2020;22(4). doi: 10.1111/tid.13343. [PubMed: 32473046] [CrossRef]
102.: Escolano S, Hill C, Tubert-Bitter P. Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach. Vaccine. 2015 Feb 18;33(8):1017–20. doi: 10.1016/j.vaccine.2015.01.005. PMID: 25596460. [PubMed: 25596460] [CrossRef]
103.: Essink B, Fierro C, Rosen J, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2020;38(2):242–50. doi: 10.1016/j.vaccine.2019.10.021. [PubMed: 31635976] [CrossRef]
104.: Esteves-Jaramillo A, Koehler T, Jeanfreau R, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >/=56-year-olds: A Phase III randomized study. Vaccine. 2020 Jun 9;38(28):4405–11. doi: 10.1016/j.vaccine.2020.04.067. PMID: 32387012. [PubMed: 32387012] [CrossRef]
105.: Euctr Outside EU/EEA. Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age. 2014. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01819276/full,
106.: Fernandes EG, Leshem E, Patel M, et al. Hospital-based surveillance of intussusception among infants. Jornal de pediatria. 2016;92(2):181–7. doi: 10.1016/j.jped.2015.06.008. [PubMed: 26804014] [CrossRef]
107.: Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study. Arthritis research & therapy. 2015;17:151. doi: 10.1186/s13075-015-0663-9. [PMC free article: PMC4481118] [PubMed: 26048579] [CrossRef]
108.: Fotso Kamdem A, Vidal C, Pazart L, et al. A case-control study of risk factors for intussusception among infants in eastern France after the introduction of the rotavirus vaccine. Vaccine. 2019;37(32):4587–93. doi: 10.1016/j.vaccine.2019.02.053. [PubMed: 30851968] [CrossRef]
109.: Frenck RW, Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clinical & Vaccine Immunology: CVI. 2012 Aug;19(8):1296–303. doi: 10.1128/CVI.00176-12. PMID: 22739693. [PMC free article: PMC3416075] [PubMed: 22739693] [CrossRef]
110.: Frey SE, Reyes MRA-DL, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027–34. doi: 10.1016/j.vaccine.2014.07.013. [PubMed: 25045825] [CrossRef]
111.: Garland SM, Cheung T-H, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–64. doi: 10.1016/j.vaccine.2015.08.059. [PubMed: 26411885] [CrossRef]
112.: Gasparini R, Johnston W, Conversano M, et al. Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents. J Vaccines Vaccin. 2014;5(3):231.
113.: Geier DA, Geier MR. A longitudinal cohort study of childhood MMR vaccination and seizure disorder among American children. Brain and Development. 2020. doi: 10.1016/j.braindev.2020.09.001. [PubMed: 32981784] [CrossRef]
114.: Gilca V, Sauvageau C, Panicker G, et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018;36(46):7017–24. doi: 10.1016/j.vaccine.2018.09.057. [PMC free article: PMC6497054] [PubMed: 30314913] [CrossRef]
115.: Glanz JM, Clarke CL, Xu S, et al. Association between Rotavirus Vaccination and Type 1 Diabetes in Children. JAMA Pediatrics. 2020:E1–E8. doi: 10.1001/jamapediatrics.2019.6324. [PMC free article: PMC7063538] [PubMed: 32150236] [CrossRef]
116.: Glover C, Crawford N, Leeb A, et al. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. Vaccine. 2020a;38(31):4892–900. doi: 10.1016/j.vaccine.2020.04.056. [PubMed: 32499067] [CrossRef]
117.: Greenberg DP, Robertson CA, Landolfi VA, et al. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. The Pediatric infectious disease journal. 2014;33(6):630–6. doi: 10.1097/INF.0000000000000254. [PubMed: 24445833] [CrossRef]
118.: Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013 Jan 21;31(5):770–6. doi: 10.1016/j.vaccine.2012.11.074. PMID: 23228813. [PubMed: 23228813] [CrossRef]
119.: Greenberg DP, Robertson CA, Talbot HK, et al. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older. Human vaccines & immunotherapeutics. 2017;13(9):2058–64. doi: 10.1080/21645515.2017.1344375. [PMC free article: PMC5612218] [PubMed: 28700265] [CrossRef]
120.: Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364–74. doi: 10.1016/j.vaccine.2014.02.002. [PubMed: 24606865] [CrossRef]
121.: Griffin JB, Yu L, Watson D, et al. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine. 2018;36(34):5173–9. doi: 10.1016/j.vaccine.2018.07.011. [PubMed: 30031662] [CrossRef]
122.: Groome MJ, Tate JE, Arnold M, et al. Evaluation of intussusception after oral monovalent rotavirus vaccination in South Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019. doi: 10.1093/cid/ciz431. [PMC free article: PMC7146001] [PubMed: 31125061] [CrossRef]
123.: Hall C, Abramovitz LM, Bukowinski AT, et al. Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women. Vaccine. 2020;38(8):1982–8. doi: 10.1016/j.vaccine.2020.01.009. [PubMed: 31952872] [CrossRef]
124.: Halperin SA, Donovan C, Marshall GS, et al. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. Journal of the Pediatric Infectious Diseases Society. 2019;8(2):105–14. doi: 10.1093/jpids/pix113. [PMC free article: PMC6510947] [PubMed: 29438562] [CrossRef]
125.: Halperin SA, Langley JM, Ye L, et al. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(7):1063–71. doi: 10.1093/cid/ciy244. [PubMed: 30010773] [CrossRef]
126.: Hansen J, Timbol J, Lewis N, et al. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine. 2016;34(35):4172–9. doi: 10.1016/j.vaccine.2016.06.062. [PubMed: 27373595] [CrossRef]
127.: Hansen J, Zhang L, Eaton A, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine. 2018;36(16):2133–8. doi: 10.1016/j.vaccine.2018.02.107. [PubMed: 29550195] [CrossRef]
128.: Hansen J, Zhang L, Klein NP, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017;35(49 Pt B):6879–84. doi: 10.1016/j.vaccine.2017.09.032. [PubMed: 28941623] [CrossRef]
129.: Hartvickson R, Cruz M, Ervin J, et al. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2015;41:65–72. doi: 10.1016/j.ijid.2015.11.004. [PubMed: 26585940] [CrossRef]
130.: Hattori F, Kawamura Y, Kawada JI, et al. Survey of rotavirus-associated severe complications in Aichi Prefecture. Pediatrics International. 2018;60(3):259–63. doi: 10.1111/ped.13506. [PubMed: 29288522] [CrossRef]
131.: Hawken S, Ducharme R, Rosella LC, et al. Assessing the risk of intussusception and rotavirus vaccine safety in Canada. Human vaccines & immunotherapeutics. 2017;13(3):703–10. doi: 10.1080/21645515.2016.1240846. [PMC free article: PMC5360150] [PubMed: 27835525] [CrossRef]
132.: Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5. doi: 10.1016/j.vaccine.2013.05.068. [PubMed: 23727002] [CrossRef]
133.: Hoffman V, Abu-Elyazeed R, Enger C, et al. Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans. Human vaccines & immunotherapeutics. 2018;14(7):1782–90. doi: 10.1080/21645515.2018.1450123. [PMC free article: PMC6067866] [PubMed: 29533129] [CrossRef]
134.: Huang J, Ou HY, Lin J, et al. The impact of hepatitis B vaccination status on the risk of diabetes, implicating diabetes risk reduction by successful vaccination. PLoS ONE. 2015;10(10). doi: 10.1371/journal.pone.0139730. [PMC free article: PMC4624985] [PubMed: 26509504] [CrossRef]
135.: Huang W-T, Juan Y-C, Liu C-H, et al. Intussusception and Kawasaki disease after rotavirus vaccination in Taiwanese infants. Vaccine. 2020;38(40):6299–303. doi: 10.1016/j.vaccine.2020.07.038. [PubMed: 32736940] [CrossRef]
136.: Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet (London, England). 2017;390(10108):2143–59. doi: 10.1016/S0140-6736(17)31821-4. [PubMed: 28886907] [CrossRef]
137.: Hung IFN, Leung AYM, Chu DWS, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clinical Infectious Diseases. 2010 Nov 1;51(9):1007–16. PMID: 20887208. [PubMed: 20887208]
138.: Hviid A, Hansen JV, Frisch M, et al. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Annals of internal medicine. 2019;170(8):513–20. doi: 10.7326/M18-2101. [PubMed: 30831578] [CrossRef]
139.: Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human vaccines & immunotherapeutics. 2013;9(8):1626–33. doi: 10.4161/hv.24846. [PMC free article: PMC3906258] [PubMed: 23732903] [CrossRef]
140.: Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31(35):3577–84. doi: 10.1016/j.vaccine.2013.04.085. [PubMed: 23688526] [CrossRef]
141.: Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015;313(15):1534–40. doi: 10.1001/jama.2015.3077. [PubMed: 25898051] [CrossRef]
142.: Juergens C, de Villiers PJT, Moodley K, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Human vaccines & immunotherapeutics. 2014;10(5):1343–53. doi: 10.4161/hv.27998. [PMC free article: PMC4896606] [PubMed: 24576885] [CrossRef]
143.: Kantso B, Halkjaer SI, Thomsen OO, et al. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn’s disease. Vaccine. 2015;33(41):5464–9. doi: 10.1016/j.vaccine.2015.08.011. [PubMed: 26275480] [CrossRef]
144.: Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. Vaccine. 2016;34(7):968–73. doi: 10.1016/j.vaccine.2015.12.046. [PMC free article: PMC6506839] [PubMed: 26765288] [CrossRef]
145.: Kieninger D, Sheldon E, Lin W-Y, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years. BMC infectious diseases. 2013;13:343. doi: 10.1186/1471-2334-13-343. [PMC free article: PMC3750613] [PubMed: 23883186] [CrossRef]
146.: Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines. Pediatric Infectious Disease Journal. 2013 Mar;32(3):266–73. doi: 10.1097/INF.0b013e3182748bb6. PMID: 23011012. [PubMed: 23011012] [CrossRef]
147.: Kirstein J, Pina M, Pan J, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Human Vaccines and Immunotherapeutics. 2020;16(6):1299–305. doi: 10.1080/21645515.2020.1733868. [PMC free article: PMC7482642] [PubMed: 32233961] [CrossRef]
148.: Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul;126(1):e1–8. PMID: 20587679. [PubMed: 20587679]
149.: Klein NP, Lewis E, Fireman B, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015;135(2):e321–9. doi: 10.1542/peds.2014-1822. [PubMed: 25560438] [CrossRef]
150.: Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. The New England journal of medicine. 2015;372(22):2087–96. doi: 10.1056/NEJMoa1501184. [PubMed: 25916341] [CrossRef]
151.: Langer-Gould A, Qian L, Tartof SY, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA neurology. 2014;71(12):1506–13. doi: 10.1001/jamaneurol.2014.2633. [PubMed: 25329096] [CrossRef]
152.: Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. The Journal of infectious diseases. 2013;208(4):544–53. doi: 10.1093/infdis/jit263. [PMC free article: PMC3719910] [PubMed: 23847058] [CrossRef]
153.: Langley JM, Wang L, Aggarwal N, et al. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. Journal of the Pediatric Infectious Diseases Society. 2015;4(3):242–51. doi: 10.1093/jpids/piu098. [PMC free article: PMC4554197] [PubMed: 26336604] [CrossRef]
154.: Layton JB, Butler AM, Li D, et al. Prenatal Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 2017;35(33):4072–8. doi: 10.1016/j.vaccine.2017.06.071. [PMC free article: PMC5546155] [PubMed: 28669620] [CrossRef]
155.: Layton JB, Butler AM, Panozzo CA, et al. Rotavirus vaccination and short-term risk of adverse events in US infants. Paediatric and perinatal epidemiology. 2018;32(5):448–57. doi: 10.1111/ppe.12496. [PMC free article: PMC6191318] [PubMed: 30048564] [CrossRef]
156.: Lee HJ, Choe YJ, Hong Y-J, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial. Vaccine. 2016;34(9):1180–6. doi: 10.1016/j.vaccine.2016.01.033. [PubMed: 26826544] [CrossRef]
157.: Lee HJ, Chung M-H, Kim WJ, et al. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2014;28:204–10. doi: 10.1016/j.ijid.2014.06.008. [PubMed: 25316331] [CrossRef]
158.: Leslie DL, Kobre RA, Richmand BJ, et al. Temporal Association of Certain Neuropsychiatric Disorders Following Vaccination of Children and Adolescents: A Pilot Case-Control Study. Front Psychiatry. 2017;8:3. doi: 10.3389/fpsyt.2017.00003. PMID: 28154539. [PMC free article: PMC5244035] [PubMed: 28154539] [CrossRef]
159.: Li C-Y, Chen L-C, Lin H-Y, et al. Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study. Cancer. 2020. doi: 10.1002/cncr.33203. [PubMed: 32997342] [CrossRef]
160.: Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons. Pharmacoepidemiology and drug safety. 2016;25(8):928–34. doi: 10.1002/pds.3996. [PubMed: 27037540] [CrossRef]
161.: Li R-c, Huang T, Li Y, et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human vaccines & immunotherapeutics. 2014;10(1):11–8. doi: 10.4161/hv.26319. [PMC free article: PMC4181005] [PubMed: 24013441] [CrossRef]
162.: Lombardi F, Belmonti S, Fabbiani M, et al. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. PloS one. 2016;11(6):e0156523. doi: 10.1371/journal.pone.0156523. [PMC free article: PMC4892598] [PubMed: 27258647] [CrossRef]
163.: Mallory RM, Nyborg A, Kalyani RN, et al. A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24–<48 months of age. Vaccine. 2020;38(5):1001–8. doi: 10.1016/j.vaccine.2019.11.055. [PubMed: 31796225] [CrossRef]
164.: Mallory RM, Yu J, Kameo S, et al. The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2–18 years: Results of two phase 3 studies. Influenza and other respiratory viruses. 2018a;12(4):438–45. doi: 10.1111/irv.12555. [PMC free article: PMC6005581] [PubMed: 29573143] [CrossRef]
165.: Maréchal C, Lal H, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: a randomized trial. Vaccine. 2018;36(29):4278–86. doi: 10.1016/j.vaccine.2018.05.110. PMID: CN-01642678. [PubMed: 29903674] [CrossRef]
166.: Marshall GS, Adams GL, Leonardi ML, et al. Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants. Pediatrics. 2015;136(2):e323–32. doi: 10.1542/peds.2014-4102. [PubMed: 26216331] [CrossRef]
167.: McClure DL, Jacobsen SJ, Klein NP, et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine. 2019 Jan 3;37(1):76–9. doi: 10.1016/j.vaccine.2018.11.038. PMID: 30478005. [PMC free article: PMC6530777] [PubMed: 30478005] [CrossRef]
168.: McGeoch LJ, Finn A, Marlow RD. Impact of rotavirus vaccination on intussusception hospital admissions in England. Vaccine. 2020;38(35):5618–26. doi: 10.1016/j.vaccine.2020.06.078. [PubMed: 32654906] [CrossRef]
169.: Mo Z, Mo Y, Li M, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Vaccine. 2017;35(43):5897–904. doi: 10.1016/j.vaccine.2017.08.081. [PubMed: 28935470] [CrossRef]
170.: Morgan JL, Baggari SR, McIntire DD, et al. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstetrics and gynecology. 2015;125(6):1433–8. doi: 10.1097/AOG.0000000000000862. [PubMed: 26000515] [CrossRef]
171.: Munnoch SA, Cashman P, Peel R, et al. Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study. Journal of medical Internet research. 2019;21(10):e14791. doi: 10.2196/14791. [PMC free article: PMC6835470] [PubMed: 31647470] [CrossRef]
172.: Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014;311(17):1760–9. doi: 10.1001/jama.2014.3633. [PMC free article: PMC4333147] [PubMed: 24794369] [CrossRef]
173.: Naleway AL, Mittendorf KF, Irving SA, et al. Primary Ovarian Insufficiency and Adolescent Vaccination. Pediatrics. 2018;142(3). doi: 10.1542/peds.2018-0943. [PMC free article: PMC6719304] [PubMed: 30131438] [CrossRef]
174.: Nelson JC, Yu O, Dominguez-Islas CP, et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. American Journal of Epidemiology. 2013 Jan 15;177(2):131–41. doi: 10.1093/aje/kws317. PMID: 23292957. [PubMed: 23292957] [CrossRef]
175.: Oberle D, Hoffelner M, Pavel J, et al. Retrospective multicenter matched case-control study on the risk factors for intussusception in infants less than 1 year of age with a special focus on rotavirus vaccines - the German Intussusception Study. Human vaccines & immunotherapeutics. 2020:1–14. doi: 10.1080/21645515.2020.1726679. [PMC free article: PMC7644239] [PubMed: 32271647] [CrossRef]
176.: Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: The CAPAMIS study, three-year follow-up. Vaccine. 2014;32(2):252–7. doi: 10.1016/j.vaccine.2013.11.017. [PubMed: 24262314] [CrossRef]
177.: Ofori-Anyinam O, Leroux-Roels G, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >=50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017;35(46):6321–8. doi: 10.1016/j.vaccine.2017.09.012. [PubMed: 28987445] [CrossRef]
178.: Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 2016;34(12):1465–71. doi: 10.1016/j.vaccine.2016.01.044. [PubMed: 26845739] [CrossRef]
179.: Perez JZV, Aranda JMR, de la O Cavazos M, et al. Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women. Human Vaccines & Immunotherapeutics. 2017;13(1):128–35. doi: 10.1080/21645515.2016.1232786. PMID: WOS:000394951100018. [PMC free article: PMC5287315] [PubMed: 27686182] [CrossRef]
180.: Perez-Vilar S, Wernecke M, Arya D, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017–2018 season. Vaccine. 2019;37(29):3856–65. doi: 10.1016/j.vaccine.2019.05.041. [PubMed: 31122853] [CrossRef]
181.: Perrett KP, Halperin SA, Nolan T, et al. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. Vaccine. 2019. doi: 10.1016/j.vaccine.2019.10.105. [PubMed: 31776029] [CrossRef]
182.: Petousis-Harris H, Jiang YN, Yu L, et al. A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. Vaccines. 2019 Dec;7(4):15. doi: 10.3390/vaccines7040147. PMID: WOS:000505709700077. [PMC free article: PMC6963487] [PubMed: 31614582] [CrossRef]
183.: Petrecz M, Ramsey KP, Stek JE, et al. Concomitant use of VAQTA® with PedvaxHIB® and Infanrix® in 12 to 17 month old children. Human Vaccines and Immunotherapeutics. 2016;12(2):503–11. doi: 10.1080/21645515.2015.1080395. [PMC free article: PMC5049725] [PubMed: 26308112] [CrossRef]
184.: Pfizer. Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults. https://ClinicalTrials.gov/show/NCT00427895; 2007.
185.: Puig-Barbera J, Diez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007 Oct 16;25(42):7313–21. PMID: 17889411. [PubMed: 17889411]
186.: Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2012 August;12(8):597–607. PMID: 2012432636. [PubMed: 22569484]
187.: Rivera L, Schwarz TF, Kim KH, et al. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. Vaccine. 2018;36(31):4750–8. doi: 10.1016/j.vaccine.2018.04.034. [PubMed: 29960800] [CrossRef]
188.: Rodriguez Weber MA, Claeys C, Aranza Doniz C, et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18–47 months of age. The Pediatric infectious disease journal. 2014;33(12):1262–9. doi: 10.1097/INF.0000000000000463. [PubMed: 25386965] [CrossRef]
189.: Rogers MAM, Basu T, Kim C. Lower Incidence Rate of Type 1 Diabetes after Receipt of the Rotavirus Vaccine in the United States, 2001–2017. Scientific Reports. 2019;9(1). doi: 10.1038/s41598-019-44193-4. [PMC free article: PMC6565744] [PubMed: 31197227] [CrossRef]
190.: Salas A, Pardo-Seco J, Cebey-Lopez M, et al. Impact of rotavirus vaccination on childhood hospitalizations for seizures: Heterologous or unforeseen direct vaccine effects? Vaccine. 2019;37(25):3362–8. doi: 10.1016/j.vaccine.2019.04.086. [PubMed: 31064673] [CrossRef]
191.: Sancovski M, Mesaros N, Feng Y, et al. Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study. Human vaccines & immunotherapeutics. 2019;15(12):2873–81. doi: 10.1080/21645515.2019.1627161. [PMC free article: PMC6930109] [PubMed: 31216218] [CrossRef]
192.: Sanofi Pasteur aSC, Sanofi. Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018–2019 Formulations. 2018.
193.: Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617–24. PMID: 22260988. [PubMed: 22260988]
194.: Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older. The Journal of infectious diseases. 2017;216(11):1352–61. doi: 10.1093/infdis/jix481. [PMC free article: PMC5853904] [PubMed: 29029224] [CrossRef]
195.: Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >=65 years. Vaccine. 2011 Jul 18;29(32):5195–202. PMID: 21619909. [PubMed: 21619909]
196.: Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. The Pediatric infectious disease journal. 2016;35(5):548–54. doi: 10.1097/INF.0000000000001072. [PubMed: 26835974] [CrossRef]
197.: Seo YB, Choi WS, Lee J, et al. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. Clinical and Experimental Vaccine Research. 2017;6(1):38–44. doi: 10.7774/cevr.2017.6.1.38. [PMC free article: PMC5292355] [PubMed: 28168172] [CrossRef]
198.: Shakib JH, Korgenski K, Sheng X, et al. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. The Journal of pediatrics. 2013;163(5):1422–4. doi: 10.1016/j.jpeds.2013.06.021. [PMC free article: PMC4102585] [PubMed: 23896191] [CrossRef]
199.: Shimada K, Morinaga H, Kiyanagi T, et al. Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease. Journal of atherosclerosis and thrombosis. 2020. doi: 10.5551/jat.58297. [PMC free article: PMC8326172] [PubMed: 33055462] [CrossRef]
200.: Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Human vaccines & immunotherapeutics. 2015;11(9):2198–206. doi: 10.1080/21645515.2015.1030550. [PMC free article: PMC4635730] [PubMed: 26176163] [CrossRef]
201.: Siriwardena AN, Asghar Z, Coupland CC. Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-matched case control study. Vaccine. 2014 Mar 10;32(12):1354–61. doi: 10.1016/j.vaccine.2014.01.029. PMID: 24486370. [PubMed: 24486370] [CrossRef]
202.: Song JY, Cheong HJ, Hyun HJ, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in 60-year-old adults. Vaccine. 2017;35(2):313–20. doi: 10.1016/j.vaccine.2016.11.047. [PubMed: 27919632] [CrossRef]
203.: Song JY, Cheong HJ, Noh JY, et al. Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in >= 50-year-old adults. BMC infectious diseases. 2018;18(1):628. doi: 10.1186/s12879-018-3479-9. [PMC free article: PMC6282243] [PubMed: 30518331] [CrossRef]
204.: Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015a;33(36):4647–52. doi: 10.1016/j.vaccine.2015.05.003. [PubMed: 25980426] [CrossRef]
205.: Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015b;33(36):4647–52. doi: 10.1016/j.vaccine.2015.05.003. [PubMed: 25980426] [CrossRef]
206.: Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA pediatrics. 2014;168(3):211–9. doi: 10.1001/jamapediatrics.2013.4469. [PMC free article: PMC6693332] [PubMed: 24395025] [CrossRef]
207.: Stockwell MS, Broder KR, Lewis P, et al. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination. Journal of the Pediatric Infectious Diseases Society. 2017;6(3):e7–e14. doi: 10.1093/jpids/piw028. [PMC free article: PMC6675416] [PubMed: 27302328] [CrossRef]
208.: Stowe J, Andrews N, Ladhani S, et al. The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation. Vaccine. 2016;34(32):3684–9. doi: 10.1016/j.vaccine.2016.04.050. [PubMed: 27286641] [CrossRef]
209.: Strezova A, Lal H, Enweonye I, et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged >=50 years: A randomized trial. Vaccine. 2019;37(39):5877–85. doi: 10.1016/j.vaccine.2019.08.001. [PubMed: 31443993] [CrossRef]
210.: Svensson T, Kattstrom M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701–7. doi: 10.1016/j.vaccine.2018.05.012. [PubMed: 29748028] [CrossRef]
211.: Tapiero B, Halperin SA, Dionne M, et al. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Pediatric Infectious Disease Journal. 2013 Jan;32(1):54–61. doi: 10.1097/INF.0b013e3182717edf. PMID: 23241989. [PubMed: 23241989] [CrossRef]
212.: Tate JE, Mwenda JM, Armah G, et al. Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa. N Engl J Med. 2018 Apr 19;378(16):1521–8. doi: 10.1056/NEJMoa1713909. PMID: 29669224. [PubMed: 29669224] [CrossRef]
213.: Tate JE, Yen C, Steiner CA, et al. Intussusception Rates Before and After the Introduction of Rotavirus Vaccine. Pediatrics. 2016;138(3). doi: 10.1542/peds.2016-1082. [PubMed: 27558938] [CrossRef]
214.: Thompson AR, Klein NP, Downey HJ, et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Human vaccines & immunotherapeutics. 2019;15(2):444–51. doi: 10.1080/21645515.2018.1533777. [PMC free article: PMC6422453] [PubMed: 30303436] [CrossRef]
215.: Timmermann CAG, Osuna CE, Steuerwald U, et al. Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2015;26(8):742–9. doi: 10.1111/pai.12391. [PMC free article: PMC6190691] [PubMed: 25845848] [CrossRef]
216.: Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >=18 years: a phase III, randomized trial. Vaccine. 2014;32(13):1480–7. doi: 10.1016/j.vaccine.2014.01.022. [PubMed: 24486352] [CrossRef]
217.: Togashi T, Okada K, Yamaji M, et al. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan. The Pediatric infectious disease journal. 2015;34(10):1096–104. doi: 10.1097/INF.0000000000000819. [PubMed: 26121200] [CrossRef]
218.: Treanor JT, Albano FR, Sawlwin DC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017;35(15):1856–64. doi: 10.1016/j.vaccine.2017.02.066. [PubMed: 28302411] [CrossRef]
219.: Tregnaghi M, Lopez P, Stamboulian D, et al. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2014;26:22–30. doi: 10.1016/j.ijid.2014.03.1390. [PubMed: 24980467] [CrossRef]
220.: Tseng H-F, Sy LS, Ackerson BK, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics. 2017;139(1). doi: 10.1542/peds.2016-2084. [PubMed: 28025240] [CrossRef]
221.: Tseng HF, Sy LS, Liu ILA, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31(22):2578–83. doi: 10.1016/j.vaccine.2013.03.040. [PubMed: 23579258] [CrossRef]
222.: Tseng HF, Sy LS, Qian L, et al. Pneumococcal Conjugate Vaccine Safety in Elderly Adults. Open forum infectious diseases. 2018;5(6):ofy100. doi: 10.1093/ofid/ofy100. [PMC free article: PMC6016414] [PubMed: 29977960] [CrossRef]
223.: Uhlig U, Kostev K, Schuster V, et al. Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines. The Pediatric infectious disease journal. 2014;33(11):e299–304. doi: 10.1097/INF.0000000000000441. [PubMed: 24911897] [CrossRef]
224.: Uno Y, Uchiyama T, Kurosawa M, et al. Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine. 2015 May 15;33(21):2511–6. doi: 10.1016/j.vaccine.2014.12.036. PMID: 25562790. [PubMed: 25562790] [CrossRef]
225.: Vaarala O, Jokinen J, Lahdenkari M, et al. Rotavirus Vaccination and the Risk of Celiac Disease or Type 1 Diabetes in Finnish Children at Early Life. The Pediatric infectious disease journal. 2017;36(7):674–5. doi: 10.1097/INF.0000000000001600. [PubMed: 28399059] [CrossRef]
226.: Van Damme P, Meijer CJLM, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–12. doi: 10.1016/j.vaccine.2016.06.056. [PubMed: 27354258] [CrossRef]
227.: Vandecasteele SJ, De Bacquer D, Caluwe R, et al. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(1):65–71. doi: 10.1016/j.cmi.2017.05.016. [PubMed: 28559003] [CrossRef]
228.: Vesikari T, Brodszki N, van Damme P, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil in 9–15-Year-Old Girls. The Pediatric infectious disease journal. 2015;34(9):992–8. doi: 10.1097/INF.0000000000000773. [PubMed: 26090572] [CrossRef]
229.: Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007 24;370(9601):1757–63. PMID: 2007564672 MEDLINE PMID 18037080 (http://www.ncbi.nlm.nih.gov/pubmed/18037080). [PubMed: 18037080]
230.: Vesikari T, Wysocki J, Beeslaar J, et al. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society. 2016;5(2):180–7. doi: 10.1093/jpids/piv064. [PMC free article: PMC5407129] [PubMed: 26803328] [CrossRef]
231.: Vila-Corcoles A, Ochoa-Gondar O, de Diego C, et al. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. BMC Infectious Diseases. 2018 2018/04/27;18(1):196. doi: 10.1186/s12879-018-3096-7. [PMC free article: PMC5921259] [PubMed: 29699550] [CrossRef]
232.: Villa M, Black S, Groth N, et al. Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. American journal of epidemiology. 2013;178(7):1139–45. doi: 10.1093/aje/kwt078. [PMC free article: PMC3783089] [PubMed: 23863759] [CrossRef]
233.: Walter EB, Klein NP, Wodi AP, et al. Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations. Pediatrics. 2020;145(3). doi: 10.1542/peds.2019-1909. [PMC free article: PMC7055925] [PubMed: 32029684] [CrossRef]
234.: Wang L, Chandrasekaran V, Domachowske JB, et al. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. Journal of the Pediatric Infectious Diseases Society. 2016;5(2):170–9. doi: 10.1093/jpids/piv041. [PMC free article: PMC5407130] [PubMed: 26407273] [CrossRef]
235.: Wang SV, Abdurrob A, Spoendlin J, et al. Methods for addressing “innocent bystanders” when evaluating safety of concomitant vaccines. Pharmacoepidemiology and drug safety. 2018;27(4):405–12. doi: 10.1002/pds.4399. [PMC free article: PMC5937260] [PubMed: 29441647] [CrossRef]
236.: Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. The New England journal of medicine. 2014;370(6):503–12. doi: 10.1056/NEJMoa1303164. [PubMed: 24422676] [CrossRef]
237.: Yung CF, Chan SP, Soh S, et al. Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit Study. J Pediatr. 2015 Jul;167(1):163–8.e1. doi: 10.1016/j.jpeds.2015.03.038. PMID: 25882872. [PubMed: 25882872] [CrossRef]
238.: Yung CF, Ma X, Cheung YB, et al. Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Scientific reports. 2019;9(1):14705. doi: 10.1038/s41598-019-51137-5. [PMC free article: PMC6788987] [PubMed: 31604998] [CrossRef]
239.: Zahid M, Singla I, Good CB, et al. Associations between Pneumococcal Vaccination and Adverse Outcomes in Patients with Suspected Acute Coronary Syndrome. Adv Infect Dis. 2012(2):122–34.
240.: Erratum: v72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study (The Lancet (2012) 379 (617–624)). Lancet. 2015;385(9979):1728. doi: 10.1016/S0140-6736%2815%2960893-5. PMID: CN-01088631. [PubMed: 22260988] [CrossRef]
241.: AstraZeneca. A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years. 2015.
242.: AZ Sint-Jan AV, Pfizer. 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients. 2013.
243.: Baker MA, Lieu TA, Li LL, et al. A Vaccine Study Design Selection Framework for the Postlicensure Rapid Immunization Safety Monitoring Program. American Journal of Epidemiology. 2015 Apr;181(8):608–18. doi: 10.1093/aje/kwu322. PMID: WOS:000353815700008. [PubMed: 25769306] [CrossRef]
244.: Baxter R, Lewis E, Fireman B, et al. Case-centered Analysis of Optic Neuritis After Vaccines. Clin Infect Dis. 2016 Jul 1;63(1):79–81. doi: 10.1093/cid/ciw224. PMID: 27069066. [PubMed: 27069066] [CrossRef]
245.: Clinical Trials Registry-India. CTRI/2012/07/002820: A study to evaluate safety of Rotavirus vaccine in Healthy Adult Volunteers followed by Safety, Tolerability and Immunogenicity evaluation in healthy infants. July 31, 2013. http://ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4929&EncHid=&modid=&compid=%27,%274929det%27.
246.: Colindres R, Wascotte V, Brecx A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human Vaccines and Immunotherapeutics. 2020. doi: 10.1080/21645515.2020.1741312. [PMC free article: PMC7733973] [PubMed: 32347767] [CrossRef]
247.: Columbia University, Centers for Disease Control Prevention. FeverText: Assessing Fever Rates After Vaccination During the 2011–12 Influenza Season Using Text Messaging. 2011.
248.: Columbia University, Centers for Disease Control Prevention. Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012–2013 & 2013–2014. 2013.
249.: Cowling BJ, Thompson MG, Ng TWY, et al. Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults. The Journal of infectious diseases. 2020;222(8):1383–91. doi: 10.1093/infdis/jiaa255. [PubMed: 32407535] [CrossRef]
250.: DeSilva M, Vazquez-Benitez G, Nordin JD, et al. Tdap Vaccination During Pregnancy and Microcephaly and Other Structural Birth Defects in Offspring. JAMA. 2016 Nov 1;316(17):1823–5. doi: 10.1001/jama.2016.14432. PMID: 27802536. [PubMed: 27802536] [CrossRef]
251.: Dezure A, Marechal C, Lal H, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine candidate when coadministered with a 23-valent pneumococcal polysaccharide vaccine in adults 50 years of age or older: a phase iii, randomized clinical trial. Journal of the american pharmacists association. 2018;58(3):e72–e3. doi: 10.1016/j.japh.2018.04.004. PMID: CN-01612158. [CrossRef]
252.: Dynavax Technologies Corporation. Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine. 2010.
253.: Euctr BE. Evaluation of the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) when co-administered with Pneumovax™ 23 in adults 50 years of age and older. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-001118-24-BE. 2014. PMID: CN-01800759.
254.: Euctr CZ. Immunogenicity and safety study of Boostrix in pregnant women. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-001119-38-CZ. 2015. PMID: CN-01813329.
255.: Everett D. Hepatitis B Vaccine (Recombinant), Adjuvanted (Heplisav-B): Review of Safety. Vaccines and Related Biological Products Advisory Committee Meeting; July 28, 2017. U.S. Food & Drug Administration.
256.: Garland SM, Pitisuttithum P, Ngan HYS, et al. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. The Journal of infectious diseases. 2018;218(1):95–108. doi: 10.1093/infdis/jiy133. [PMC free article: PMC5989602] [PubMed: 29767739] [CrossRef]
257.: Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic oncology. 2019;154(1):110–7. doi: 10.1016/j.ygyno.2019.03.253. [PubMed: 30982556] [CrossRef]
258.: GlaxoSmithKline. To Test 2 Doses of GSK Biologicals’ Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines. https://ClinicalTrials.gov/show/NCT00140686; 2004.
259.: GlaxoSmithKline. Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults. 2008.
260.: GlaxoSmithKline. Immunogenicity and Safety Study of GSK Biologicals’ Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years. 2009.
261.: GlaxoSmithKline. Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals’ Candidate Influenza Vaccine in Healthy Children. https://ClinicalTrials.gov/show/NCT00985790; 2009.
262.: GlaxoSmithKline. Safety and Immunogenicity Study of GSK Biologicals’ Seasonal Influenza Candidate Vaccine (GSK2321138A). 2010.
263.: GlaxoSmithKline. A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals’ Seasonal Influenza Vaccine in Children. 2010.
264.: GlaxoSmithKline. A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals’ Seasonal Influenza Vaccine in Adults. 2010.
265.: GlaxoSmithKline. Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants. 2010.
266.: GlaxoSmithKline. Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older. 2010.
267.: GlaxoSmithKline. Immunogenicity and Safety Study of GSK Biologicals’ Influenza Vaccine When Administered in Children. https://ClinicalTrials.gov/show/NCT01196988; 2010.
268.: GlaxoSmithKline. Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age. 2012.
269.: GlaxoSmithKline. Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age. 2014.
270.: GlaxoSmithKline. Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age. 2014.
271.: GlaxoSmithKline. Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals’ Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older. 2014.
272.: GlaxoSmithKline. Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals’ Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older. 2015.
273.: GlaxoSmithKline. Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older. 2015.
274.: GlaxoSmithKline. Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older. 2015.
275.: GlaxoSmithKline. A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. 2017.
276.: GlaxoSmithKline. Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ Vaccine in Pregnant Women. 2017.
277.: GlaxoSmithKline. Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older. 2017.
278.: GlaxoSmithKline. Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery. 2018.
279.: GlaxoSmithKline. Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery. 2019.
280.: Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine. 2017;35(37):5050–7. doi: 10.1016/j.vaccine.2017.07.017. [PubMed: 28789851] [CrossRef]
281.: Guevara AM, Suarez E, Victoria A, et al. Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. Human Vaccines and Immunotherapeutics. 2019;15(1):141–5. doi: 10.1080/21645515.2018.1514227. [PMC free article: PMC6363163] [PubMed: 30261146] [CrossRef]
282.: Hambidge SJ, Newcomer SR, Narwaney KJ, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014;133(6):e1492–9. doi: 10.1542/peds.2013-3429. [PubMed: 24843064] [CrossRef]
283.: Hedrick J, Christensen S, Chang LJ, et al. Study of the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine (MENACYW-TT) when co-administered with other vaccines in healthy adolescents. Open forum infectious diseases. 2018;5:S570-. doi: 10.1093/ofid/ofy210.1623. PMID: CN-01989456. [CrossRef]
284.: Hedrick J, Simon MW, Christensen S, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) in adolescents and adults. Open forum infectious diseases. 2019;6:S959-. doi: 10.1093/ofid/ofz360.2402. PMID: CN-02073117. [CrossRef]
285.: Helsinki University Central Hospital, Tampere University Hospital. Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients. https://ClinicalTrials.gov/show/NCT01781871; 2013.
286.: Hospital Universitario Dr. Jose E. Gonzalez. Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy. 2011.
287.: Hyer R, McGuire DK, Xing B, et al. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine. 2018;36(19):2604–11. doi: 10.1016/j.vaccine.2018.03.067. [PubMed: 29628151] [CrossRef]
288.: Hyer RN, Janssen RS. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70years. Vaccine. 2019;37(39):5854–61. doi: 10.1016/j.vaccine.2019.08.005. [PubMed: 31431412] [CrossRef]
289.: Jeanfreau R, Esteves-Jaramillo A, Neveu D, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in individuals 56 years of age and older. Open forum infectious diseases. 2018;5. doi: 10.1093/ofid/ofy210.2115. PMID: CN-01989050. [CrossRef]
290.: Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England journal of medicine. 2015;372(8):711–23. doi: 10.1056/NEJMoa1405044. [PubMed: 25693011] [CrossRef]
291.: Kantso B, Halkjaer S, Thomsen O, et al. Specific antibody response to two pneumococcal vaccines in crohn’s disease patients treated with immunosuppressive drugs alone or in combination with biological therapy. Gastroenterology. 2015;148(4 SUPPL. 1):S176–S7. PMID: CN-01102679.
292.: Karolinska University Hospital. Pneumococcal Vaccine in Untreated CLL Patients. 2013.
293.: Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014;312(18):1897–904. doi: 10.1001/jama.2014.14825. [PMC free article: PMC6599584] [PubMed: 25387187] [CrossRef]
294.: Korea University Guro Hospital. Influenza Vaccine and Pneumococcal Vaccine. https://ClinicalTrials.gov/show/NCT02582047; 2012.
295.: Korea University Guro Hospital. Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine. 2013.
296.: Korea University Guro Hospital, Novartis. MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine. 2013. [PubMed: 25980426]
297.: Korea University Guro Hospital, Pfizer. Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years. 2014.
298.: Laval University. Immunogenicity and Safety of Gardasil-9 and Cervarix. 2015.
299.: Li R-C, Huang T, Li Y, et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human vaccines & immunotherapeutics. 2016;12(3):785–93. doi: 10.1080/21645515.2015.1085143. [PMC free article: PMC4964624] [PubMed: 27149266] [CrossRef]
300.: Li R-C, Li Y-P, Mo Z-J, et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies. Human vaccines & immunotherapeutics. 2013;9(8):1638–42. doi: 10.4161/hv.25076. [PMC free article: PMC3906260] [PubMed: 23807360] [CrossRef]
301.: Lopez-Fauqued M, Campora L, Delannois F, et al. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37(18):2482–93. doi: 10.1016/j.vaccine.2019.03.043. [PubMed: 30935742] [CrossRef]
302.: Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines and Immunotherapeutics. 2015;11(6):1313–22. doi: 10.1080/21645515.2015.1012010. [PMC free article: PMC4514333] [PubMed: 25912208] [CrossRef]
303.: Mayrand MH, Bautista O, Moeller E, et al. End of study efficacy, immunogenicity and safety of a novel 9-valent HPV l1 virus-like particle vaccine in 16–26 year old women. International journal of gynecology and obstetrics. ( var.pagings). 2015;131:E270. PMID: CN-01136212.
304.: McElhaney JE, Lal H, Cunningham AL, et al. Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the zoe-50 and zoe-70 efficacy studies. Open forum infectious diseases. 2016;3. doi: 10.1093/ofid/ofw194.40. PMID: CN-01934009. [CrossRef]
305.: MedImmune LLC. A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age. https://ClinicalTrials.gov/show/NCT00860067; 2009.
306.: MedImmune LLC. A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children. https://ClinicalTrials.gov/show/NCT01091246; 2010.
307.: MedImmune LLC. Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age. https://ClinicalTrials.gov/show/NCT01985997; 2014.
308.: MedImmune LLC, AstraZeneca. Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age. 2017.
309.: Merck Sharp, Dohme Corp. Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024). 2015.
310.: Merck Sharp, Dohme Corp. Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068). 2006.
311.: Merck Sharp, Dohme Corp. Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001). 2007.
312.: Merck Sharp, Dohme Corp. Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035). 2007.
313.: Merck Sharp, Dohme Corp. Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED). https://ClinicalTrials.gov/show/NCT00718237; 2008.
314.: Merck Sharp, Dohme Corp. A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12–26 Years of Age Who Have Previously Received GARDASIL™ (V503-006). 2010.
315.: Merck Sharp, Dohme Corp. Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009). 2011.
316.: Merck Sharp, Dohme Corp. A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020). 2014.
317.: Merck Sharp, Dohme Corp., MCM Vaccines B.V. A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006). 2011.
318.: Merck Sharp, Dohme Corp., MCM Vaccines B.V. Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005). 2011.
319.: Munoz FM, Bond NH, Maccato M. Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial (vol 311, pg 1760, 2014). Jama-Journal of the American Medical Association. 2017 Jan;317(4):442-. doi: 10.1001/jama.2016.20705. PMID: WOS:000392509600032. [PMC free article: PMC4333147] [PubMed: 24794369] [CrossRef]
320.: National Institute of Allergy Infectious Diseases. Pertussis Vaccine in Healthy Pregnant Women. 2009.
321.: Novartis, Novartis Vaccines. Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants. 2008.
322.: Novartis, Novartis Vaccines. A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults. 2011.
323.: Novartis, Novartis Vaccines. A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents. 2011.
324.: Novartis Vaccines, GlaxoSmithKline, Novartis. Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine. 2011.
325.: Novartis Vaccines, Novartis. Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age. 2006.
326.: Novartis Vaccines, Novartis. A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants. 2007.
327.: Novartis Vaccines, Novartis. Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules. 2008.
328.: Novartis Vaccines, Novartis. A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea. 2010.
329.: Novartis Vaccines, Novartis. Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects. 2010.
330.: Novartis Vaccines, Novartis. Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older. 2014.
331.: Novartis Vaccines, Novartis. Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old. 2014.
332.: Novartis Vaccines, Novartis. Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11–17 Years. 2014.
333.: Novartis Vaccines and Diagnostics S.r.l. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. 2014. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003514-91.
334.: Oostvogels L, Heineman TC, Johnson RW, et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Human vaccines & immunotherapeutics. 2019;15(12):2865–72. doi: 10.1080/21645515.2019.1627818. [PMC free article: PMC6930113] [PubMed: 31216205] [CrossRef]
335.: Perrett K, Garcia IC, Halperin S, et al. Pertussis vaccination during pregnancy: a multicountry randomised placebo-controlled trial assessing immunogenicity and safety of dTpa in mothers and their infants. BJOG. 2019;126:173–4. doi: 10.1111/1471-0528.12_15703. PMID: CN-01960579. [CrossRef]
336.: Perrett KP, Halperin SA, Nolan T, et al. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine. 2020 Feb;38(8):2105–14. doi: 10.1016/j.vaccine.2019.10.104. PMID: WOS:000518490000029. [PubMed: 31776027] [CrossRef]
337.: Petersen LK, Restrepo J, Moreira ED, et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Research. 2017;3:105–15. doi: 10.1016/j.pvr.2017.03.002. [PMC free article: PMC5883201] [PubMed: 28720442] [CrossRef]
338.: Peterson J, Hedrick J, Pan J, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in adults 18–55 years of age. Open forum infectious diseases. 2019;6:S957-. doi: 10.1093/ofid/ofz360.2396. PMID: CN-02075077. [CrossRef]
339.: Peterson J, Hedrick J, Pan J, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in adolescents 10–17 years of age. Open forum infectious diseases. 2019;6:S958-. doi: 10.1093/ofid/ofz360.2400. PMID: CN-02073064. [CrossRef]
340.: Pfizer. Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization. 2007.
341.: Pfizer. Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine. https://ClinicalTrials.gov/show/NCT00521586; 2007.
342.: Pfizer. Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults. https://ClinicalTrials.gov/show/NCT00492557; 2007.
343.: Pfizer. Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults. 2008.
344.: Pfizer. A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents. 2009.
345.: Pfizer. Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. 2010.
346.: Pfizer. A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. 2011.
347.: Pfizer. A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years. 2012.
348.: Pfizer. Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13™Vaccine. 2013.
349.: Pfizer. Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. 2015.
350.: Pfizer Winawoso. Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea. https://ClinicalTrials.gov/show/NCT00689351; 2008.
351.: Protein Sciences Corporation. Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age. 2015. [PubMed: 26529070]
352.: Protein Sciences Corporation, Syneos Health, Department of Health Human Services. Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18–49 Years of Age. 2015.
353.: Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA pediatrics. 2013;167(12):1111–7. doi: 10.1001/jamapediatrics.2013.2745. [PubMed: 24126936] [CrossRef]
354.: Ruiz-Sternberg AM, Moreira ED, Jr., Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus research (Amsterdam, Netherlands). 2018;5:63–74. doi: 10.1016/j.pvr.2017.12.004. [PMC free article: PMC5887018] [PubMed: 29269325] [CrossRef]
355.: Sanofi Pasteur a Sanofi Company. Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine.
356.: Sanofi Pasteur a Sanofi Company, Merck Sharp, Dohme Corp., et al. Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®. 2006.
357.: Sanofi Pasteur a Sanofi Company, Sanofi. 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2–10 Year Olds. 2005.
358.: Sanofi Pasteur a Sanofi Company, Sanofi. Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine. 2005.
359.: Sanofi Pasteur a Sanofi Company, Sanofi. Database Surveillance Safety Study of PENTACEL® Vaccine. 2008.
360.: Sanofi Pasteur a Sanofi Company, Sanofi. A Study of Influenza Virus Vaccines in Children and Adults. 2009.
361.: Sanofi Pasteur a Sanofi Company, Sanofi. Study of Quadrivalent Influenza Vaccine Among Children. 2010.
362.: Sanofi Pasteur a Sanofi Company, Sanofi. Study of Quadrivalent Influenza Vaccine Among Adults. https://ClinicalTrials.gov/show/NCT01218646; 2010.
363.: Sanofi Pasteur a Sanofi Company, Sanofi. Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children. 2011.
364.: Sanofi Pasteur a Sanofi Company, Sanofi. Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose. 2011.
365.: Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents. 2014.
366.: Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine. 2016.
367.: Sanofi Pasteur a Sanofi Company, Sanofi. Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older. 2016.
368.: Sanofi Pasteur a Sanofi Company, Sanofi. Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US. 2017.
369.: Sanofi Pasteur aSC, Sanofi. Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older. https://ClinicalTrials.gov/show/NCT01732627; 2012.
370.: Sanofi Pasteur aSC, Sanofi. Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years. https://ClinicalTrials.gov/show/NCT03077438; 2017.
371.: Scott Halperin, IWK Health Centre, Sanofi Pasteur a Sanofi Company, et al. Pertussis Maternal Immunization Study. 2007.
372.: Scott J. Statistical Analysis of Heplisav-B AMI Risk. Vaccines and Related Biological Products Advisory Committee Meeting; July 28, 2017. U.S. Food & Drug Administration.
373.: Seqirus. Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults.
374.: Seqirus. A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above. 2014.
375.: Simon MW, Brandon D, Christensen S, et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (menacyw-TT) administered in healthy meningococcal vaccine-naïve children (2–9 years). Open forum infectious diseases. 2019;6:S958–S9. doi: 10.1093/ofid/ofz360.2401. PMID: CN-02076016. [CrossRef]
376.: Statens Serum Institut. Pneumococcal vaccination of Crohn patients - A randomized, non-blinded phase 4 clinical trial with the purpose of investigating the immune response against two different pneumococcal vaccines in patients with Crohn’s disease. 2013. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002867-86.
377.: Statens Serum Institut, Hvidovre University Hospital, Herlev Hospital. Pneumococcal Vaccination of Crohn Patients. 2013.
378.: The University of Hong Kong, Centers for Disease Control Prevention. Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong. 2017.
379.: U.S Food and Drug Administration. Clinical Review, November 9, 2017-Heplisav-B: BLA Clinical Review Memorandum. 2017. https://www.fda.gov/media/109802/download. Accessed on September 29, 2020.
380.: University D, Centers for Disease Control Prevention, Kaiser Permanente. Fever After Simultaneous Versus Sequential Vaccination in Young Children. 2018.
381.: University of Newcastle, National Health and Medical Research Council. Pneumococcal polysaccharide vaccine versus Normal Saline for primary prevention of heart attacks and strokes in at-risk Australians aged 55–60. 2015. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000536561.
382.: University of Siena, Ministry of Education Universities, Research Italy. Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults. 2011.
383.: van Werkhoven CH, Bonten MJM. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly? Future microbiology. 2015;10(9):1405–13. doi: 10.2217/fmb.15.80. [PubMed: 26347153] [CrossRef]
384.: Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS Study, 3-year follow-up. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2014;23(6):1577–84. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.047. [PubMed: 24656243] [CrossRef]
385.: Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health. 2012;12:222. PMID: 22436146. [PMC free article: PMC3331814] [PubMed: 22436146]
386.: Wyeth is now a wholly owned subsidiary of Pfizer. Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects. https://ClinicalTrials.gov/show/NCT00269672; 2005.
387.: Wyeth is now a wholly owned subsidiary of Pfizer. Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS. https://ClinicalTrials.gov/show/NCT00574548; 2007.
388.: Yih K, Lieu T, Kulldorff M, et al. Intussusception Risk After Rotavirus Vaccination in U.S. Infants. Available at: http://www.mini-sentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Rotavirus-and-intussusception-Report.pdf Mini-Sentinel Coordinating Center. June 2013.
389.: 130 STUDIES LINKING VACCINES TO NEUROLOGICAL AND AUTOIMMUNE ISSUES COMMON TO AUTISM. https://go.thetruthaboutvaccines.com/wp-content/uploads/130-STUDIES-LINKING-VACCINES-TO-NEUROLOGICAL-AND-AUTOIMMUNE-ISSUES-COMMON-TO-AUTISM.pdf.
390.: Package Insert - Adacel.
391.: Package insert - Boostrix.
392.: Package insert - Infanrix.
393.: Package insert - Daptacel.
394.: Package insert - Pediarix.
395.: Package insert - Kinrix.
396.: Package insert - Quadracel.
397.: Package insert - Vaxelis.
398.: Package insert - Pentacel.
399.: Package insert - Tdvax.
400.: Package insert - Tenivac.
401.: Package insert - Twinrix.
402.: Package insert - Vaqta.
403.: Package insert - Havrix.
404.: Package insert - Energix-B.
405.: Package insert - Recombivax-HB.
406.: Package insert - Heplisav-B.
407.: Package insert - Pedvaxhib.
408.: Package insert - Acthib.
409.: Package insert - Hiberix.
410.: Package insert - Gardasil-9.
411.: Package insert - IPOL.
412.: Package insert - Fluad and Fluad QUADRIVALENT
413.: Package insert - Afluria QUADRIVALENT
414.: Package insert - Flucelvax QUADRIVALENT
415.: Package insert - Flulaval QUADRIVALENT
416.: Package insert -Flumist QUADRIVALENT
417.: Package insert - Fluarix QUADRIVALENT
418.: Package insert - Fluzone QUADRIVALENT (including high dose and intradermal).
419.: Package insert - Flublok QUADRIVALENT
420.: Package insert - Proquad (includes fridge stable and frozen(s)).
421.: Package insert - Prevnar-13.
422.: Package insert - Menacetra.
423.: Package insert - MenQuadFi.
424.: Package insert - Menveo.
425.: Package insert - Bexsero.
426.: Package insert - Trumenba.
427.: Package insert - Rotarix.
428.: Package insert - Rotateq.
429.: Package insert - Varivax.
430.: Package insert - Shingrix.
431.: Package insert - Zostavax.
432.: Package insert - Pneumovax 23.
433.: In: Stratton KR, Howe CJ, Johnston RB, Jr., eds. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington (DC); 1994. [PubMed: 25077265]
434.: Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep. 2010 Jun 11;59(22):687–8. PMID: 20535093. [PubMed: 20535093]
435.: Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR Morb Mortal Wkly Rep. 2011 Oct 21;60(41):1427. PMID: 22012117. [PubMed: 22012117]
436.: Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011 Nov 11;60(44):1528. PMID: 22071592. [PubMed: 22071592]
437.: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):613–8. PMID: 22895385. [PubMed: 22895385]
438.: FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep. 2012 Mar 30;61(12):212. PMID: 22456121. [PubMed: 22456121]
439.: Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013–2014. MMWR Recomm Rep. 2013 Sep 20;62(Rr-07):1–43. PMID: 24048214. [PubMed: 24048214]
440.: Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):356. PMID: 23657110. [PMC free article: PMC4605018] [PubMed: 23657110]
441.: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013 Jun 28;62(25):521–4. PMID: 23803961. [PMC free article: PMC4604951] [PubMed: 23803961]
442.: Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep. 2013 Jul 19;62(28):574–6. PMID: 23863705. [PMC free article: PMC4604813] [PubMed: 23863705]
443.: Flu vaccine and egg allergy. Archives of disease in childhood. 2015;100(12):1162. doi: 10.1136/archdischild-2015-309894. [PubMed: 26507815] [CrossRef]
444.: Vaccine Peer Review: The History Of The Global Vaccination Program In 1000 Peer Reviewed Reports And Studies: 1915–2015 Jeff Prager. 2015.
445.: Vaccines and Autoimmunity. 1st ed. Hoboken, New Jersey: Wiley Blackwell; 2015.
446.: Assessing the State of Vaccine Confidence in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015 [corrected]. Public Health Rep. 2015 Nov-Dec;130(6):573–95. doi: 10.1177/003335491513000606. PMID: 26556929. [PMC free article: PMC4612166] [PubMed: 26556929] [CrossRef]
447.: Results of a safety pooled analysis of an adjuvanted herpes zoster subunit vaccine in more than 14,500 participants aged 50 years or older. Open forum infectious diseases. 2017;4:S416-. doi: 10.1093/ofid/ofx163.1042. PMID: CN-02002230. [CrossRef]
448.: Erratum: Vol. 67, No. 43 - Hepatitis A. MMWR Morb Mortal Wkly Rep. 2019 Mar 8;68(9):233. doi: 10.15585/mmwr.mm6809a4. PMID: 30845122. [PMC free article: PMC6421972] [PubMed: 30845122] [CrossRef]
449.: (ACIP) ACoIP. Vaccine Recommendations and Guidelines of the ACIP. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html#recs. Accessed on July 7. 2020.
450.: Abu-Raya B, Giles ML. Extending Antenatal Pertussis Immunization to Second Trimester or At-Birth Pertussis Immunization of Premature Infants?…Wood N, Nolan T, Marshall H, et al. Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr. 2018;172(11):1045–1052. Chicago, Illinois: American Medical Association; 2019. p. 294–5. [PMC free article: PMC6248137] [PubMed: 30208475]
451.: Adawi M, Bragazzi NL, McGonagle D, et al. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmunity reviews. 2019;18(1):73–92. doi: 10.1016/j.autrev.2018.08.002. [PubMed: 30408581] [CrossRef]
452.: Ahmed F, Lindley MC, Allred N, et al. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(1):50–7. doi: 10.1093/cid/cit580. [PubMed: 24046301] [CrossRef]
453.: Allali S, Chalumeau M, Launay O, et al. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. The Cochrane database of systematic reviews. 2018;8:CD011199. doi: 10.1002/14651858.CD011199.pub3. [PMC free article: PMC6513445] [PubMed: 30125338] [CrossRef]
454.: Alqahtani AS, Rashid H, Heywood AE. Vaccinations against respiratory tract infections at Hajj. Clinical Microbiology and Infection. 2015 Feb;21(2):115–27. doi: 10.1016/j.cmi.2014.11.026. PMID: WOS:000351648600003. [PubMed: 25682277] [CrossRef]
455.: American Academy of Family Physicians, American College of Nurse-Midwives, American College of Obstetricians and Gynecologists, et al. Maternal Immunization Task Force for Pregnant Women: A Call to Action American College of Obstetricians and Gynecologists,. 2020. https://www.aafp.org/dam/AAFP/documents/journals/fpm/supplement_maternal_immunization.pdf [PubMed: 33161992]
456.: American College of Pediatricians. New Concerns about the Human Papillomavirus Vaccine. January 2016.
457.: Anania C, Olivero F, Spagnolo A, et al. Immune response to vaccines in children with celiac disease. World Journal of Gastroenterology. 2017 May;23(18):3205–13. doi: 10.3748/wjg.v23.i18.3205. PMID: WOS:000401320900002. [PMC free article: PMC5434426] [PubMed: 28566880] [CrossRef]
458.: Angelo M-G, David M-P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiology and drug safety. 2014;23(5):466–79. doi: 10.1002/pds.3554. [PMC free article: PMC4230467] [PubMed: 24644063] [CrossRef]
459.: Anonymous. Meningococcal B vaccine. An immunogenic vaccine possibly useful during outbreaks. Prescrire international. 2014;23(152):201–4. [PubMed: 25325113]
460.: Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews. 2018(5):241. doi: 10.1002/14651858.CD009069.pub3. PMID: WOS:000433887900008. [PMC free article: PMC6494566] [PubMed: 29740819] [CrossRef]
461.: Ateudjieu J, Stoll B, Bisseck AC, et al. Safety profile of the meningococcal conjugate vaccine (MenafrivacTM) in clinical trials and vaccination campaigns: a review of published studies. Human vaccines & immunotherapeutics. 2019:1–15. doi: 10.1080/21645515.2019.1652041. [PMC free article: PMC7482715] [PubMed: 31403358] [CrossRef]
462.: Augustynowicz E, Lutynska A, Piotrowska A, et al. The safety and effectiveness of vaccination against influenza and pertussis in pregnant women. Przeglad epidemiologiczny. 2017;71(1):55–67. [PubMed: 28654742]
463.: Azami M, Jaafari Z, Soleymani A, et al. Rubella Immunity in Pregnant Iranian Women: A Systematic Review and Meta-Analysis. International journal of fertility & sterility. 2019;13(3):169–77. doi: 10.22074/ijfs.2019.5562. [PMC free article: PMC6642423] [PubMed: 31310069] [CrossRef]
464.: Baay M, Bollaerts K, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine. 2018;36(29):4207–14. doi: 10.1016/j.vaccine.2018.06.004. [PubMed: 29885773] [CrossRef]
465.: Bark T, Glaser GJ. Best Practices for Physicians Recommending a Medical Exemption to Vaccination. March 17, 2019. https://physiciansforinformedconsent.org/wp-content/uploads/2020/03/Bark-and-Glaser-Best-Practices-for-Physicians-Writing-a-Medical-Exemption-to-Vaccination.pdf. Accessed on June 25 2020.
466.: Basu P, Banerjee D, Singh P, et al. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs. South Asian journal of cancer. 2013;2(4):187–92. doi: 10.4103/2278-330X.119877. [PMC free article: PMC3889021] [PubMed: 24455618] [CrossRef]
467.: Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza and other respiratory viruses. 2013;7 Suppl 2:72–5. doi: 10.1111/irv.12084. [PMC free article: PMC5909396] [PubMed: 24034488] [CrossRef]
468.: Bekkat-Berkani R, Ray R, Jain VK, et al. Evidence update: GlaxoSmithKline’s inactivated quadrivalent influenza vaccines. Expert Review of Vaccines. 2016 Feb;15(2):201–14. doi: 10.1586/14760584.2016.1113878. PMID: WOS:000368644100002. [PubMed: 26641539] [CrossRef]
469.: Bennett NM, Pilishvili T, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2013;62(25):521–4. [PMC free article: PMC4604951] [PubMed: 23803961]
470.: Bergman H, Buckley BS, Villanueva G, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database of Systematic Reviews. 2019(11):156. doi: 10.1002/14651858.Cd013479. PMID: WOS:000504427100033. [PMC free article: PMC6873216] [PubMed: 31755549] [CrossRef]
471.: Beyer WEP, Palache AM, Boulfich M, et al. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017 Jul;35(33):4167–76. doi: 10.1016/j.vaccine.2017.06.038. PMID: WOS:000406735500018. [PubMed: 28655451] [CrossRef]
472.: Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews. 2018(2):54. doi: 10.1002/14651858.CD008983.pub3. PMID: WOS:000426476500002. [PMC free article: PMC6491273] [PubMed: 29388675] [CrossRef]
473.: Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine. 2015 Jun;33:B3–B5. doi: 10.1016/j.vaccine.2014.11.062. PMID: WOS:000356548400002. [PubMed: 26022564] [CrossRef]
474.: Black S, Block SL. Use of MenACWY-CRM in Adolescents in the United States. Journal of Adolescent Health. 2013 Mar;52(3):271–7. doi: 10.1016/j.jadohealth.2012.07.017. PMID: WOS:000315289900004. [PubMed: 23299001] [CrossRef]
475.: Bollaerts K, Verstraeten T, Cohet C. Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. Vaccine. 2019 Jan;37(1):34–40. doi: 10.1016/j.vaccine.2018.11.049. PMID: WOS:000454374100006. [PubMed: 30471957] [CrossRef]
476.: Bombatch C, Pallotta A, Neuner EA, et al. Evaluation of Herpes Zoster Vaccination in HIV-Infected Patients 50 Years of Age and Older. The Annals of pharmacotherapy. 2016;50(4):326–7. doi: 10.1177/1060028016632262. [PubMed: 26861991] [CrossRef]
477.: Bonde U, Joergensen JS, Lamont RF, et al. Is HPV vaccination in pregnancy safe? Human Vaccines & Immunotherapeutics. 2016;12(8):1960–4. doi: 10.1080/21645515.2016.1160178. PMID: WOS:000382781800004. [PMC free article: PMC4994723] [PubMed: 27172372] [CrossRef]
478.: Bratton KN, Wardle MT, Orenstein WA, et al. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;60(5):e11–9. doi: 10.1093/cid/ciu915. [PubMed: 25409473] [CrossRef]
479.: Briere EC. Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series. MMWR Morb Mortal Wkly Rep. 2016 Apr 29;65(16):418–9. doi: 10.15585/mmwr.mm6516a3. PMID: 27124887. [PubMed: 27124887] [CrossRef]
480.: Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014 Feb 28;63(Rr-01):1–14. PMID: 24572654. [PubMed: 24572654]
481.: Brosio F, Masetti G, Matteo G, et al. A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. Infection and Drug Resistance. 2018;11:1401–11. doi: 10.2147/idr.S148303. PMID: WOS:000443767300001. [PMC free article: PMC6130298] [PubMed: 30233219] [CrossRef]
482.: Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Practice & Research Clinical Obstetrics & Gynaecology. 2018 Feb;47:42–58. doi: 10.1016/j.bpobgyn.2017.08.010. PMID: WOS:000427214300005. [PubMed: 28986092] [CrossRef]
483.: Bulik NB, Bucsa C, Farcas A, et al. HEXAVALENT VACCINE IN EUROPE: SAFETY DATA FROM THE RANDOMIZED CLINICAL TRIALS. Farmacia. 2018 Sep-Oct;66(5):747–57. doi: 10.31925/farmacia.2018.5.2. PMID: WOS:000447181100002. [CrossRef]
484.: Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews. 2014 Aug(8):11. doi: 10.1002/14651858.CD008865.pub3. PMID: WOS:000209651900031. [PubMed: 25093421] [CrossRef]
485.: Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews. 2016(9):13. doi: 10.1002/14651858.CD008865.pub4. PMID: WOS:000389598700030. [PMC free article: PMC6457746] [PubMed: 27654832] [CrossRef]
486.: Burnett E, Parashar U, Tate J. Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Pediatric Drugs. 2018 Jun;20(3):223–33. doi: 10.1007/s40272-018-0283-3. PMID: WOS:000432367500003. [PMC free article: PMC5955791] [PubMed: 29388076] [CrossRef]
487.: Buyse H, Vinals C, Karkada N, et al. The human rotavirus vaccine RotarixTM in infants: an integrated analysis of safety and reactogenicity. Human vaccines & immunotherapeutics. 2014;10(1):19–24. doi: 10.4161/hv.26476. [PMC free article: PMC4181014] [PubMed: 24047799] [CrossRef]
488.: Buyse H, Vinals C, Karkada N, et al. The human rotavirus vaccine Rotarix in infants: an integrated analysis of safety and reactogenicity. Human vaccines and immunotherapeutics. 2014;10(1):2695–700. doi: 10.4161/hv.26476. PMID: CN-00986485. [PMC free article: PMC4181014] [PubMed: 24047799] [CrossRef]
489.: Byington CL, Maldonado Y. Rotavirus Vaccines-OK to Mix and Match. Pediatrics. 2016;137(2):e20153618. doi: 10.1542/peds.2015-3618. [PMC free article: PMC4732364] [PubMed: 26823542] [CrossRef]
490.: Caldeira D, Rodrigues B, David C, et al. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert review of vaccines. 2019;18(11):1211–7. doi: 10.1080/14760584.2019.1690459. [PubMed: 31693865] [CrossRef]
491.: Campbell-Scherer D. Evidence from large Danish cohort does not support an association between the MMR vaccine and autism: facts in a post-truth world. BMJ evidence-based medicine. 2019;24(5):198–9. doi: 10.1136/bmjebm-2019-111212. [PubMed: 31217233] [CrossRef]
492.: Carnahan A, Perez JJ, Robertson A, et al. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. Control ECfDPa; 2020.
493.: Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep. 2006 Feb 3;55(Rr-1):1–16. PMID: 16456528. [PubMed: 16456528]
494.: Caya CA, Boikos C, Desai S, et al. Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Vaccine. 2015;33(11):1302–12. doi: 10.1016/j.vaccine.2015.01.060. [PubMed: 25660650] [CrossRef]
495.: Cecinati V, Principi N, Brescia L, et al. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013 May;9(5):1158–62. doi: 10.4161/hv.23601. PMID: 23324619. [PMC free article: PMC3899154] [PubMed: 23324619] [CrossRef]
496.: Centers for Disease C, Prevention. Pertussis epidemic--Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012 Jul 20;61(28):517–22. PMID: 22810264. [PubMed: 22810264]
497.: Centers for Disease Control and Prevention. Vaccination Coverage among Adults in the United States, 2017. National Center for Immunization and Respiratory Diseases; 2018. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html.
498.: Centers for Disease Control and Prevention. Cases in the U.S.; 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. Accessed on August 5, 2020.
499.: Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2018–19 Influenza Season. September 26, 2019. https://www.cdc.gov/flu/fluvaxview/coverage-1819estimates.htm. Accessed on January 8, 2020.
500.: Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), (HHS) AotUSDoHaHS. Vaccine Adverse Event Reporting System. https://vaers.hhs.gov. Accessed on August 5, 2020.
501.: Chahal D, Aleshin M, Turegano M, et al. Vaccine-induced toxic epidermal necrolysis: A case and systematic review. Dermatology online journal. 2018;24(1). [PubMed: 29469759]
502.: Chahine EB. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults. Annals of Pharmacotherapy. 2020. doi: 10.1177/1060028020935645. [PubMed: 32578447] [CrossRef]
503.: Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database of Systematic Reviews. 2015(1):37. doi: 10.1002/14651858.CD004903.pub4. PMID: WOS:000349688600007. [PMC free article: PMC9436174] [PubMed: 25613573] [CrossRef]
504.: Chan T-C, Fan-Ngai Hung I, Ka-Hay Luk J, et al. Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. Journal of the American Medical Directors Association. 2014;15(3):226.e1–.e6. doi: 10.1016/j.jamda.2013.10.008. [PubMed: 24321878] [CrossRef]
505.: Chen Y-C, Zhou J-H, Tian J-M, et al. Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety. Human vaccines & immunotherapeutics. 2019:1–11. doi: 10.1080/21645515.2019.1672492. [PMC free article: PMC7227622] [PubMed: 31567058] [CrossRef]
506.: Chiappini E, Petrolini C, Sandini E, et al. Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology. Expert review of vaccines. 2019;18(5):523–45. doi: 10.1080/14760584.2019.1604230. [PubMed: 30952198] [CrossRef]
507.: Children’s Health Defense. World Mercury Project: Peer-Reviewed, Published Research on Mercury and Autism. 2018. https://childrenshealthdefense.org/wp-content/uploads/autism-mercury-abstracts-4.2.18.pdf
508.: Chiyaka ET, Nghiem VT, Zhang L, et al. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. PharmacoEconomics. 2019;37(2):169–200. doi: 10.1007/s40273-018-0735-1. [PubMed: 30367401] [CrossRef]
509.: Chong PP, Handler L, Weber DJ. A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;66(11):1802–11. doi: 10.1093/cid/cix1081. [PubMed: 29253095] [CrossRef]
510.: Ciapponi A, Lee A, Bardach A, et al. Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis. Value in health regional issues. 2016;11:24–34. doi: 10.1016/j.vhri.2015.12.001. [PubMed: 27986195] [CrossRef]
511.: Coelingh K, Olajide IR, MacDonald P, et al. Efficacy and effectiveness of live attenuated influenza vaccine in school-age children. Expert Review of Vaccines. 2015;14(10):1331–46. doi: 10.1586/14760584.2015.1078732. PMID: WOS:000361329300004. [PubMed: 26372891] [CrossRef]
512.: Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Mar 22;62(Rr-2):1–28. PMID: 23515099. [PubMed: 23515099]
513.: Colafrancesco S, Perricone C, Priori R, et al. Sjögren’s syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun. 2014 Jun;51:10–6. doi: 10.1016/j.jaut.2014.03.003. PMID: 24774584. [PubMed: 24774584] [CrossRef]
514.: Constenla DO. Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Paraguay. Revista Panamericana De Salud Publica-Pan American Journal of Public Health. 2015 Nov;38(5):388–95. PMID: WOS:000369704700006. [PubMed: 26837524]
515.: Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009 Feb 6;58(Rr-2):1–25. PMID: 19194371. [PubMed: 19194371]
516.: Cristina G, vinCenza LF, Giuseppe T, et al. HPV VACCINE AND NEUROLOGICAL DISEASES: SYSTEMATIC REVIEW AND META-ANALYSIS OF THE LITERATURE. Acta Medica Mediterranea. 2019;35(4):2203–10. doi: 10.19193/0393-6384_2019_4_345. [CrossRef]
517.: Croce E, Hatz C, Jonker EF, et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35(9):1216–26. doi: 10.1016/j.vaccine.2017.01.048. [PubMed: 28162821] [CrossRef]
518.: Ctri. A Phase 3 clinical study of 6-in-1 vaccine (SHAN6™) to check immunity equivalence of 3 different batches and immunity non-inferiority to 5-in-1 vaccine (SHAN-5^®) PLUS SHANIPV™, when given as 3 doses schedule at 6–8, 10–12 and 14–16 weeks of age along with Oral Rotavirus Vaccine. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2019/01/017155. 2019. PMID: CN-01971414.
519.: Cui FQ, Liang XF, Wang FZ, et al. Development, Production, and Postmarketing Surveillance of Hepatitis A Vaccines in China. Journal of Epidemiology. 2014 May;24(3):169–77. doi: 10.2188/jea.JE20130022. PMID: WOS:000336248600001. [PMC free article: PMC4000763] [PubMed: 24681843] [CrossRef]
520.: Cunningham AL. The herpes zoster subunit vaccine. Expert Opinion on Biological Therapy. 2016;16(2):265–71. doi: 10.1517/14712598.2016.1134481. [PubMed: 26865048] [CrossRef]
521.: D’Heilly C, Switzer C, Macina D. Safety of Maternal Immunization Against Pertussis: A Systematic Review. Infectious diseases and therapy. 2019. doi: 10.1007/s40121-019-00265-6. [PMC free article: PMC6856234] [PubMed: 31531826] [CrossRef]
522.: Dagnew A, Rausch D, Herve C, et al. Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials. Arthritis & Rheumatology. 2019 Oct;71:3. PMID: WOS:000507466903437. [PMC free article: PMC7937016] [PubMed: 32910152]
523.: Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PloS one. 2014;9(9):e106629. doi: 10.1371/journal.pone.0106629. [PMC free article: PMC4152293] [PubMed: 25180516] [CrossRef]
524.: Demicheli V, Jefferson T, Al-Ansary LA, et al. Vaccines for preventing influenza in healthy adults. The Cochrane database of systematic reviews. 2014(3):CD001269. doi: 10.1002/14651858.CD001269.pub5. [PubMed: 24623315] [CrossRef]
525.: Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. The Cochrane database of systematic reviews. 2018;2:CD004876. doi: 10.1002/14651858.CD004876.pub4. [PMC free article: PMC6491101] [PubMed: 29388197] [CrossRef]
526.: Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. The Cochrane database of systematic reviews. 2018;2:CD001269. doi: 10.1002/14651858.CD001269.pub6. [PMC free article: PMC6491184] [PubMed: 29388196] [CrossRef]
527.: Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Evidence-Based Child Health. 2013;8(6):2076–238. doi: 10.1002/ebch.1948. [CrossRef]
528.: Denny L. Safety of HPV vaccination: A FIGO statement. International Journal of Gynecology and Obstetrics. 2013;123(3):187–8. doi: 10.1016/j.ijgo.2013.09.009. [PubMed: 24139200] [CrossRef]
529.: Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. The Cochrane database of systematic reviews. 2020;4:CD004407. doi: 10.1002/14651858.CD004407.pub4. [PMC free article: PMC7169657] [PubMed: 32309885] [CrossRef]
530.: Dimova RB, Egelebo CC, Izurieta HS. Systematic Review of Published Meta-Analyses of Vaccine Safety. Statistics in Biopharmaceutical Research. 2020;12(3):293–302. doi: 10.1080/19466315.2020.1763833. [CrossRef]
531.: Dolhain J, Janssens W, Sohn W-Y, et al. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert review of vaccines. 2019;18(9):921–33. doi: 10.1080/14760584.2019.1646643. [PubMed: 31328999] [CrossRef]
532.: Donzelli A. Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring. International journal of environmental research and public health. 2019;16(22). doi: 10.3390/ijerph16224347. [PMC free article: PMC6887964] [PubMed: 31703366] [CrossRef]
533.: Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Human vaccines & immunotherapeutics. 2018;14(8):1853–66. doi: 10.1080/21645515.2018.1446719. [PMC free article: PMC6149986] [PubMed: 29517396] [CrossRef]
534.: Doshani M, Weng M, Moore KL, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness. MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):153–6. doi: 10.15585/mmwr.mm6806a6. PMID: 30763295. [PMC free article: PMC6375653] [PubMed: 30763295] [CrossRef]
535.: Dudley MZ, Halsey NA, Omer SB, et al. The state of vaccine safety science: systematic reviews of the evidence. Lancet Infect Dis. 2020 May;20(5):e80–e9. doi: 10.1016/S1473-3099(20)30130-4. PMID: 32278359. [PubMed: 32278359] [CrossRef]
536.: Dunkle LM, Izikson R. Recombinant hemagglutinin influenza vaccine provides broader spectrum protection. Expert Review of Vaccines. 2016;15(8):957–66. doi: 10.1080/14760584.2016.1203261. [PubMed: 27314982] [CrossRef]
537.: Eckerle I, Rosenberger KD, Zwahlen M, et al. Serologic Vaccination Response after Solid Organ Transplantation: A Systematic Review. PLoS ONE. 2013;8(2). doi: 10.1371/journal.pone.0056974. [PMC free article: PMC3579937] [PubMed: 23451126] [CrossRef]
538.: Ecollan M, Partouche H, Gilberg S. Vaccination against human papillomavirus State of the art in 2018. Exercer-La Revue Francophone De Medecine Generale. 2018 Nov(147):412–7. PMID: WOS:000463772900007.
539.: Eke AC, Eleje GU, Eke UA, et al. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database of Systematic Reviews. 2017(2):105. doi: 10.1002/14651858.CD008545.pub2. PMID: WOS:000396096600032. [PMC free article: PMC6464495] [PubMed: 28188612] [CrossRef]
540.: Eliakim-Raz N, Vinograd I, Trestioreanu AZ, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews. 2013(10):39. doi: 10.1002/14651858.CD008983.pub2. PMID: WOS:000326373200022. [PMC free article: PMC6457732] [PubMed: 24166741] [CrossRef]
541.: Erickson BK, Landers EE, Huh WK. Update on Vaccination Clinical Trials for HPV-Related Disease. Clinical Therapeutics. 2014 Jan;36(1):8–16. doi: 10.1016/j.clinthera.2013.11.003. PMID: WOS:000330254100003. [PubMed: 24417781] [CrossRef]
542.: Esposito S, Principi N. Safety and tolerability of pneumococcal vaccines in children. Expert Opinion on Drug Safety. 2016;15(6):777–85. doi: 10.1517/14740338.2016.1160056. PMID: WOS:000376526100008. [PubMed: 26923347] [CrossRef]
543.: Euctr BE. A trial to compare the immune response and safety of 3 doses of Sci-B-Vac™ compared to 3 doses of Engerix-B® in Adults. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-001819-36-BE. 2017. PMID: CN-01909296.
544.: Euctr BE. A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adults 18 to 40 years of age. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-003692-61-BE. 2018. PMID: CN-01908668.
545.: Euctr DE. Staggered vaccination compared to simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and Pneumokokkenpolysaccharidvakzine (PPV23) in unvaccinated older adults: immunological memory and antibody levels. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-004013-85-DE. 2015. PMID: CN-01802632.
546.: Euctr DE. Safety and tolerability of V114 in healthy infants. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003308-38-DE. 2018. PMID: CN-02068222.
547.: Euctr DK. Study of a Quadrivalent Meningococcal Conjugate Vaccine Compared with Two Meningococcal Reference Vaccines in Europeans Toddlers. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003790-10-DK. 2019. PMID: CN-02068307.
548.: Euctr DK. Lot-to-lot consistency of V114 in healthy adults. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-004266-33-DK. 2019. PMID: CN-02068391.
549.: Euctr EE. A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12–23 months of age. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-003535-30-EE. 2015. PMID: CN-01830164.
550.: Euctr EE. Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-001220-22-EE. 2017. PMID: CN-01900157.
551.: Euctr EE. A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults 10 to 40 years of age. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-003456-23-EE. 2018. PMID: CN-01896078.
552.: Euctr ES. Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increased antigenic load. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-002368-18-ES. 2018. PMID: CN-01905973.
553.: Euctr ES. A study to evaluate the safety and immunogenicity of GlaxoSmithKline’s Shingrix vaccine when given on a two-dose schedule to adults at least 50 years of age (YOA) who had prior episode of shingles. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-000744-34-ES. 2019. PMID: CN-02067567.
554.: Euctr ES. Safety and immunogenicity of V114 in healthy adults. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-004316-22-ES. 2019. PMID: CN-02068401.
555.: Euctr ES. A study to test GlaxoSmithKline’s (GSK) candidate vaccine-GSK1437173A for prevention of shingles in children with kidney transplant. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-000607-33-ES. 2019. PMID: CN-02068554.
556.: Euctr FI. A study to find out if vaccines designed to protect against a disease (meningococcal meningitis) is safe and protects people aged 10 to < 26 years. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-004421-17-FI. 2017. PMID: CN-01893293.
557.: Euctr FI. A trial to compare the immune response and safety of 3 doses of Sci-B-Vac™ compared to 3 doses of Engerix-B® in Adults. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-001819-36-FI. 2017. PMID: CN-01900905.
558.: Euctr FI. A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults 10 to 40 years of age. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-003456-23-FI. 2018. PMID: CN-01905343.
559.: Euctr FI. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine when co-administered with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-004731-36-FI. 2018. PMID: CN-01909382.
560.: Euctr FI. Safety and Immunogenicity of Catch-up Vaccination Regimens of V114. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003706-88-FI. 2019. PMID: CN-02068293.
561.: Euctr FI. Safety, Tolerability and Immunogenecity of V114 in healthy infants (PNEU-PED-EU-2). http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003788-70-FI. 2019. PMID: CN-02068306.
562.: Euctr GB. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-004520-30-GB. 2018. PMID: CN-02067784.
563.: Euctr GB. The 6-in-1 Vaccine Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003451-38-GB. 2019. PMID: CN-02068251.
564.: Euctr GR. Safety and Immunogenicity of V114 in Children with Sickle Cell Disease. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-001152-35-GR. 2019. PMID: CN-02067934.
565.: Euctr HU. A study to compare the safety and efficacy of Abbott’s Quadrivalent Influenza Vaccine versus a non-influenza vaccine in children aged 6–35 Months. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-004904-74-HU. 2018. PMID: CN-01910377.
566.: Euctr NL. A phase 2 clinical study into the immune responde and adverse effects of a Hepatitis B vaccine in subjects that do not respond (non-responders) to the Hepatitis B vaccine. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-002720-91-NL. 2016. PMID: CN-01884888.
567.: Euctr NL. Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and Older. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-000655-14-NL. 2019. PMID: CN-02068562.
568.: Euctr PL. Safety, Tolerability and Immunogenecity of V114 in healthy infants (PNEU-PED-EU-1). http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003787-31-PL. 2019. PMID: CN-02068305.
569.: Euctr SI. A study to compare the safety and efficacy of Abbott’s Quadrivalent Influenza Vaccine versus a non-influenza vaccine in children aged 6–35 Months. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-004904-74-SI. 2017. PMID: CN-01894679.
570.: Fell DB, Bhutta ZA, Hutcheon JA, et al. Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30–October 1, 2015. Vaccine. 2017;35(18):2279–87. doi: 10.1016/j.vaccine.2017.03.056. [PMC free article: PMC8274346] [PubMed: 28343772] [CrossRef]
571.: Fell DB, Platt RW, Lanes A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG : an international journal of obstetrics and gynaecology. 2015;122(1):17–26. doi: 10.1111/1471-0528.12977. [PubMed: 25040307] [CrossRef]
572.: Fiorito TM, Baird GL, Alexander-Scott N, et al. Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review. The Pediatric infectious disease journal. 2018;37(1):e13–e9. doi: 10.1097/INF.0000000000001742. [PubMed: 28834957] [CrossRef]
573.: Fischer BL. The Emerging Risks of Live Virus & Virus Vectored Vaccines: Vaccine Strain Virus Infection, Shedding & Transmission National Vaccine Information Center. 2014. https://www.nvic.org/vaccine-strain-virus-shedding-and-transmission.aspx
574.: Flacco ME, Manzoli L, Rosso A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. The Lancet. Infectious diseases. 2018;18(4):461–72. doi: 10.1016/S1473-3099(18)30048-3. [PubMed: 29371070] [CrossRef]
575.: Folaranmi T, Rubin L, Martin SW, et al. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):608–12. PMID: 26068564. [PMC free article: PMC4584923] [PubMed: 26068564]
576.: Foo DYP, Sarna M, Pereira G, et al. Early Childhood Health Outcomes Following In Utero Exposure to Influenza Vaccines: A Systematic Review. Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2020-0375. PMID: 32719088. [PubMed: 32719088] [CrossRef]
577.: Fortanier AC, Venekamp RP, Boonacker CWB, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews. 2014(4):57. doi: 10.1002/14651858.CD001480.pub4. PMID: WOS:000335885000003. [PubMed: 24696098] [CrossRef]
578.: Fortanier AC, Venekamp RP, Boonacker CWB, et al. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database of Systematic Reviews. 2019(5):74. doi: 10.1002/14651858.CD001480.pub5. PMID: WOS:000470014800026. [PMC free article: PMC6537667] [PubMed: 31135969] [CrossRef]
579.: Frederiksen JL, Topsoe Mailand M. Vaccines and multiple sclerosis. Acta Neurol Scand. 2017 Nov;136 Suppl 201:49–51. doi: 10.1111/ane.12837. PMID: 29068486. [PubMed: 29068486] [CrossRef]
580.: Fukuta H, Goto T, Wakami K, et al. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart failure reviews. 2019;24(1):109–14. doi: 10.1007/s10741-018-9736-6. [PubMed: 30367316] [CrossRef]
581.: Fulton TR, Narayanan D, Bonhoeffer J, et al. A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine. 2015;33(47):6453–65. doi: 10.1016/j.vaccine.2015.08.043. [PMC free article: PMC8290429] [PubMed: 26413879] [CrossRef]
582.: Fund CsH. Vaxxed Unvaxxed. https://childrenshealthdefense.org/wp-content/uploads/Vaxxed-Unvaxxed-Full-Presentation-1.pdf. Accessed on June 26, 2020.
583.: Furuta M, Sin J, Ng ESW, et al. Efficacy and safety of pertussis vaccination for pregnant women - a systematic review of randomised controlled trials and observational studies. BMC pregnancy and childbirth. 2017;17(1):390. doi: 10.1186/s12884-017-1559-2. [PMC free article: PMC5700667] [PubMed: 29166874] [CrossRef]
584.: Gagiardi AMZ, Andriolo BNG, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews. 2019(11):119. doi: 10.1002/14651858.CD008858.pub4. PMID: WOS:000504427100043. [PMC free article: PMC6836378] [PubMed: 31696946] [CrossRef]
585.: Gagliardi AMZ, Andriolo BNG, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews. 2016(3):165. doi: 10.1002/14651858.CD008858.pub3. PMID: WOS:000373475200029. [PMC free article: PMC6516976] [PubMed: 26937872] [CrossRef]
586.: Gagliardi AMZ, Silva BNG, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Sao Paulo Medical Journal. 2014;132(4):255-. doi: 10.1590/1516-3180.20141324t1. PMID: WOS:000341780600012. [PMC free article: PMC10496737] [PubMed: 25055074] [CrossRef]
587.: Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Human Vaccines and Immunotherapeutics. 2015;11(11):2556–63. doi: 10.1080/21645515.2015.1074358. [PMC free article: PMC4685684] [PubMed: 26291883] [CrossRef]
588.: Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. The Pediatric infectious disease journal. 2016;35(1):81–93. doi: 10.1097/INF.0000000000000930. [PubMed: 26398743] [CrossRef]
589.: Genovese C, La Fauci V, Squeri A, et al. HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. Journal of preventive medicine and hygiene. 2018;59(3):E194–E9. doi: 10.15167/2421-4248/jpmh2018.59.3.998. [PMC free article: PMC6196376] [PubMed: 30397675] [CrossRef]
590.: Giles ML, Krishnaswamy S, Macartney K, et al. The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review. Human vaccines & immunotherapeutics. 2019;15(3):687–99. doi: 10.1080/21645515.2018.1540807. [PMC free article: PMC6605784] [PubMed: 30380986] [CrossRef]
591.: Gkentzi D, Katsakiori P, Marangos M, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Archives of disease in childhood. Fetal and neonatal edition. 2017;102(5):F456–F63. doi: 10.1136/archdischild-2016-312341. [PubMed: 28468899] [CrossRef]
592.: Glanz JM, Newcomer SR, Jackson ML, et al. White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine. 2016;34:A1–A29. doi: 10.1016/j.vaccine.2015.10.082. [PubMed: 26830300] [CrossRef]
593.: Goossen GM, Kremer LCM, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database of Systematic Reviews. 2013(8):37. doi: 10.1002/14651858.CD006484.pub3. PMID: WOS:000323928600043. [PMC free article: PMC6466690] [PubMed: 23904194] [CrossRef]
594.: Grande AJ, Reid H, Thomas EE, et al. Exercise prior to influenza vaccination for limiting influenza incidence and its related complications in adults. Cochrane Database of Systematic Reviews. 2016(8):46. doi: 10.1002/14651858.CD011857.pub2. PMID: WOS:000389598200038. [PMC free article: PMC8504432] [PubMed: 27545762] [CrossRef]
595.: Grazina I, Mannocci A, Meggiolaro A, et al. Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. Annali di igiene : medicina preventiva e di comunita. 2020;32(1):81–96. doi: 10.7416/ai.2020.2333. [PubMed: 31713580] [CrossRef]
596.: GreenMedinfo. Vaccination: All. https://www.greenmedinfo.com/anti-therapeutic-action/vaccination-all. Accessed on June 26 2020.
597.: Gresset-Bourgeois V, Leventhal PS, Pepin S, et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Review of Vaccines. 2018;17(1):1–11. doi: 10.1080/14760584.2018.1407650. [PubMed: 29157068] [CrossRef]
598.: Griffin MR. Influenza Vaccination of Healthcare Workers: Making the Grade for Action. Clinical Infectious Diseases. 2014 Jan;58(1):58–60. doi: 10.1093/cid/cit590. PMID: WOS:000329044800015. [PubMed: 24046312] [CrossRef]
599.: Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Aug 15;63(32):691–7. PMID: 25121712. [PMC free article: PMC4584910] [PubMed: 25121712]
600.: Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818–25. doi: 10.15585/mmwr.mm6430a3. PMID: 26247435. [PMC free article: PMC5779578] [PubMed: 26247435] [CrossRef]
601.: Guido M, Bruno A, Tagliaferro L, et al. Universal Human Papillomavirus Vaccination and its Impact on the Southern Italian Region. Current Pharmaceutical Design. 2020;26(3):343–57. doi: 10.2174/1381612826666200212115840. PMID: WOS:000520856900007. [PubMed: 32048956] [CrossRef]
602.: Guo B, Page A, Wang H, et al. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. Vaccine. 2013 Jan 11;31(4):603–17. doi: 10.1016/j.vaccine.2012.11.051. PMID: 23200940. [PubMed: 23200940] [CrossRef]
603.: Guo J, Bolivar-Wagers S, Srinivas N, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235–42. doi: 10.1016/j.vaccine.2015.01.018. [PMC free article: PMC5529169] [PubMed: 25600519] [CrossRef]
604.: Guo Q, Liu Z, Gao J, et al. Immunogenicity and Safety of Pandemic Influenza H5N1 Vaccines in Healthy Adults through Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016;40(5):921–32. [PubMed: 27941323]
605.: Hale SF, Camaione L, Lomaestro BM. MenHibrix: A New Combination Meningococcal Vaccine for Infants and Toddlers. Annals of Pharmacotherapy. 2014 Mar;48(3):404–11. doi: 10.1177/1060028013514375. PMID: WOS:000332497600014. [PubMed: 24353263] [CrossRef]
606.: Halsey NA, Talaat KR, Greenbaum A, et al. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine. 2015 Dec;33:F1–F67. doi: 10.1016/j.vaccine.2015.10.080. PMID: WOS:000370087400001. [PubMed: 26822822] [CrossRef]
607.: Han HH. The human rotavirus vaccine Rotarix in infants: an integrated analysis of safety and reactogenicity. Human vaccines & immunotherapeutics. 2014;10(1):19–24. doi: 10.4161/hv.26476. PMID: CN-01047260. [PMC free article: PMC4181014] [PubMed: 24047799] [CrossRef]
608.: Harder T, Wichmann O, Klug SJ, et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: A systematic review. BMC Medicine. 2018;16(1). doi: 10.1186/s12916-018-1098-3. [PMC free article: PMC6050686] [PubMed: 30016957] [CrossRef]
609.: Harmala S, Parisinos C, Shallcross L, et al. Effectiveness of pneumococcal and influenza vaccines to prevent serious health complications in adults with chronic liver disease: a protocol for a systematic review. BMJ open. 2018;8(3):e018223. doi: 10.1136/bmjopen-2017-018223. [PMC free article: PMC5857657] [PubMed: 29549199] [CrossRef]
610.: Harmala S, Parisinos CA, Shallcross L, et al. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ open. 2019;9(9):e031070. doi: 10.1136/bmjopen-2019-031070. [PMC free article: PMC6731888] [PubMed: 31494620] [CrossRef]
611.: Haugh M, Gresset-Bourgeois V, Macabeo B, et al. A trivalent, inactivated influenza vaccine (Vaxigrip (R)): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Review of Vaccines. 2017;16(6):545–64. doi: 10.1080/14760584.2017.1324302. PMID: WOS:000401437800004. [PubMed: 28460594] [CrossRef]
612.: Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):77–83. doi: 10.15585/mmwr.mm6903a5. PMID: 31971933. [PMC free article: PMC7367039] [PubMed: 31971933] [CrossRef]
613.: Hawkes N. HPV vaccine safety: Cochrane launches urgent investigation into review after criticisms. BMJ. 2018 Aug 9;362:k3472. doi: 10.1136/bmj.k3472. PMID: 30101747. [PubMed: 30101747] [CrossRef]
614.: Hebsur S, Vakil E, Oetgen WJ, et al. Influenza and coronary artery disease: Exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction. Reviews in Cardiovascular Medicine. 2014;15(2):168–75. doi: 10.3909/ricm0692. [PubMed: 25051134] [CrossRef]
615.: Higgins JPT, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: Systematic review. BMJ (Online). 2016;355. doi: 10.1136/bmj.i5170. [PMC free article: PMC5063034] [PubMed: 27737834] [CrossRef]
616.: Hills SL, Walter EB, Atmar RL, et al. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019 Jul 19;68(2):1–33. doi: 10.15585/mmwr.rr6802a1. PMID: 31518342. [PMC free article: PMC6659993] [PubMed: 31518342] [CrossRef]
617.: Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis care & research. 2014;66(7):1016–26. doi: 10.1002/acr.22246. [PubMed: 24339395] [CrossRef]
618.: Huang CY, Fu XF, Zhou YG, et al. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine. 2020 Feb;38(6):1332–44. doi: 10.1016/j.vaccine.2019.11.071. PMID: WOS:000515445900007. [PubMed: 31948819] [CrossRef]
619.: Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Current medical research and opinion. 2017;33(10):1901–8. doi: 10.1080/03007995.2017.1329140. [PubMed: 28489423] [CrossRef]
620.: Huang Y, Wang H, Wan L, et al. Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis. Medicine. 2016;95(19):e3637. doi: 10.1097/MD.0000000000003637. [PMC free article: PMC4902520] [PubMed: 27175678] [CrossRef]
621.: Hughes MM, Reed C, Flannery B, et al. Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden in the United States. Clin Infect Dis. 2020 Jun 10;70(12):2496–502. doi: 10.1093/cid/ciz676. PMID: 31344229. [PMC free article: PMC6980871] [PubMed: 31344229] [CrossRef]
622.: Hung IFN, Yuen KY. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Human Vaccines & Immunotherapeutics. 2018;14(3):565–70. doi: 10.1080/21645515.2017.1328332. PMID: WOS:000428053800019. [PMC free article: PMC5861844] [PubMed: 28604266] [CrossRef]
623.: International Chiropractors Association. Truth will prevail: 1200 studies to vaccinate or not to vaccinate? ; 2018. http://www.chiropractic.org/wp-content/uploads/2018/12/1200-studies-The-Truth-Will-Prevail-3.pdf.
624.: International Chiropractors Association. Truth will prevail: 1200 studies that refute vaccine claims. 2020. http://www.chiropractic.org/wp-content/uploads/2020/05/1200-studies-The-Truth-Will-Prevail-v2.6_05-05-20.pdf. Accessed on June 25 2020.
625.: IOM (Instituite of Medicine). Immunization Safety Review: Multiple Immunizations and Immune Dysfunction: The National Academies Press; 2002. [PubMed: 25057595]
626.: Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015;14(10):1313–29. doi: 10.1586/14760584.2015.1075883. PMID: 26289975. [PubMed: 26289975] [CrossRef]
627.: Isrctn. The transmission of pneumococcus in family units study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN10720581. 2019. PMID: CN-02070013.
628.: James SF, Chahine EB, Sucher AJ, et al. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Annals of Pharmacotherapy. 2018 Jul;52(7):673–80. doi: 10.1177/1060028018758431. PMID: WOS:000434314800009. [PubMed: 29457489] [CrossRef]
629.: Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. The Cochrane database of systematic reviews. 2014;3. [PubMed: 17443504]
630.: Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. The Cochrane database of systematic reviews. 2018;2:CD004879. doi: 10.1002/14651858.CD004879.pub5. [PMC free article: PMC6491174] [PubMed: 29388195] [CrossRef]
631.: Jeong S, Jang EJ, Jo J, et al. Effects of maternal influenza vaccination on adverse birth outcomes: A systematic review and Bayesian meta-analysis. PloS one. 2019;14(8):e0220910. doi: 10.1371/journal.pone.0220910. [PMC free article: PMC6693758] [PubMed: 31412058] [CrossRef]
632.: Jiang H-Y, Shi Y-D, Zhang X, et al. Human papillomavirus vaccination and the risk of autoimmune disorders: A systematic review and meta-analysis. Vaccine. 2019;37(23):3031–9. doi: 10.1016/j.vaccine.2019.04.049. [PubMed: 31036452] [CrossRef]
633.: Jorgensen L, Gotzsche PC, Jefferson T. Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. Syst Rev. 2020 Feb 28;9(1):43. doi: 10.1186/s13643-019-0983-y. PMID: 32106879. [PMC free article: PMC7047375] [PubMed: 32106879] [CrossRef]
634.: Jorgensen L, Gotzsche PC, Jefferson T. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. Syst Rev. 2020 Feb 28;9(1):42. doi: 10.1186/s13643-020-01300-1. PMID: 32106871. [PMC free article: PMC7047365] [PubMed: 32106871] [CrossRef]
635.: Joura EA. Clinical efficacy and immunogenicity of the nonavalent HPV Vaccine. Acta cytologica. 2016;Conference: 19th International Congress of Cytology. Japan. 60(Supplement 1):35–6. PMID: CN-01707304.
636.: Juergens C, Trammel J, Shoji Y, et al. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Human vaccines & immunotherapeutics. 2018;14(8):1948–56. doi: 10.1080/21645515.2018.1452576. [PMC free article: PMC6149808] [PubMed: 29543583] [CrossRef]
637.: Kahn KE, Black CL, Ding H, et al. Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018. MMWR Morb Mortal Wkly Rep. 2018 Sep 28;67(38):1055–9. doi: 10.15585/mmwr.mm6738a3. PMID: 30260946. [PMC free article: PMC6188122] [PubMed: 30260946] [CrossRef]
638.: Karnchanasorn R, Ou HY, Lin J, et al. Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination. Curr Diab Rep. 2016 Oct;16(10):101. doi: 10.1007/s11892-016-0790-y. PMID: 27620495. [PubMed: 27620495] [CrossRef]
639.: Kash N, Lee MA, Kollipara R, et al. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. Journal of Clinical Medicine. 2015 Apr;4(4):614–33. doi: 10.3390/jcm4040614. PMID: WOS:000363138900007. [PMC free article: PMC4470159] [PubMed: 26239350] [CrossRef]
640.: Kassim P, Eslick GD. Risk of intussusception following rotavirus vaccination: An evidence based meta-analysis of cohort and case-control studies. Vaccine. 2017;35(33):4276–86. doi: 10.1016/j.vaccine.2017.05.064. [PubMed: 28648544] [CrossRef]
641.: Kct. A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 years in Korea. http://www.who.int/trialsearch/Trial2.aspx?TrialID=KCT0001103. 2014. PMID: CN-01875083.
642.: Keating GM. Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia. BioDrugs. 2016;30(3):243–54. doi: 10.1007/s40259-016-0180-7. [PubMed: 27189459] [CrossRef]
643.: King JP, Hanson KE, Donahue JG, et al. Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016–17 season. Vaccine. 2020 Feb 24;38(9):2202–8. doi: 10.1016/j.vaccine.2020.01.039. PMID: 31992481. [PMC free article: PMC7869019] [PubMed: 31992481] [CrossRef]
644.: Kliner M, Keenan A, Sinclair D, et al. Influenza vaccination for healthcare workers in the UK: appraisal of systematic reviews and policy options. BMJ open. 2016;6(9):e012149. doi: 10.1136/bmjopen-2016-012149. [PMC free article: PMC5030547] [PubMed: 27625062] [CrossRef]
645.: Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):944–7. doi: 10.15585/mmwr.mm6434a4. PMID: 26334788. [PubMed: 26334788] [CrossRef]
646.: Koch J, Harder T, von Kries R, et al. Risk of Intussusception After Rotavirus Vaccination. Dtsch Arztebl Int. 2017 Apr 14;114(15):255–62. doi: 10.3238/arztebl.2017.0255. PMID: 28468712. [PMC free article: PMC5424085] [PubMed: 28468712] [CrossRef]
647.: Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews. 2018(6):76. doi: 10.1002/14651858.CD002733.pub3. PMID: WOS:000436781300041. [PMC free article: PMC6513384] [PubMed: 29943802] [CrossRef]
648.: Kuehn B. US Narrowly Preserves Measles Elimination Status. JAMA. 2019;322(20):1949-. doi: 10.1001/jama.2019.18901. [PubMed: 31769833] [CrossRef]
649.: Kuter BJ, Brown M, Wiedmann RT, et al. Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009. The Pediatric infectious disease journal. 2016;35(9):1011–20. doi: 10.1097/INF.0000000000001241. [PubMed: 27254037] [CrossRef]
650.: La Torre G, Mannocci A, Colamesta V, et al. Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety. Mediterranean journal of hematology and infectious diseases. 2016;8(1):e2016044. doi: 10.4084/MJHID.2016.044. [PMC free article: PMC5016013] [PubMed: 27648207] [CrossRef]
651.: Lai J-J, Lin C, Ho C-L, et al. Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials. Journal of clinical medicine. 2019;8(5). doi: 10.3390/jcm8050590. [PMC free article: PMC6571572] [PubMed: 31035712] [CrossRef]
652.: Laris-Gonzalez A, Bernal-Serrano D, Jarde A, et al. Safety of Administering Live Vaccines During Pregnancy: A Systematic Review and Meta-Analysis of Pregnancy Outcomes. Vaccines (Basel). 2020 Mar 11;8(1). doi: 10.3390/vaccines8010124. PMID: 32168941. [PMC free article: PMC7157743] [PubMed: 32168941] [CrossRef]
653.: LeBras MH, Barry AR. Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review. The Canadian journal of hospital pharmacy. 2017;70(1):27–34. [PMC free article: PMC5358055] [PubMed: 28348430]
654.: Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert review of vaccines. 2018;17(5):435–43. doi: 10.1080/14760584.2018.1471989. [PubMed: 29715054] [CrossRef]
655.: Lee KR, Bae JH, Hwang IC, et al. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48(3–4):103–10. doi: 10.1159/000478017. PMID: 28628919. [PubMed: 28628919] [CrossRef]
656.: Lee M-D, Lin C-H, Lei W-T, et al. Does Vitamin D Deficiency Affect the Immunogenic Responses to Influenza Vaccination? A Systematic Review and Meta-Analysis. Nutrients. 2018;10(4). doi: 10.3390/nu10040409. [PMC free article: PMC5946194] [PubMed: 29587438] [CrossRef]
657.: Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology. 2013 Jul;10(7):400–10. doi: 10.1038/nrclinonc.2013.84. PMID: WOS:000321009700007. [PubMed: 23736648] [CrossRef]
658.: Leite A, Andrews NJ, Thomas SL. Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods. Pharmacoepidemiology and drug safety. 2016;25(3):225–37. doi: 10.1002/pds.3966. [PMC free article: PMC5021108] [PubMed: 26817940] [CrossRef]
659.: Leung JH, Hirai HW, Tsoi KK. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Expert review of vaccines. 2015;14(8):1149–57. doi: 10.1586/14760584.2015.1057572. [PubMed: 26081133] [CrossRef]
660.: Levin MJ, Bresnitz E, Popmihajlov Z, et al. Studies with herpes zoster vaccines in immune compromised patients. Expert Review of Vaccines. 2017;16(12):1217–30. doi: 10.1080/14760584.2017.1395703. PMID: WOS:000415967400006. [PubMed: 29053937] [CrossRef]
661.: Li X, Ma S-J, Liu X, et al. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Human vaccines & immunotherapeutics. 2014;10(12):3579–93. doi: 10.4161/21645515.2014.980197. [PMC free article: PMC4514081] [PubMed: 25668666] [CrossRef]
662.: Li-Kim-Moy J, Yin JK, Rashid H, et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2015;20(24). [PubMed: 26111238]
663.: Liang J, Wallace G, Mootrey G. Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose. MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):948–9. doi: 10.15585/mmwr.mm6434a5. PMID: 26334944. [PubMed: 26334944] [CrossRef]
664.: Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018 Apr 27;67(2):1–44. doi: 10.15585/mmwr.rr6702a1. PMID: 29702631. [PMC free article: PMC5919600] [PubMed: 29702631] [CrossRef]
665.: Lim SG, Agcaoili J, De Souza NNA, et al. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. Journal of viral hepatitis. 2019;26(7):803–17. doi: 10.1111/jvh.13085. [PubMed: 30801899] [CrossRef]
666.: Lin YJ, Wen CN, Lin YY, et al. Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis. Nature Communications. 2020;11(1). doi: 10.1038/s41467-019-14230-x. [PMC free article: PMC6965081] [PubMed: 31949137] [CrossRef]
667.: Lindley MC, Kahn KE, Bardenheier BH, et al. Vital Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants - United States. MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):885–92. doi: 10.15585/mmwr.mm6840e1. PMID: 31600186. [PMC free article: PMC6788399] [PubMed: 31600186] [CrossRef]
668.: Lindsey BB, Armitage EP, Kampmann B, et al. The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. The Lancet. Infectious diseases. 2019;19(4):e110–e9. doi: 10.1016/S1473-3099(18)30490-0. [PubMed: 30553695] [CrossRef]
669.: Liu XC, Bell CA, Simmonds KA, et al. Adverse events following HPV vaccination, Alberta 2006–2014. Vaccine. 2016 Apr 4;34(15):1800–5. doi: 10.1016/j.vaccine.2016.02.040. PMID: 26921782. [PubMed: 26921782] [CrossRef]
670.: Loevinsohn G, Rosman L, Moss WJ. Measles Seroprevalence and Vaccine Responses in Human Immunodeficiency Virus-infected Adolescents and Adults: A Systematic Review. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;69(5):836–44. doi: 10.1093/cid/ciy980. [PubMed: 30452621] [CrossRef]
671.: Loharikar A, Suragh TA, MacDonald NE, et al. Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness. Vaccine. 2018;36(2):299–305. doi: 10.1016/j.vaccine.2017.11.017. [PubMed: 29198916] [CrossRef]
672.: Lorenc T, Marshall D, Wright K, et al. Seasonal influenza vaccination of healthcare workers: systematic review of qualitative evidence. BMC health services research. 2017;17(1):732. doi: 10.1186/s12913-017-2703-4. [PMC free article: PMC5688738] [PubMed: 29141619] [CrossRef]
673.: Loubet P, Loulergue P, Galtier F, et al. Seasonal influenza vaccination of high-risk adults. Expert Review of Vaccines. 2016 Dec;15(12):1507–18. doi: 10.1080/14760584.2016.1188696. PMID: WOS:000388964400005. [PubMed: 27169689] [CrossRef]
674.: Lu H-L, Ding Y, Goyal H, et al. Association Between Rotavirus Vaccination and Risk of Intussusception Among Neonates and Infants: A Systematic Review and Meta-analysis. JAMA network open. 2019;2(10):e1912458. doi: 10.1001/jamanetworkopen.2019.12458. [PMC free article: PMC6784808] [PubMed: 31584679] [CrossRef]
675.: Ma S-J, Li X, Xiong Y-Q, et al. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. Medicine. 2015;94(44):e1721. doi: 10.1097/MD.0000000000001721. [PMC free article: PMC4915870] [PubMed: 26554769] [CrossRef]
676.: Ma S-J, Xiong Y-Q, Jiang L-N, et al. Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A systematic review and meta-analysis. Vaccine. 2015;33(31):3636–49. doi: 10.1016/j.vaccine.2015.06.009. [PubMed: 26073015] [CrossRef]
677.: Machaira M, Papaevangelou V, Vouloumanou EK, et al. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg− mothers: a systematic review and meta-analysis. The Journal of antimicrobial chemotherapy. 2015;70(2):396–404. doi: 10.1093/jac/dku404. [PubMed: 25362571] [CrossRef]
678.: Macias Saint-Gerons D, Solà Arnau I, De Mucio B, et al. Adverse events associated with the use of recommended vaccines during pregnancy: An overview of systematic reviews. Vaccine. 2020 Sep 21. doi: 10.1016/j.vaccine.2020.07.048. PMID: 32972737. [PubMed: 32972737] [CrossRef]
679.: Macki M, Dabaja AA. Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic and clinical andrology. 2016;26:16. [PMC free article: PMC5116857] [PubMed: 27895921]
680.: Macklin G, Liao Y, Takane M, et al. Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry. Front Immunol. 2017;8:1103. doi: 10.3389/fimmu.2017.01103. PMID: 28993765. [PMC free article: PMC5622164] [PubMed: 28993765] [CrossRef]
681.: MacNeil JR, Rubin L, Folaranmi T, et al. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Oct 23;64(41):1171–6. doi: 10.15585/mmwr.mm6441a3. PMID: 26492381. [PubMed: 26492381] [CrossRef]
682.: MacNeil JR, Rubin LG, Patton M, et al. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2016 Nov 4;65(43):1189–94. doi: 10.15585/mmwr.mm6543a3. PMID: 27811836. [PubMed: 27811836] [CrossRef]
683.: Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017 Jun;264(6):1035–50. doi: 10.1007/s00415-016-8263-4. PMID: 27604618. [PubMed: 27604618] [CrossRef]
684.: Marangu D, Kovacs S, Walson J, et al. Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. Vaccine. 2015;33(41):5333–41. doi: 10.1016/j.vaccine.2015.08.060. [PMC free article: PMC4743983] [PubMed: 26319071] [CrossRef]
685.: Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Jun 22;56(Rr-4):1–40. PMID: 17585291. [PubMed: 17585291]
686.: Marin M, Patel M, Oberste S, et al. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States. MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):23–5. doi: 10.15585/mmwr.mm6601a6. PMID: 28081056. [PMC free article: PMC5687270] [PubMed: 28081056] [CrossRef]
687.: Marra F, Vadlamudi NK. Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults. Aging and Disease. 2019 Apr;10(2):404–18. doi: 10.14336/ad.2018.0512. PMID: WOS:000463718400014. [PMC free article: PMC6457056] [PubMed: 31011485] [CrossRef]
688.: Martin Arias LH, Sanz R, Sainz M, et al. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015 Jul 17;33(31):3773–8. doi: 10.1016/j.vaccine.2015.05.013. PMID: 25999283. [PubMed: 25999283] [CrossRef]
689.: Martínez-Lavín M, Amezcua-Guerra L. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clinical Rheumatology. 2017;36(10):2169–78. doi: 10.1007/s10067-017-3768-5. [PubMed: 28730271] [CrossRef]
690.: Martinez-Sernandez V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. Journal of neurology. 2013;260(8):1951–9. doi: 10.1007/s00415-012-6716-y. [PubMed: 23086181] [CrossRef]
691.: Masuka JT, Khoza S. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase(R) from 1997 to 2017. BMC Public Health. 2019 Aug 27;19(1):1166. doi: 10.1186/s12889-019-7482-x. PMID: 31455314. [PMC free article: PMC6712865] [PubMed: 31455314] [CrossRef]
692.: Matanock A, Lee G, Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069–75. doi: 10.15585/mmwr.mm6846a5. PMID: 31751323. [PMC free article: PMC6871896] [PubMed: 31751323] [CrossRef]
693.: Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. Mmwr Recommendations and Reports. 2020 Sep;69(9):41. PMID: WOS:000575106400001. [PMC free article: PMC7527029] [PubMed: 33417592]
694.: McKeage K, Lyseng-Williamson KA. 9-Valent human papillomavirus recombinant vaccine (Gardasil® 9): a guide to its use in the EU. Drugs and Therapy Perspectives. 2016;32(10):414–21. doi: 10.1007/s40267-016-0337-y. [CrossRef]
695.: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Jun 14;62(Rr-04):1–34. PMID: 23760231. [PubMed: 23760231]
696.: McMillan M, Clarke M, Parrella A, et al. Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy: A Systematic Review. Obstetrics and gynecology. 2017;129(3):560–73. doi: 10.1097/AOG.0000000000001888. [PubMed: 28178054] [CrossRef]
697.: McMillan M, Kralik D, Porritt K, et al. Influenza vaccination during pregnancy: A systematic review of effectiveness and safety. JBI Database of Systematic Reviews and Implementation Reports. 2014;12(6):281–381. doi: 10.11124/jbisrir-2014-1269. [CrossRef]
698.: McMillan M, Porritt K, Kralik D, et al. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine. 2015;33(18):2108–17. doi: 10.1016/j.vaccine.2015.02.068. [PubMed: 25758932] [CrossRef]
699.: Mehtani NJ, Rosman L, Moss WJ. Immunogenicity and Safety of Measles Vaccine in HIV-infected Children: an Updated Systematic Review. American journal of epidemiology. 2019. doi: 10.1093/aje/kwz144. [PubMed: 31210268] [CrossRef]
700.: Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702. doi: 10.15585/mmwr.mm6832a3. [PMC free article: PMC6818701] [PubMed: 31415491] [CrossRef]
701.: Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405–8. doi: 10.15585/mmwr.mm6549a5. PMID: 27977643. [PubMed: 27977643] [CrossRef]
702.: Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698–702. doi: 10.15585/mmwr.mm6832a3. PMID: 31415491. [PMC free article: PMC6818701] [PubMed: 31415491] [CrossRef]
703.: Mellerson J, Maxwell C, Knighton C, et al. Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten – United States, 2017–18 School Year. Morbidity and Mortality Weekly Report (MMWR). 2018;67(40):1115–22. [PMC free article: PMC6181259] [PubMed: 30307904]
704.: Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Human Vaccines and Immunotherapeutics. 2015;11(11):2582–98. doi: 10.1080/21645515.2015.1055424. [PMC free article: PMC4685678] [PubMed: 26208678] [CrossRef]
705.: Meng ZY, Zhang JY, Zhang ZG, et al. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18–64 years: A systematic review and Meta-analysis]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2018;39(12):1636–41. doi: 10.3760/cma.j.issn.0254-6450.2018.12.019. [PubMed: 30572392] [CrossRef]
706.: Miller N. Aluminum in Childhood Vaccines is Unsafe. 2016 12/21;21:109–17.
707.: Mo Y, Zeng J, Xiao C, et al. Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis. Vaccine. 2020. doi: 10.1016/j.vaccine.2020.09.080. [PubMed: 33059969] [CrossRef]
708.: Moa AM, Chughtai AA, Muscatello DJ, et al. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092–102. doi: 10.1016/j.vaccine.2016.06.064. [PubMed: 27381642] [CrossRef]
709.: Montomoli E, Torelli A, Manini I, et al. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children >= 6 Months and Older Adults. Vaccines. 2018 Mar;6(1):19. doi: 10.3390/vaccines6010014. PMID: WOS:000443917800013. [PMC free article: PMC5874655] [PubMed: 29518013] [CrossRef]
710.: Moreira ED, Jr., Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016;138(2). doi: 10.1542/peds.2015-4387. [PubMed: 27422279] [CrossRef]
711.: Moreira ED, Giuliano AR, de Hoon J, et al. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Human vaccines & immunotherapeutics. 2018;14(2):396–403. doi: 10.1080/21645515.2017.1403700. [PMC free article: PMC5806635] [PubMed: 29211620] [CrossRef]
712.: Morgan E, Halliday SR, Campbell GR, et al. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia. 2016 Feb;59(2):237–43. doi: 10.1007/s00125-015-3800-8. PMID: 26564178. [PMC free article: PMC4705121] [PubMed: 26564178] [CrossRef]
713.: Mouchet J, Salvo F, Raschi E, et al. Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. Vaccine. 2018;36(12):1548–55. doi: 10.1016/j.vaccine.2018.02.036. [PubMed: 29454521] [CrossRef]
714.: Mulley WR, Le STT, Ives KE. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017;32(1):136–43. doi: 10.1093/ndt/gfv443. [PubMed: 26763670] [CrossRef]
715.: Munoz-Alia MA, Muller CP, Russell SJ. Antigenic Drift Defines a New D4 Subgenotype of Measles Virus. J Virol. 2017 Jun 1;91(11). doi: 10.1128/JVI.00209-17. PMID: 28356529. [PMC free article: PMC5432853] [PubMed: 28356529] [CrossRef]
716.: Mutsaerts EAML, Nunes MC, van Rijswijk MN, et al. Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis. EClinicalMedicine. 2018;1:28–42. doi: 10.1016/j.eclinm.2018.06.002. [PMC free article: PMC6537570] [PubMed: 31193646] [CrossRef]
717.: Myers TR, McNeil MM. Current safety issues with quadrivalent meningococcal conjugate vaccines. Human Vaccines & Immunotherapeutics. 2018;14(5):1175–8. doi: 10.1080/21645515.2017.1366393. PMID: WOS:000433960500029. [PMC free article: PMC5989904] [PubMed: 28934061] [CrossRef]
718.: Myers TR, McNeil MM, Ng CS, et al. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010–2015. Vaccine. 2017 Mar 27;35(14):1758–63. doi: 10.1016/j.vaccine.2017.02.030. PMID: 28262331. [PMC free article: PMC5444082] [PubMed: 28262331] [CrossRef]
719.: Naleway AL, Irving SA, Henninger ML, et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine. 2014 May 30;32(26):3122–7. doi: 10.1016/j.vaccine.2014.04.021. PMID: 24742490. [PMC free article: PMC5898611] [PubMed: 24742490] [CrossRef]
720.: Nasser R, Rakedzon S, Dickstein Y, et al. Are all vaccines safe for the pregnant traveler? A systematic review and metaanalysis. Journal of travel medicine. 2019. doi: 10.1093/jtm/taz074. [PubMed: 31616947] [CrossRef]
721.: National Center for Immunization and Respiratory Diseases Office of the Director. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. 2016 11/29.
722.: National Vaccine Information Center. Merck’s Gardasil Vaccine Not Proven Safe for Little Girls. June 27, 2006. https://protect2.fireeye.com/url?k=fdc3511e-a19658ce-fdc36021-0cc47a6a52de-071930cdc1bf753e&u=https://www.nvic.org/nvic-archives/pressrelease/gardasilgirls.aspx. Accessed on June 25 2020.
723.: Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018 Nov 2;67(43):1216–20. doi: 10.15585/mmwr.mm6743a5. PMID: 30383742. [PMC free article: PMC6319798] [PubMed: 30383742] [CrossRef]
724.: Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1–38. doi: 10.15585/mmwr.rr6905a1. PMID: 32614811. [PMC free article: PMC8631741] [PubMed: 32614811] [CrossRef]
725.: Nolan T, O’Ryan M, Wassil J, et al. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine. 2015 Aug;33(36):4437–45. doi: 10.1016/j.vaccine.2015.06.011. PMID: WOS:000360867500013. [PubMed: 26187261] [CrossRef]
726.: Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine. 2014;32(23):2670–4. doi: 10.1016/j.vaccine.2013.12.037. [PubMed: 24412351] [CrossRef]
727.: Nunes MC, Aqil AR, Omer SB, et al. The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis. American Journal of Perinatology. 2016;33(11):1104–14. doi: 10.1055/s-0036-1586101. [PubMed: 27603545] [CrossRef]
728.: Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Dec 10;59(Rr-11):1–18. PMID: 21150868. [PubMed: 21150868]
729.: O’Ryan M, Giaquinto C, Benninghoff B. Human rotavirus vaccine (Rotarix): focus on effectiveness and impact 6 years after first introduction in Africa. Expert Review of Vaccines. 2015 Aug;14(8):1099–112. doi: 10.1586/14760584.2015.1059282. PMID: WOS:000357952200008. [PubMed: 26098566] [CrossRef]
730.: O’Ryan M, Stoddard J, Toneatto D, et al. A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs. 2014 Jan;74(1):15–30. doi: 10.1007/s40265-013-0155-7. PMID: WOS:000329827400003. [PMC free article: PMC3890039] [PubMed: 24338083] [CrossRef]
731.: Ogawa Y, Takei H, Ogawa R, et al. Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. Journal of pharmaceutical health care and sciences. 2017;3:18. doi: 10.1186/s40780-017-0087-6. [PMC free article: PMC5504559] [PubMed: 28702209] [CrossRef]
732.: Omeñaca F, Vázquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK’s hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine. 2018;36(7):986–96. doi: 10.1016/j.vaccine.2018.01.005. [PubMed: 29336924] [CrossRef]
733.: Omer SB, Enger KS, Moulton LH, et al. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol. 2008 Dec 15;168(12):1389–96. doi: 10.1093/aje/kwn263. PMID: 18922998. [PubMed: 18922998] [CrossRef]
734.: Opri R, Veneri D, Mengoli C, et al. Immune response to Hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis. Human vaccines & immunotherapeutics. 2015;11(12):2800–5. doi: 10.1080/21645515.2015.1069448. [PMC free article: PMC5054794] [PubMed: 26378476] [CrossRef]
735.: Østerhus SF. Influenza vaccination: a summary of Cochrane Reviews. European Journal of Clinical Microbiology & Infectious Diseases. 2014. doi: 10.1007/s10096-014-2236-2. [PubMed: 25185860] [CrossRef]
736.: Panozzo CA, Pourmalek F, Brauchli Pernus Y, et al. Arthritis and arthralgia as an adverse event following immunization: A systematic literature review. Vaccine. 2019;37(2):372–83. doi: 10.1016/j.vaccine.2018.06.067. [PubMed: 30502066] [CrossRef]
737.: Patterson J, Kagina BM, Gold M, et al. Adverse events following primary and secondary immunisation with whole-cell pertussis: a systematic review protocol. BMJ open. 2017;7(1):e012945. doi: 10.1136/bmjopen-2016-012945. [PMC free article: PMC5278269] [PubMed: 28122832] [CrossRef]
738.: Patterson J, Kagina BM, Gold M, et al. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine. 2018;36(40):6007–16. doi: 10.1016/j.vaccine.2018.08.022. [PubMed: 30143272] [CrossRef]
739.: Patton ME, Stephens D, Moore K, et al. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):509–13. doi: 10.15585/mmwr.mm6619a6. PMID: 28520709. [PMC free article: PMC5657641] [PubMed: 28520709] [CrossRef]
740.: Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014 Jul;13(7):736–41. doi: 10.1016/j.autrev.2014.01.054. PMID: 24468416. [PubMed: 24468416] [CrossRef]
741.: Pereira P, Vetter V, Standaert B, et al. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert review of vaccines. 2020;19(8):755–69. doi: 10.1080/14760584.2020.1800459. [PubMed: 32729747] [CrossRef]
742.: Perricone C, Shoenfeld Y. Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia). J Clin Rheumatol. 2013 Aug;19(5):231–3. doi: 10.1097/RHU.0b013e31829d56f1. PMID: 23884184. [PubMed: 23884184] [CrossRef]
743.: Petersen BW, Harms TJ, Reynolds MG, et al. Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep. 2016 Mar 18;65(10):257–62. doi: 10.15585/mmwr.mm6510a2. PMID: 26985679. [PubMed: 26985679] [CrossRef]
744.: Petrecz M, Acosta CJ, Klopfer SO, et al. Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines. Human Vaccines and Immunotherapeutics. 2019;15(2):426–32. doi: 10.1080/21645515.2018.1530934. [PMC free article: PMC6422454] [PubMed: 30431383] [CrossRef]
745.: Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300–4. PMID: 25811679. [PMC free article: PMC4584883] [PubMed: 25811679]
746.: Phuong LK, Bonetto C, Buttery J, et al. Kawasaki disease and immunisation: A systematic review. Vaccine. 2017;35(14):1770–9. doi: 10.1016/j.vaccine.2016.09.033. [PubMed: 28259442] [CrossRef]
747.: Pichichero ME, Stonehocker Quick L. Clinical evaluation of Pediarix: a new pediatric combination vaccine. Clin Pediatr (Phila). 2003 Jun;42(5):393–400. doi: 10.1177/000992280304200502. PMID: 12862341. [PubMed: 12862341] [CrossRef]
748.: Pileggi C, Mascaro V, Bianco A, et al. Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials. Drugs & aging. 2015;32(10):857–69. doi: 10.1007/s40266-015-0303-8. [PubMed: 26442860] [CrossRef]
749.: Pineton de Chambrun G, Dauchet L, Gower-Rousseau C, et al. Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies. Clinical Gastroenterology and Hepatology. 2015;13(8):1405–15. doi: 10.1016/j.cgh.2015.04.179. [PubMed: 25956840] [CrossRef]
750.: Pitts SI, Maruthur NM, Millar KR, et al. A systematic review of mandatory influenza vaccination in healthcare personnel. American journal of preventive medicine. 2014;47(3):330–40. doi: 10.1016/j.amepre.2014.05.035. [PubMed: 25145618] [CrossRef]
751.: Plosker GL. 13-Valent Pneumococcal Conjugate Vaccine: a Review of Its Use in Adults. Drugs. 2015;75(13):1535–46. doi: 10.1007/s40265-015-0449-z. PMID: CN-01475782. [PubMed: 26242768] [CrossRef]
752.: Poliquin V, Greyson D, Castillo E. A Systematic Review of Barriers to Vaccination During Pregnancy in the Canadian Context. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC. 2019;41(9):1344–55. doi: 10.1016/j.jogc.2018.05.042. [PubMed: 30361161] [CrossRef]
753.: Polyzos KA, Konstantelias AA, Pitsa CE, et al. Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. Obstetrics and gynecology. 2015;126(5):1075–84. doi: 10.1097/AOG.0000000000001068. [PubMed: 26444106] [CrossRef]
754.: Poudel S, Shehadeh F, Zacharioudakis IM, et al. The effect of influenza vaccination on mortality and risk of hospitalization in patients with heart failure: A systematic review and meta-analysis. Open Forum Infectious Diseases. 2019;6(4). doi: 10.1093/ofid/ofz159. [PMC free article: PMC6483130] [PubMed: 31041354] [CrossRef]
755.: Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000 May 9;49(Rr-5):1–22; quiz CE1–7. PMID: 15580728. [PubMed: 15580728]
756.: Prutsky GJ, Domecq JP, Elraiyah T, et al. Assessing the evidence: live attenuated influenza vaccine in children younger than 2 years. A systematic review. The Pediatric infectious disease journal. 2014;33(4):e106–15. doi: 10.1097/INF.0000000000000200. [PubMed: 24632668] [CrossRef]
757.: Puges M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664–72. doi: 10.1093/rheumatology/kew211. PMID: 27160278. [PubMed: 27160278] [CrossRef]
758.: Quach THT, Mallis NA, Cordero JF. Influenza Vaccine Efficacy and Effectiveness in Pregnant Women: Systematic Review and Meta-analysis. Maternal and child health journal. 2019. doi: 10.1007/s10995-019-02844-y. [PubMed: 31865602] [CrossRef]
759.: Regan AK. The safety of maternal immunization. Human Vaccines & Immunotherapeutics. 2016;12(12):3132–6. doi: 10.1080/21645515.2016.1222341. PMID: WOS:000392826800024. [PMC free article: PMC5215589] [PubMed: 27541370] [CrossRef]
760.: Remschmidt C, Harder T, Wichmann O, et al. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC infectious diseases. 2016;16(1):711. [PMC free article: PMC5124290] [PubMed: 27887596]
761.: Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine. 2014;32(43):5585–92. doi: 10.1016/j.vaccine.2014.07.101. [PubMed: 25131742] [CrossRef]
762.: Remschmidt C, Wichmann O, Harder T. Influenza vaccination in patients with end-stage renal disease: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Medicine. 2014;12(1). doi: 10.1186/s12916-014-0244-9. [PMC free article: PMC4298993] [PubMed: 25523432] [CrossRef]
763.: Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC infectious diseases. 2015;15:429. doi: 10.1186/s12879-015-1154-y. [PMC free article: PMC4609091] [PubMed: 26474974] [CrossRef]
764.: Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis. BMC Medicine. 2015;13(1). doi: 10.1186/s12916-015-0295-6. [PMC free article: PMC4373029] [PubMed: 25857236] [CrossRef]
765.: Rezaee R, Aghcheli B, Poortahmasebi V, et al. Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study. Hepatitis monthly. 2015;15(5):e23618. doi: 10.5812/hepatmon.15(04)2015.23618. [PMC free article: PMC4451270] [PubMed: 26045701] [CrossRef]
766.: Rodrigues BS, David C, Costa J, et al. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart (British Cardiac Society). 2019. doi: 10.1136/heartjnl-2019-315193. [PubMed: 31444266] [CrossRef]
767.: Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. The Journal of infectious diseases. 2019;219(7):1016–25. doi: 10.1093/infdis/jiy616. [PubMed: 30358875] [CrossRef]
768.: Rosenblatt AE, Stein SL. Cutaneous reactions to vaccinations. Clin Dermatol. 2015 May-Jun;33(3):327–32. doi: 10.1016/j.clindermatol.2014.12.009. PMID: 25889134. [PubMed: 25889134] [CrossRef]
769.: Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep. 2001 Jun 22;50(Rr-10):1–25; quiz CE1–7. PMID: 15580803. [PubMed: 15580803]
770.: Ruiz-Aragon J, Grande Tejada AM, Marquez-Pelaez S, et al. [Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature]. Evaluacion de la vacuna pandemica antigripal A/H1N1 adyuvada MF59. Revision sistematica de la literatura. 2013;79(4):208–17. doi: 10.1016/j.anpedi.2013.01.022. [PubMed: 23490433] [CrossRef]
771.: Salam RA, Das JK, Soeandy CD, et al. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Cochrane Database of Systematic Reviews. 2015(6):43. doi: 10.1002/14651858.CD009982.pub2. PMID: WOS:000357606400050. [PubMed: 26059051] [CrossRef]
772.: Samson SI, Leventhal PS, Salamand C, et al. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert review of vaccines. 2019;18(3):295–308. doi: 10.1080/14760584.2019.1575734. [PubMed: 30689467] [CrossRef]
773.: Sangar VC, Ghongane BB, Mathur G, et al. Safety and adverse events of prophylactic HPV vaccines among healthy women: A systematic review & meta analysis. International Journal of Pharmaceutical Sciences and Research. 2015;6(4):1779–91. doi: 10.13040/IJPSR.0975-8232.6(4).1779-91. [CrossRef]
774.: Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database of Systematic Reviews. 2014(11):17. doi: 10.1002/14651858.CD007879.pub3. PMID: WOS:000347646200025. [PMC free article: PMC7185858] [PubMed: 25385500] [CrossRef]
775.: Santos VS, Marques DP, Martins-Filho PRS, et al. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infectious diseases of poverty. 2016;5(1):83. doi: 10.1186/s40249-016-0173-2. [PMC free article: PMC4982225] [PubMed: 27514855] [CrossRef]
776.: Sarkanen TO, Alakuijala APE, Dauvilliers YA, et al. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep medicine reviews. 2018;38:177–86. doi: 10.1016/j.smrv.2017.06.006. [PubMed: 28847694] [CrossRef]
777.: Sawlwin DC, Graves Jones A, Albano FR. Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children. Vaccine. 2019;37(18):2447–54. doi: 10.1016/j.vaccine.2019.03.056. [PubMed: 30935743] [CrossRef]
778.: Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA. 2020 May 18. doi: 10.1001/jama.2020.8711. PMID: 32421155. [PubMed: 32421155] [CrossRef]
779.: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1–31. doi: 10.15585/mmwr.rr6701a1. PMID: 29939980. [PMC free article: PMC5837403] [PubMed: 29939980] [CrossRef]
780.: Scott LJ, McCormack PL. Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix (R)) A Guide to Its Use as a Single-Dose Booster Immunization Against Pertussis. Biodrugs. 2013 Feb;27(1):75–81. doi: 10.1007/s40259-012-0009-y. PMID: WOS:000318512200007. [PubMed: 23329401] [CrossRef]
781.: Setiawan D, Luttjeboer J, Pouwels KB, et al. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis. Japanese journal of clinical oncology. 2017;47(3):265–76. doi: 10.1093/jjco/hyw192. [PubMed: 28042137] [CrossRef]
782.: Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36(13):1711–9. doi: 10.1016/j.vaccine.2018.02.059. [PubMed: 29478755] [CrossRef]
783.: Shah RA, Limmer AL, Nwannunu CE, et al. Shingrix for Herpes Zoster: A Review. Skin therapy letter. 2019;24(4):5–7. [PubMed: 31339679]
784.: Sheldenkar A, Lim F, Yung CF, et al. Acceptance and uptake of influenza vaccines in Asia: A systematic review. Vaccine. 2019;37(35):4896–905. doi: 10.1016/j.vaccine.2019.07.011. [PubMed: 31301918] [CrossRef]
785.: Soares-Weiser K, Bergman H, Henschke N, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2019 Oct 28;2019(10). doi: 10.1002/14651858.CD008521.pub5. PMID: 31684685. [PMC free article: PMC6816010] [PubMed: 31684685] [CrossRef]
786.: Sousa S, Duarte AC, Cordeiro I, et al. Efficacy and Safety of Vaccination in Pediatric Patients with Systemic Inflammatory Rheumatic Diseases: a systematic review of the literature. Efficacy and Safety of Vaccination in Pediatric Patients with Systemic Inflammatory Rheumatic Diseases: a systematic review of the literature. 2017;42(1):8–16.
787.: Stassijns J, Bollaerts K, Baay M, et al. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016;34(6):714–22. doi: 10.1016/j.vaccine.2015.12.024. [PubMed: 26740250] [CrossRef]
788.: Stone J. Written evidence from John Stone. http://data.parliament.uk/writtenevidence/committeeevidence.svc/evidencedocument/health-and-social-care-committee/antimicrobial-resistance/written/86156.pdf. Accessed on June 25, 2020.
789.: Stowe J, Andrews N, Miller E. Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barre Syndrome and Narcolepsy. CNS drugs. 2019. doi: 10.1007/s40263-019-00670-y. [PMC free article: PMC7224038] [PubMed: 31576507] [CrossRef]
790.: Strassberg ER, Power M, Schulkin J, et al. Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. Vaccine. 2018 Jul 16;36(30):4548–54. doi: 10.1016/j.vaccine.2018.05.121. PMID: 29907484. [PubMed: 29907484] [CrossRef]
791.: Subesinghe S, Bechman K, Rutherford AI, et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. The Journal of rheumatology. 2018;45(6):733–44. doi: 10.3899/jrheum.170710. [PubMed: 29545454] [CrossRef]
792.: Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert review of vaccines. 2014;13(12):1571–91. doi: 10.1586/14760584.2014.966695. [PMC free article: PMC4277796] [PubMed: 25348015] [CrossRef]
793.: Switzer C, Babiuk L, Loeb M. Determining optimal community protection strategies for the influenza vaccine. Expert review of vaccines. 2019;18(8):755–64. doi: 10.1080/14760584.2019.1642110. [PubMed: 31288585] [CrossRef]
794.: Syed YY. DTaP5-HB-IPV-Hib Vaccine (Vaxelis®): A Review of its Use in Primary and Booster Vaccination. Pediatric Drugs. 2017;19(1):69–80. doi: 10.1007/s40272-016-0208-y. [PubMed: 28035545] [CrossRef]
795.: Syed YY. Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster. Drugs and Aging. 2018;35(12):1031–40. doi: 10.1007/s40266-018-0603-x. [PubMed: 30370455] [CrossRef]
796.: Symoniak MR, Farrokh P, Gandhi MA, et al. Herpes zoster subunit vaccine for the prevention of herpes zoster. American Journal of Health-System Pharmacy. 2018 Jun;75(12):861–9. doi: 10.2146/ajhp170399. PMID: WOS:000434783300015. [PubMed: 29880523] [CrossRef]
797.: Tafreshi S-YH. Efficacy, safety, and formulation issues of the combined vaccines. Expert review of vaccines. 2020. doi: 10.1080/14760584.2020.1843434. [PubMed: 33118470] [CrossRef]
798.: Tan J, Xiong Y-Q, He Q, et al. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis. BMC pregnancy and childbirth. 2019;19(1):302. doi: 10.1186/s12884-019-2425-1. [PMC free article: PMC6699066] [PubMed: 31426762] [CrossRef]
799.: Tan P, Wang X, Wei S, et al. Efficacy and safety of prophylactic human papillomavirus vaccination in healthy males: A meta-analysis. Reviews in Medical Microbiology. 2015;26(4):143–53. doi: 10.1097/MRM.0000000000000053. [CrossRef]
800.: Tang G, Yin W, Cao Y, et al. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis. Human vaccines & immunotherapeutics. 2018;14(11):2636–43. doi: 10.1080/21645515.2018.1489188. [PMC free article: PMC6314415] [PubMed: 29985751] [CrossRef]
801.: Tarakji B, Ashok N, Alakeel R, et al. Hepatitis B vaccination and associated oral manifestations: a non-systematic review of literature and case reports. Annals of medical and health sciences research. 2014;4(6):829–36. doi: 10.4103/2141-9248.144870. [PMC free article: PMC4250977] [PubMed: 25506472] [CrossRef]
802.: Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623–9. doi: 10.1016/j.vaccine.2014.04.085. [PubMed: 24814559] [CrossRef]
803.: Tctr. Immunogenicity and Safety of recombinant acellular pertusis-containing vaccine (TdaP) and a pedriatric recombinant acellular pertussis-containing vaccine (DTaP) in healthy children. http://www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20190201001. 2019. PMID: CN-01993113.
804.: The Sabin-Aspen Vaccine Science & Policy Group. Meeting the challenge of vaccination hesistancy Washington, DC. Sabin Vaccine Institute: May 2020. https://www.sabin.org/sites/sabin.org/files/sabin-aspen-report-2020_meeting_the_challenge_of_vaccine_hesitancy.pdf
805.: Théophile H, Moore N, Robinson P, et al. Vaccine Case–Population: A New Method for Vaccine Safety Surveillance. Drug Safety. 2016;39(12):1197–209. doi: 10.1007/s40264-016-0449-2. [PubMed: 27612460] [CrossRef]
806.: Thomas RE, Lorenzetti DL, Spragins W. Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review. American journal of public health. 2013;103(3):e16–29. doi: 10.2105/AJPH.2012.301158. [PMC free article: PMC3673520] [PubMed: 23327242] [CrossRef]
807.: Thomas TN, Reef S, Neff L, et al. A review of the smallpox vaccine adverse events active surveillance system. Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S212–20. doi: 10.1086/524742. PMID: 18284361. [PubMed: 18284361] [CrossRef]
808.: Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013;31(45):5289–95. doi: 10.1016/j.vaccine.2013.08.025. [PubMed: 23973321] [CrossRef]
809.: Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822–5. PMID: 25233284. [PMC free article: PMC5779453] [PubMed: 25233284]
810.: Tricco AC, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ (Clinical research ed.). 2018;363:k4029. doi: 10.1136/bmj.k4029. [PMC free article: PMC6201212] [PubMed: 30361202] [CrossRef]
811.: Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Human Vaccines & Immunotherapeutics. 2018;14(3):657–70. doi: 10.1080/21645515.2017.1423153. PMID: WOS:000428053800031. [PMC free article: PMC5861790] [PubMed: 29297746] [CrossRef]
812.: Tsivgoulis G, Katsanos AH, Zand R, et al. The association of adult vaccination with the risk of cerebrovascular ischemia: A systematic review and meta-analysis. Journal of the neurological sciences. 2018;386:12–8. doi: 10.1016/j.jns.2018.01.007. [PubMed: 29406959] [CrossRef]
813.: Tyring SK. Vaccination of older adults against herpes zoster is safe and effective. Evidence Based Medicine. 2013;18(5):e43–e. doi: 10.1136/eb-2012-101138. PMID: 90401129. Language: English. Entry Date: 20131001. Revision Date: 20190102. Publication Type: Article. [PubMed: 23416421] [CrossRef]
814.: U.S. Department of Health and Human Services. Healthy People 2020. Washington, D.C. : 2011.
815.: U.S. Food and Drug Administration. 522 Fluzone High-Dose Quadrivalent https://www.fda.gov/media/139731/download. Accessed on August 13, 2020.
816.: U.S. Food and Drug Administration. FLUAD QUADRIVALENT. June 25, 2020. https://www.fda.gov/media/135432/download. Accessed on August 13, 2020.
817.: Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711–20. doi: 10.1001/jama.2013.279206. [PubMed: 24150467] [CrossRef]
818.: United States District Court Southern District of New York. Institute for Autism Science and Informed Consent Action Network vs. Centers for Disease Control and Prevention. New York. https://cdn1.collective-evolution.com/assets/uploads/2020/03/Stipulation-and-Order-Fully-Executed.pdf. Accessed on June 25 202.
819.: US Food & Drug Administration. ROTATEQ. 2018.
820.: US Food & Drug Administration. VARIVAX. 2018.
821.: US Food & Drug Administration. TDVAX. 2018.
822.: US Food & Drug Administration. DAPTACEL. 2019.
823.: US Food & Drug Administration. INFANRIX. 2019.
824.: US Food & Drug Administration. HAVRIX. 2019.
825.: US Food & Drug Administration. VAQTA. 2019.
826.: US Food & Drug Administration. ENGERIX-B. 2019.
827.: US Food & Drug Administration. RECOMBIVAX HB. 2019.
828.: US Food & Drug Administration. Haemophilus B Conjugate Vaccine (Meningococcal Protein Conjugate). 2019.
829.: US Food & Drug Administration. ActHIB. 2019.
830.: US Food & Drug Administration. HIBERIX. 2019.
831.: US Food & Drug Administration. IPOL. 2019.
832.: US Food & Drug Administration. MENACTRA. 2019.
833.: US Food & Drug Administration. BEXSERO. 2019.
834.: US Food & Drug Administration. TRUMENBA. 2019.
835.: US Food & Drug Administration. PREVNAR 13. 2019.
836.: US Food & Drug Administration. PNEUMOVAX 23 - Pneumococcal Vaccine, Polyvalent. 2019.
837.: US Food & Drug Administration. ROTARIX. 2019.
838.: US Food & Drug Administration. BOOSTRIX. 2019.
839.: US Food & Drug Administration. KINRIX. 2019.
840.: US Food & Drug Administration. ADACEL. 2019.
841.: US Food & Drug Administration. PEDIARIX. 2019.
842.: US Food & Drug Administration. Package insert for PROQUAD. 2019.
843.: US Food & Drug Administration. SHINGRIX. 2019.
844.: US Food & Drug Administration. TENIVAC. 2019.
845.: US Food & Drug Administration. TWINRIX. 2019.
846.: US Food & Drug Administration. ZOSTAVAX. 2019.
847.: US Food & Drug Administration. GARDASIL 9. 2020.
848.: US Food & Drug Administration. AFLURIA QUADRIVALENT. 2020.
849.: US Food & Drug Administration. FLUARIX QUADRIVALENT. 2020.
850.: US Food & Drug Administration. FLULAVAL QUADRIVALENT. 2020.
851.: US Food & Drug Administration. FLUZONE QUADRIVALENT, FLUZONE HIGH-DOSE QUADRIVALENT, FLUZONE, INTRADERMAL QUADRIVALENT, FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE. 2020.
852.: US Food & Drug Administration. FLUCELVAX QUADRIVALENT. 2020.
853.: US Food & Drug Administration. FLUMIST QUADRIVALENT. 2020.
854.: US Food & Drug Administration. MEASLES, MUMPS AND RUBELLA VIRUS VACCINE LIVE. 2020.
855.: US Food & Drug Administration. MENVEO. 2020.
856.: US Food & Drug Administration. MENQUADFI. 2020.
857.: US Food & Drug Administration. PENTACEL. 2020.
858.: US Food & Drug Administration. QUADRACEL. 2020.
859.: US Food & Drug Administration. VAXELIS. 2020.
860.: US Food & Drug Administration. FLUAD. 2020.
861.: US Food & Drug Administration. FLUBLOK QUADRIVALENT. 2020.
862.: US Food & Drug Administration. FLUZONE, FLUZONE HIGH-DOSE AND FLUZONE INTRADERMAL. 2020.
863.: US Food & Drug Administration. HEPLISAV-B. 2020.
864.: Vadlamudi NK, Chen A, Marra F. Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;69(1):34–49. doi: 10.1093/cid/ciy872. [PubMed: 30312379] [CrossRef]
865.: Vadlamudi NK, Parhar K, Altre Malana KL, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. 2019;37(8):1021–9. doi: 10.1016/j.vaccine.2019.01.014. [PubMed: 30685252] [CrossRef]
866.: van Aalst M, Langedijk AC, Spijker R, et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018;36(39):5832–45. doi: 10.1016/j.vaccine.2018.07.039. [PubMed: 30122649] [CrossRef]
867.: van den Ende C, Marano C, van Ahee A, et al. The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience. Expert review of vaccines. 2017;16(8):789–809. doi: 10.1080/14760584.2017.1338569. [PubMed: 28586278] [CrossRef]
868.: Vasilevska M, Ku J, Fisman DN. Factors associated with healthcare worker acceptance of vaccination: a systematic review and meta-analysis. Infection control and hospital epidemiology. 2014;35(6):699–708. doi: 10.1086/676427. [PubMed: 24799647] [CrossRef]
869.: Velazquez RF, Linhares AC, Munoz S, et al. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC pediatrics. 2017;17(1):14. doi: 10.1186/s12887-016-0771-y. [PMC free article: PMC5237165] [PubMed: 28086819] [CrossRef]
870.: Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014 Apr;58(8):1149–55. doi: 10.1093/cid/ciu005. PMID: 24415636. [PubMed: 24415636] [CrossRef]
871.: Vera-Lastra O, Medina G, Cruz-Dominguez M, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): Clinical and immunological spectrum. Expert review of clinical immunology. 2013 04/01;9:361–73. doi: 10.1586/eci.13.2. [PubMed: 23557271] [CrossRef]
872.: Verstraeten T, Cohet C, Dos Santos G, et al. Pandemrix (TM) and narcolepsy: A critical appraisal of the observational studies. Human Vaccines & Immunotherapeutics. 2016 Jan;12(1):187–93. doi: 10.1080/21645515.2015.1068486. PMID: WOS:000375931700035. [PMC free article: PMC4962758] [PubMed: 26379011] [CrossRef]
873.: Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews. J Am Dent Assoc. 2020 Apr;151(4):245–54.e24. doi: 10.1016/j.adaj.2019.10.010. PMID: 31983391. [PubMed: 31983391] [CrossRef]
874.: Villanueva-Cabezas JP, Coppo MJC, Durr PA, et al. Vaccine efficacy against Indonesian Highly Pathogenic Avian Influenza H5N1: systematic review and meta-analysis. Vaccine. 2017;35(37):4859–69. doi: 10.1016/j.vaccine.2017.07.059. [PubMed: 28780119] [CrossRef]
875.: Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015 Sep;22(9):1185–99. doi: 10.1177/2047487314549512. PMID: 25252595. [PubMed: 25252595] [CrossRef]
876.: Voysey M, Sadarangani M, Clutterbuck E, et al. The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(34):3986–92. doi: 10.1016/j.vaccine.2016.06.038. [PubMed: 27349840] [CrossRef]
877.: Walters JAE, Tang JNQ, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2017(1):84. doi: 10.1002/14651858.CD001390.pub4. PMID: WOS:000396095800004. [PMC free article: PMC6422320] [PubMed: 28116747] [CrossRef]
878.: Wang A, Liu C, Wang Y, et al. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. Human Vaccines and Immunotherapeutics. 2019. doi: 10.1080/21645515.2019.1662363. [PMC free article: PMC7227696] [PubMed: 31486334] [CrossRef]
879.: Wang Y, Li JX, Wang YX, et al. Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations. Human Vaccines & Immunotherapeutics. 2018;14(4):1003–12. doi: 10.1080/21645515.2017.1409316. PMID: WOS:000429600000040. [PMC free article: PMC5893217] [PubMed: 29261406] [CrossRef]
880.: Warren-Gash C, Breuer J. CNS Infections: A new herpes zoster subunit vaccine for older adults. Nature reviews. Neurology. 2016;12(12):682–3. doi: 10.1038/nrneurol.2016.168. [PubMed: 27834395] [CrossRef]
881.: Watkins RR. High-Dose Flu Vaccine has Increased Immunogenicity in HIV Patients. Infectious Disease Alert. 2013;32(7):76–7. PMID: 86441575. Language: English. Entry Date: 20130403. Revision Date: 20130405. Publication Type: Article.
882.: Weber SK, Schlagenhauf P. Childhood vaccination associated adverse events by sex: A literature review. Travel Medicine and Infectious Disease. 2014;12(5):459–80. doi: 10.1016/j.tmaid.2014.01.008. [PubMed: 24680600] [CrossRef]
883.: Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003 Apr 4;52(Rr-7):1–16. PMID: 12710832. [PubMed: 12710832]
884.: Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: Why and what to do? Hum Vaccin Immunother. 2016;12(1):239–43. doi: 10.1080/21645515.2015.1093263. PMID: 26836329. [PMC free article: PMC4962729] [PubMed: 26836329] [CrossRef]
885.: Wilck MB, Xu ZJ, Stek JE, et al. Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants. Human Vaccines and Immunotherapeutics. 2020. doi: 10.1080/21645515.2020.1756668. [PMC free article: PMC7872088] [PubMed: 32750261] [CrossRef]
886.: Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine. 2018 Aug;36(36):5470–6. doi: 10.1016/j.vaccine.2017.07.056. PMID: WOS:000444360200020. [PubMed: 28778616] [CrossRef]
887.: Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017;35(21):2775–80. doi: 10.1016/j.vaccine.2017.03.092. [PubMed: 28431815] [CrossRef]
888.: Winter K, Glaser C, Watt J, et al. Pertussis epidemic--California, 2014. MMWR Morb Mortal Wkly Rep. 2014 Dec 5;63(48):1129–32. PMID: 25474033. [PMC free article: PMC4584602] [PubMed: 25474033]
889.: Xu J, Liu S, Liu Q, et al. The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis. Medicine. 2019;98(16):e15281. doi: 10.1097/MD.0000000000015281. [PMC free article: PMC6494346] [PubMed: 31008974] [CrossRef]
890.: Xu J, Stek JE, Ziani E, et al. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine. Pediatric Infectious Disease Journal. 2019;38(4):439–43. doi: 10.1097/INF.0000000000002257. [PubMed: 30882742] [CrossRef]
891.: Xu L, Selk A, Garland SM, et al. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. Expert Review of Vaccines.10. doi: 10.1080/14760584.2019.1692658. PMID: WOS:000500104000001. [PubMed: 31718338] [CrossRef]
892.: Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Canadian Family Physician. 2016 May;62(5):399–402. PMID: WOS:000376126000016. [PMC free article: PMC4865336] [PubMed: 27255620]
893.: Yang J, Zhang J, Han T, et al. Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis. Medicine. 2020;99(7):e19095. doi: 10.1097/MD.0000000000019095. [PMC free article: PMC7035094] [PubMed: 32049815] [CrossRef]
894.: Yang LPH. Recombinant trivalent influenza vaccine (Flublok®): A review of its use in the prevention of seasonal influenza in adults. Drugs. 2013;73(12):1357–66. doi: 10.1007/s40265-013-0103-6. [PubMed: 23928902] [CrossRef]
895.: Yin M, Xu X, Liang Y, et al. Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination:a meta-analysis. Expert Review of Vaccines. 2018;17(4):351–62. doi: 10.1080/14760584.2018.1433999. [PubMed: 29388450] [CrossRef]
896.: Younossi Z, Kochems K, de Ridder M, et al. Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. Human vaccines & immunotherapeutics. 2017;13(11):2695–706. doi: 10.1080/21645515.2017.1353850. [PMC free article: PMC5703367] [PubMed: 28742983] [CrossRef]
897.: Yousaf F, Gandham S, Galler M, et al. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Renal failure. 2015;37(7):1080–8. [PubMed: 26258528]
898.: Yue X, Black CL, Williams WW, et al. Influenza vaccination among adults living with persons at high-risk for complications from influenza during early 2016–17 influenza season. Vaccine. 2018 Dec 18;36(52):7987–92. doi: 10.1016/j.vaccine.2018.11.001. PMID: 30448066. [PMC free article: PMC6478164] [PubMed: 30448066] [CrossRef]
899.: Zachariah P, Stockwell MS. Measles Vaccine: Past, Present, and Future. Journal of Clinical Pharmacology. 2016 Feb;56(2):1–8. doi: 10.1002/jcph.606. PMID: WOS:000368280600001. [PubMed: 26239158] [CrossRef]
900.: Zafack JG, De Serres G, Kiely M, et al. Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review. Pediatrics. 2017;140(3). doi: 10.1542/peds.2016-3707. [PubMed: 28847985] [CrossRef]
901.: Zbinden D, Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy. 2014 Feb;6(2):131–9. doi: 10.2217/imt.13.171. PMID: WOS:000337967400010. [PubMed: 24491087] [CrossRef]
902.: Zhang C, Wang X, Liu D, et al. A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018;141(2):141–50. doi: 10.1002/ijgo.12394. [PubMed: 29149524] [CrossRef]
903.: Zhang LJ, Prietsch SOM, Axelsson I, et al. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews. 2014(9):154. doi: 10.1002/14651858.CD001478.pub6. PMID: WOS:000347645800007. [PMC free article: PMC9722541] [PubMed: 25228233] [CrossRef]
904.: Zhu BD, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology. 2018 Apr;23(4):359–68. doi: 10.1111/resp.13245. PMID: WOS:000427591200006. [PubMed: 29341430] [CrossRef]
905.: Zhu YS, Wang Y, Hirschhorn J, et al. Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. In: Makowski GS, ed Advances in Clinical Chemistry, Vol 81. Vol. 81. San Diego: Elsevier Academic Press Inc; 2017:135–92. [PubMed: 28629588]
906.: Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Frontiers in Immunology. 2019 Aug;10:10. doi: 10.3389/fimmu.2019.01883. PMID: WOS:000479152300001. [PMC free article: PMC6693409] [PubMed: 31440255] [CrossRef]
907.: Andrews N, Stowe J, Miller E, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine. 2012 Apr 19;30(19):3042–6. PMID: 21699947. [PubMed: 21699947]
908.: Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010 Oct 18;28(44):7215–20. PMID: 20800702. [PubMed: 20800702]
909.: Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):606–14. PMID: 20692030. [PubMed: 20692030]
910.: Barbosa CM, Terreri MT, Rosario PO, et al. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clinical & Experimental Rheumatology. 2012 Sep-Oct;30(5):791–8. PMID: 22935227. [PubMed: 22935227]
911.: Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011 Feb 26;377(9767):751–9. PMID: 21329971. [PubMed: 21329971]
912.: Baxter R, Bakshi N, Fireman B, et al. Lack of association of guillain-barre syndrome with vaccinations. Clin Infect Dis. 2013 Jul;57(2):197–204. doi: 10.1093/cid/cit222. PMID: 23580737. [PubMed: 23580737] [CrossRef]
913.: Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age. Vaccine. 2012 Apr 26;30(20):3053–60. PMID: 22425787. [PubMed: 22425787]
914.: Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine. 2012 Apr 19;30(19):2989–98. PMID: 22386746. [PubMed: 22386746]
915.: Baxter R, Tran TN, Hansen J, et al. Safety of ZostavaxTM--a cohort study in a managed care organization. Vaccine. 2012 Oct 19;30(47):6636–41. doi: 10.1016/j.vaccine.2012.08.070. PMID: 22963800. [PubMed: 22963800] [CrossRef]
916.: Benchimol EI, Hawken S, Kwong JC, et al. Safety and utilization of influenza immunization in children with inflammatory bowel disease. Pediatrics. 2013 Jun;131(6):e1811–20. doi: 10.1542/peds.2012-3567. PMID: 23650306. [PubMed: 23650306] [CrossRef]
917.: Bernsen RMD, de Jongste JC, Koes BW, et al. Diphtheria tetanus pertussis poliomyelitis vaccination and reported atopic disorders in 8–12-year-old children. Vaccine. 2006 Mar 15;24(12):2035–42. PMID: 16368169. [PubMed: 16368169]
918.: Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety. 2010 Jan 1;33(1):65–72. PMID: 20000868. [PubMed: 20000868]
919.: Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.[Erratum appears in J Obstet Gynaecol Res. 2010 Apr;36(2):466]. Journal of Obstetrics & Gynaecology Research. 2010 Feb;36(1):123–32. PMID: 20178538. [PubMed: 20178538]
920.: Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatric Infectious Disease Journal. 2010 February;29(2):95–101. PMID: 2010088509 MEDLINE PMID 19952863 (http://www.ncbi.nlm.nih.gov/pubmed/19952863). [PubMed: 19952863]
921.: Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007 Jan;119(1):11–8. PMID: 17200266. [PubMed: 17200266]
922.: Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011 Apr 5;29(16):3061–6. PMID: 21316503. [PubMed: 21316503]
923.: Capeding MRZ, Nohynek H, Pascual LG, et al. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. American Journal of Tropical Medicine and Hygiene. 1996 1996;55(5):516–20. PMID: 1996357902 MEDLINE PMID 8940983 (http://www.ncbi.nlm.nih.gov/pubmed/8940983). [PubMed: 8940983]
924.: Chang C-C, Chang M-H, Lin T-Y, et al. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association. 2009 Apr;108(4):280–5. PMID: 19369174. [PubMed: 19369174]
925.: Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine. 2012 Feb;271(2):193–203. doi: 10.1111/j.1365-2796.2011.02467.x. PMID: 21973261. [PubMed: 21973261] [CrossRef]
926.: Chen RT, Glasser JW, Rhodes PH, et al. Vaccine safety datalink project: A new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997 June;99(6):765–73. PMID: 1997164925 MEDLINE PMID 9164767 (http://www.ncbi.nlm.nih.gov/pubmed/9164767). [PubMed: 9164767]
927.: Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. Journal of Adolescent Health. 2013 Mar;52(3):322–9. doi: 10.1016/j.jadohealth.2012.07.003. PMID: 23299013. [PubMed: 23299013] [CrossRef]
928.: Crawford NW, Cheng A, Andrews N, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. Medical Journal of Australia. 2012 Nov 19;197(10):574–8. PMID: 23163689. [PubMed: 23163689]
929.: De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010 Aug 31;28(38):6247–55. PMID: 20643092. [PubMed: 20643092]
930.: Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal. 2005 Jun;24(6):481–8. PMID: 15933555. [PubMed: 15933555]
931.: Dodds L, Macdonald N, Scott J, et al. The association between influenza vaccine in pregnancy and adverse neonatal outcomes. Journal of Obstetrics & Gynaecology Canada: JOGC. 2012 Aug;34(8):714–20. PMID: 22947404. [PubMed: 22947404]
932.: Duderstadt SK, Rose CE, Jr., Real TM, et al. Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002–2008. Vaccine. 2012 Jan 17;30(4):813–9. PMID: 22075092. [PubMed: 22075092]
933.: Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care and Research. 2011 August;63(8):1091–7. PMID: 2011461623 MEDLINE PMID 21560259 (http://www.ncbi.nlm.nih.gov/pubmed/21560259). [PubMed: 21560259]
934.: Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatric Infectious Disease Journal. 2010 Feb;29(2):105–10. PMID: 19934787. [PubMed: 19934787]
935.: Eurich DT, Johnstone JJ, Minhas-Sandhu JK, et al. Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. Heart. 2012 Jul;98(14):1072–7. PMID: WOS:000305886300008. [PubMed: 22739637]
936.: Farez MF, Ysrraelit MC, Fiol M, et al. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Multiple Sclerosis. 2012 Feb;18(2):254–6. PMID: 21828198. [PubMed: 21828198]
937.: Fell DB, Sprague AE, Liu N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American Journal of Public Health. 2012 Jun;102(6):e33–40. PMID: 22515877. [PMC free article: PMC3483960] [PubMed: 22515877]
938.: Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clinical Infectious Diseases. 2010 Nov 1;51(9):997–1004. PMID: 20868284. [PubMed: 20868284]
939.: Gallagher CM, Goodman MS. Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997–2002. Journal of Toxicology and Environmental Health-Part a-Current Issues. 2010;73(24):1665–77. PMID: WOS:000283878600002. [PubMed: 21058170]
940.: Garbe E, Andersohn F, Bronder E, et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. European Journal of Clinical Pharmacology. 2012;68(5):821–32. [PubMed: 22187020]
941.: Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26;29(46):8279–84. PMID: 21907257. [PubMed: 21907257]
942.: Gilbertson DT, Guo H, Arneson TJ, et al. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrology Dialysis Transplantation. 2011 Sep;26(9):2934–9. PMID: 21317410. [PubMed: 21317410]
943.: Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.[Erratum appears in N Engl J Med. 2011 Apr 14;364(15):1481]. New England Journal of Medicine. 2011 Feb 3;364(5):401–11. PMID: 21288094. [PMC free article: PMC3495065] [PubMed: 21288094]
944.: Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Archives of Pediatrics & Adolescent Medicine. 2011 Aug;165(8):749–55. PMID: 21810637. [PubMed: 21810637]
945.: Gold M, Dugdale S, Woodman RJ, et al. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. Vaccine. 2010 Jun 11;28(26):4308–11. PMID: 20430123. [PubMed: 20430123]
946.: Gotoh K, Ito Y, Suzuki E, et al. Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons. Pediatric Transplantation. 2011 Feb;15(1):112–6. doi: 10.1111/j.1399-3046.2010.01420.x. PMID: 21108713. [PubMed: 21108713] [CrossRef]
947.: Greene SK, Rett M, Weintraub ES, et al. Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009–2010. American Journal of Epidemiology. 2012 Jun 1;175(11):1100–9. PMID: 22582210. [PMC free article: PMC6272801] [PubMed: 22582210]
948.: Greenhawt MJ, Spergel JM, Rank MA, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Annals of Allergy, Asthma, & Immunology. 2012 Dec;109(6):426–30. doi: 10.1016/j.anai.2012.09.011. PMID: 23176882. [PubMed: 23176882] [CrossRef]
949.: Grimaldi-Bensouda L, Alperovitch A, Besson G, et al. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. American Journal of Epidemiology. 2011 Aug 1;174(3):326–35. PMID: 21652600. [PubMed: 21652600]
950.: Groves FD, Gridley G, Wacholder S, et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Br J Cancer. 1999 Sep;81(1):175–8. doi: 10.1038/sj.bjc.6690668. PMID: 10487630. [PMC free article: PMC2374362] [PubMed: 10487630] [CrossRef]
951.: Gruber C, Warner J, Hill D, et al. Early atopic disease and early childhood immunization--is there a link? Allergy. 2008 Nov;63(11):1464–72. PMID: 18925883. [PubMed: 18925883]
952.: Gwini SM, Coupland CAC, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine. 2011 Feb 1;29(6):1145–9. PMID: 21172383. [PubMed: 21172383]
953.: Halasa N, Englund JA, Nachman S, et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine. 2011 May 31;29(24):4110–5. PMID: 21496468. [PubMed: 21496468]
954.: Hambidge SJ, Ross C, Glanz J, et al. Trivalent inactivated influenza vaccine is not associated with sickle cell crises in children. Pediatrics. 2012 Jan;129(1):e54–9. PMID: 22157132. [PubMed: 22157132]
955.: Hambidge SJ, Ross C, McClure D, et al. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohort. Vaccine. 2011 Oct 26;29(46):8179–81. PMID: 21930176. [PubMed: 21930176]
956.: Hedlund J, Christenson B, Lundbergh P, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: A 1-year follow-up. Vaccine. 2003 August/September;21(25 26):3906–11. PMID: 2003442603 MEDLINE PMID 12922125 (http://www.ncbi.nlm.nih.gov/pubmed/12922125). [PubMed: 12922125]
957.: Hummel M, Fuchtenbusch M, Schenker M, et al. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB study. Diabetes Care. 2000 Jul;23(7):969–74. PMID: WOS:000087890200017. [PubMed: 10895848]
958.: Hurst FP, Lee JJ, Jindal RM, et al. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clinical Journal of The American Society of Nephrology: CJASN. 2011 May;6(5):1192–7. PMID: 21511837. [PMC free article: PMC3087788] [PubMed: 21511837]
959.: Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infectious Diseases. 2013;13:95. doi: 10.1186/1471-2334-13-95. PMID: 23432812. [PMC free article: PMC3608170] [PubMed: 23432812] [CrossRef]
960.: Iorio A, Basileo M, Marcucci M, et al. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. Archives of Internal Medicine. 2010 Apr 12;170(7):609–16. PMID: 20386004. [PubMed: 20386004]
961.: Irving SA, Kieke BA, Donahue JG, et al. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstetrics & Gynecology. 2013 Jan;121(1):159–65. doi: 10.1097/AOG.0b013e318279f56f. PMID: 23262941. [PubMed: 23262941] [CrossRef]
962.: Isai A, Durand J, Le Meur S, et al. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine. 2012 Nov 19;30(49):7123–9. doi: 10.1016/j.vaccine.2012.09.032. PMID: 23022149. [PubMed: 23022149] [CrossRef]
963.: Italian Multicenter Study Group for D, Vaccine Safety in C. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open. 2011 Jan 1;1(2):e000167. PMID: 22021877. [PMC free article: PMC3191592] [PubMed: 22021877]
964.: Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infectious Diseases. 2010;10:71. PMID: 20236548. [PMC free article: PMC2845585] [PubMed: 20236548]
965.: Johnstone J, Loeb M, Teo KK, et al. Influenza vaccination and major adverse vascular events in high risk patients. Circulation. 2012;21. [PubMed: 22715472]
966.: Kang S, Kim KH, Kim YT, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1013–9. doi: 10.1111/j.1525-1438.2007.01123.x. PMID: 17986242. [PubMed: 17986242] [CrossRef]
967.: Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011 26;29(37):6335–41. PMID: 2011443943 MEDLINE PMID 21640780 (http://www.ncbi.nlm.nih.gov/pubmed/21640780). [PubMed: 21640780]
968.: Kelly H, Carcione D, Dowse GK, et al. The vaccine-attributable risk for febrile convulsions following influenza vaccine. Pediatric Infectious Disease Journal. 2012 Jul;31(7):792. PMID: 22695195. [PubMed: 22695195]
969.: Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines. 2010 March;6(3):254–62. PMID: 2010340035. [PubMed: 20220306]
970.: Khalil M, Al-Mazrou Y, Findlow H, et al. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. Clinical & Vaccine Immunology: CVI. 2012 Oct;19(10):1561–6. PMID: 22855388. [PMC free article: PMC3485883] [PubMed: 22855388]
971.: Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. Japanese Journal of Clinical Oncology. 2012 Jan;42(1):36–41. PMID: 22194637. [PMC free article: PMC3244935] [PubMed: 22194637]
972.: Kim DS, Lee TJ, Kang JH, et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal. 2008 Feb;27(2):177–8. PMID: 18174862. [PubMed: 18174862]
973.: Kim JS, Bae CW, Lee KY, et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: A randomized, double-blind, placebo-controlled, phase IV study. Human Vaccines and Immunotherapeutics. 2012 June;8(6):806–12. PMID: 2012397541. [PubMed: 22699440]
974.: Kim SC, Song YS, Kim Y-T, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15–25 years old healthy Korean women. Journal of Gynecologic Oncology. 2011 Jun 30;22(2):67–75. PMID: 21860731. [PMC free article: PMC3152758] [PubMed: 21860731]
975.: Klein NP, Aukes L, Lee J, et al. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May;127(5):e1139–e46. PMID: 2011239005 MEDLINE PMID 21482602 (http://www.ncbi.nlm.nih.gov/pubmed/21482602). [PubMed: 21482602]
976.: Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Archives of Pediatrics & Adolescent Medicine. 2012 Dec;166(12):1140–8. doi: 10.1001/archpediatrics.2012.1451. PMID: 23027469. [PubMed: 23027469] [CrossRef]
977.: Klein NP, Massolo ML, Greene J, et al. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pediatrics. 2008 March;121(3):463–9. PMID: 2009129439 MEDLINE PMID 18310193 (http://www.ncbi.nlm.nih.gov/pubmed/18310193). [PubMed: 18310193]
978.: Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.[Erratum appears in Pediatr Infect Dis J. 2012 Oct;31(10):1105]. Pediatric Infectious Disease Journal. 2012 Jan;31(1):64–71. doi: 10.1097/INF.0b013e31823dce5c. PMID: 22094635. [PubMed: 22094635] [CrossRef]
979.: Langley JM, Aoki F, Ward BJ, et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine. 2011 24;29(10):1921–8. PMID: 2011100418 MEDLINE PMID 21219987 (http://www.ncbi.nlm.nih.gov/pubmed/21219987). [PubMed: 21219987]
980.: Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. American Journal of Preventive Medicine. 2011 Aug;41(2):121–8. PMID: 21767718. [PubMed: 21767718]
981.: Lee S, Park WB, Shin K-H, et al. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults. Vaccine. 2011 Oct 13;29(44):7638–43. PMID: 21864613. [PubMed: 21864613]
982.: Levin MJ, Moscicki A-B, Song L-Y, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2010 Oct;55(2):197–204. PMID: 20574412. [PMC free article: PMC3033215] [PubMed: 20574412]
983.: Li R, Li Y, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 2012 Jun 13;30(28):4284–91. PMID: 22433961. [PubMed: 22433961]
984.: Lin TH, Lin SY, Lin CH, et al. AdimFlu-S((registered trademark)) influenza A (H1N1) vaccine during pregnancy: The Taiwanese Pharmacovigilance Survey. Vaccine. 2012 30;30(16):2671–5. PMID: 2012154620. [PubMed: 22342546]
985.: Ma X, Does MB, Metayer C, et al. Vaccination history and risk of childhood leukaemia. Int J Epidemiol. 2005 Oct;34(5):1100–9. doi: 10.1093/ije/dyi113. PMID: 15951359. [PubMed: 15951359] [CrossRef]
986.: Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine. 2007 Mar 1;25(11):2139–44. doi: 10.1016/j.vaccine.2006.11.011. PMID: 17250932. [PubMed: 17250932] [CrossRef]
987.: MacArthur AC, McBride ML, Spinelli JJ, et al. Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study. Am J Epidemiol. 2008 Mar 1;167(5):598–606. doi: 10.1093/aje/kwm339. PMID: 18079130. [PubMed: 18079130] [CrossRef]
988.: Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine. 2010 Jan 28;362(4):289–98. PMID: 20107214. [PubMed: 20107214]
989.: Madhi SA, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS. 2013 Jan 28;27(3):369–79. doi: 10.1097/QAD.0b013e32835ab5b2. PMID: 23032417. [PubMed: 23032417] [CrossRef]
990.: Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clinical Infectious Diseases. 2011 Jan 1;52(1):128–37. PMID: 21148531. [PubMed: 21148531]
991.: Mallory RM, Malkin E, Ambrose CS, et al. Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials. PLoS ONE [Electronic Resource]. 2010;5(10):e13755. PMID: 21060780. [PMC free article: PMC2966412] [PubMed: 21060780]
992.: Matheson MC, Haydn Walters E, Burgess JA, et al. Childhood immunization and atopic disease into middle-age--a prospective cohort study. Pediatric Allergy & Immunology. 2010 Mar;21(2 Pt 1):301–6. PMID: 20003161. [PubMed: 20003161]
993.: Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010 Jun 7;28(25):4204–9. PMID: 20416263. [PubMed: 20416263]
994.: Mommers M, Weishoff-Houben M, Swaen GM, et al. Infant immunization and the occurrence of atopic disease in Dutch and German children: a nested case-control study. Pediatr Pulmonol. 2004 Oct;38(4):329–34. doi: 10.1002/ppul.20089. PMID: 15334511. [PubMed: 15334511] [CrossRef]
995.: Moreira Jr ED, Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Human Vaccines. 2011 July;7(7):768–75. PMID: 2011412543 MEDLINE PMID 21712645 (http://www.ncbi.nlm.nih.gov/pubmed/21712645). [PMC free article: PMC3219080] [PubMed: 21712645]
996.: Morgan TM, Schlegel C, Edwards KM, et al. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics. 2011 May;127(5):e1147–e53. PMID: 2011239006 MEDLINE PMID 21482610 (http://www.ncbi.nlm.nih.gov/pubmed/21482610). [PMC free article: PMC3387867] [PubMed: 21482610]
997.: Mullooly JP, Schuler R, Barrett M, et al. Vaccines, antibiotics, and atopy. Pharmacoepidemiology and Drug Safety. 2007 March;16(3):275–88. PMID: 2007140424 MEDLINE PMID 16794993 (http://www.ncbi.nlm.nih.gov/pubmed/16794993). [PubMed: 16794993]
998.: Mullooly JP, Schuler R, Mesa J, et al. Wheezing lower respiratory disease and vaccination of premature infants. Vaccine. 2011 Oct 13;29(44):7611–7. PMID: 21875634. [PubMed: 21875634]
999.: Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults >=60 years old. Human Vaccines. 2011 Nov;7(11):1130–6. PMID: 22048110. [PMC free article: PMC3323493] [PubMed: 22048110]
1000.: Nakajima K, Dharmage SC, Carlin JB, et al. Is childhood immunisation associated with atopic disease from age 7 to 32 years? Thorax. 2007 Mar;62(3):270–5. PMID: 17090571. [PMC free article: PMC2117158] [PubMed: 17090571]
1001.: Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human Vaccines. 2009 Jun;5(6):414–9. PMID: 19276664. [PubMed: 19276664]
1002.: Ngan HYS, Cheung ANY, Tam KF, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal. 2010 2010;16(3):171–9. PMID: 2010451858 MEDLINE PMID 20519752 (http://www.ncbi.nlm.nih.gov/pubmed/20519752). [PubMed: 20519752]
1003.: Nordin JD, Kharbanda EO, Benitez GV, et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstetrics & Gynecology. 2013 Mar;121(3):519–25. doi: 10.1097/AOG.0b013e3182831b83. PMID: 23635613. [PubMed: 23635613] [CrossRef]
1004.: O’Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012 Feb;129(2):248–55. PMID: 22232308. [PubMed: 22232308]
1005.: Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal. 2012 May;31(5):487–93. PMID: 22228231. [PubMed: 22228231]
1006.: Omer SB, Goodman D, Steinhoff MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med. 2011 May;8(5):e1000441. doi: 10.1371/journal.pmed.1000441. PMID: 21655318. [PMC free article: PMC3104979] [PubMed: 21655318] [CrossRef]
1007.: Pagaoa MA, Okcu MF, Bondy ML, et al. Associations between vaccination and childhood cancers in Texas regions. Journal of Pediatrics. 2011 June;158(6):996–1002. PMID: 2011270649 MEDLINE PMID 21227448 (http://www.ncbi.nlm.nih.gov/pubmed/21227448). [PMC free article: PMC6448142] [PubMed: 21227448]
1008.: Pahud BA, Rowhani-Rahbar A, Glaser C, et al. Lack of association between childhood immunizations and encephalitis in California, 1998–2008. Vaccine. 2012 Jan 5;30(2):247–53. PMID: 22080172. [PubMed: 22080172]
1009.: Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. New England Journal of Medicine. 2011 Jun 16;364(24):2283–92. PMID: 21675888. [PubMed: 21675888]
1010.: Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. Vaccine. 2012 22;30(30):4552–7. PMID: 2012331314. [PubMed: 22497874]
1011.: Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, A live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases. 2005 Sep;192:S6–S16. PMID: WOS:000231113500002. [PubMed: 16088807]
1012.: Ray P, Black S, Shinefield H, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011 Sep;29(38):6592–7. PMID: WOS:000295148800025. [PubMed: 21763385]
1013.: Richards JL, Hansen C, Bredfeldt C, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clinical Infectious Diseases. 2013 May;56(9):1216–22. doi: 10.1093/cid/cit045. PMID: 23378281. [PMC free article: PMC4357807] [PubMed: 23378281] [CrossRef]
1014.: Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Human Vaccines and Immunotherapeutics. 2012 March;8(3):381–8. PMID: 2012244555. [PubMed: 22327492]
1015.: Rowhani-Rahbar A, Klein NP, Lewis N, et al. Immunization and bell’s palsy in children: A case-centered analysis. American Journal of Epidemiology. 2012 1;175(9):878–85. PMID: 2012258839. [PubMed: 22411861]
1016.: Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine. 2006 Jan 5;354(1):11–22. PMID: 16394298. [PubMed: 16394298]
1017.: Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. New England Journal of Medicine. 1991 Jun 20;324(25):1767–72. PMID: 1903846. [PubMed: 1903846]
1018.: Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clinical Infectious Diseases. 2012 Apr;54(7):922–8. PMID: 22291101. [PMC free article: PMC4542655] [PubMed: 22291101]
1019.: Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years. Journal of Adolescent Health. 2012 Feb;50(2):187–94. doi: 10.1016/j.jadohealth.2011.11.004. PMID: 22265115. [PubMed: 22265115] [CrossRef]
1020.: Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012 Feb 8;307(6):598–604. PMID: 22318281. [PubMed: 22318281]
1021.: Siberry GK, Williams PL, Lujan-Zilbermann J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatric Infectious Disease Journal. 2010 May;29(5):391–6. PMID: 20431379. [PMC free article: PMC2868314] [PubMed: 20431379]
1022.: Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine. 2010 May 4;152(9):545–54. PMID: 20439572. [PubMed: 20439572]
1023.: Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ Canadian Medical Association Journal. 2010 Oct 19;182(15):1617–23. PMID: 20855479. [PMC free article: PMC2952008] [PubMed: 20855479]
1024.: Sow PS, Watson-Jones D, Kiviat N, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-Seronegative African girls and young women. Journal of Infectious Diseases. 2013 Jun 1;207(11):1753–63. doi: 10.1093/infdis/jis619. PMID: 23242542. [PMC free article: PMC3636781] [PubMed: 23242542] [CrossRef]
1025.: Steele AD, Reynders J, Scholtz F, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases. 2010 Sep 1;202 Suppl:S93–100. PMID: 20684724. [PubMed: 20684724]
1026.: Stowe J, Andrews N, Bryan P, et al. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study. Vaccine. 2011 Nov;29(51):9467–72. PMID: WOS:000298529000009. [PubMed: 22019757]
1027.: Sun YL, Christensen J, Hviid A, et al. Risk of Febrile Seizures and Epilepsy After Vaccination With Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b. Jama-Journal of the American Medical Association. 2012 Feb;307(8):823–31. PMID: WOS:000300551300025. [PubMed: 22357833]
1028.: Talaat KR, Greenberg ME, Lai MH, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. Journal of Infectious Diseases. 2010 1;202(9):1327–37. PMID: 2010579595 MEDLINE PMID 20874515 (http://www.ncbi.nlm.nih.gov/pubmed/20874515). [PubMed: 20874515]
1029.: Tanner K, Roy N, Merrill RM, et al. Case-control study of risk factors for spasmodic dysphonia: A comparison with other voice disorders. Laryngoscope. 2012 May;122(5):1082–92. PMID: 22253036. [PubMed: 22253036]
1030.: Thomson JA, Widjaja C, Darmaputra AAP, et al. Early childhood infections and immunisation and the development of allergic disease in particular asthma in a high-risk cohort: A prospective study of allergy-prone children from birth to six years. Pediatric Allergy & Immunology. 2010 Nov;21(7):1076–85. doi: 10.1111/j.1399-3038.2010.01018.x. PMID: 20337970. [PubMed: 20337970] [CrossRef]
1031.: Ting SCH, Crooks SW, South G. The effect of influenza vaccination on the incidence of chronic obstructive pulmonary disease exacerbations in the immediate postvaccination period. Journal of Epidemiology & Community Health. 2011 Feb;65(2):157–9. PMID: 19996358. [PubMed: 19996358]
1032.: Tokars JI, Lewis P, DeStefano F, et al. The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009–2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiology & Drug Safety. 2012 May;21(5):546–52. doi: 10.1002/pds.3220. PMID: 22407672. [PubMed: 22407672] [CrossRef]
1033.: Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok[REGISTERED]) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13;29(44):7733–9. PMID: 21835220. [PubMed: 21835220]
1034.: Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine. 2012 Mar 2;30(11):2024–31. PMID: 22361304. [PubMed: 22361304]
1035.: Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. Journal of Internal Medicine. 2012 May;271(5):510–20. doi: 10.1111/j.1365-2796.2011.02474.x. PMID: 22026504. [PubMed: 22026504] [CrossRef]
1036.: Tseng HF, Slezak JM, Quinn VP, et al. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA. 2010 May 5;303(17):1699–706. PMID: 20442385. [PubMed: 20442385]
1037.: Uno Y, Uchiyama T, Kurosawa M, et al. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia. Vaccine. 2012 Jun 13;30(28):4292–8. PMID: 22521285. [PubMed: 22521285]
1038.: Velazquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatric Infectious Disease Journal. 2012 Jul;31(7):736–44. PMID: 22695189. [PubMed: 22695189]
1039.: Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiology & Drug Safety. 2012 Dec;21(12):1350–8. doi: 10.1002/pds.3321. PMID: 22807266. [PubMed: 22807266] [CrossRef]
1040.: Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >=60 years of age. Vaccine. 2012 Jan 20;30(5):904–10. PMID: 22154769. [PubMed: 22154769]
1041.: Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006 May 29;24(22):4821–9. PMID: 16621194. [PubMed: 16621194]
1042.: Vesikari T, Karvonen A, Bouckenooghe A, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine. 2011 2011;29(11):2079–84. PMID: 2011104676 MEDLINE PMID 21238572 (http://www.ncbi.nlm.nih.gov/pubmed/21238572). [PubMed: 21238572]
1043.: Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004 Jul 29;22(21–22):2836–42. PMID: 15246619. [PubMed: 15246619]
1044.: Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal. 2004 Oct;23(10):937–43. PMID: 15602194. [PubMed: 15602194]
1045.: Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine. 2006 Jan 5;354(1):23–33. PMID: 16394299. [PubMed: 16394299]
1046.: Wang IK, Lin CL, Lin PC, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS ONE [Electronic Resource]. 2013;8(3):e58317. doi: 10.1371/journal.pone.0058317. PMID: 23516462. [PMC free article: PMC3596393] [PubMed: 23516462] [CrossRef]
1047.: Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Human Vaccines. 2010 Apr;6(4):318–21. PMID: 20372089. [PubMed: 20372089]
1048.: Whitehouse AJO, Maybery M, Wray JA, et al. No association between early gastrointestinal problems and autistic-like traits in the general population. Developmental Medicine & Child Neurology. 2011 May;53(5):457–62. PMID: 21418197. [PubMed: 21418197]
1049.: Wilson K, Hawken S, Kwong JC, et al. Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis. PLoS ONE [Electronic Resource]. 2011;6(12):e27897. PMID: 22174753. [PMC free article: PMC3236196] [PubMed: 22174753]
1050.: Wise ME, Viray M, Sejvar JJ, et al. Guillain-Barre Syndrome During the 2009–2010 H1N1 Influenza Vaccination Campaign: Population-based Surveillance Among 45 Million Americans. American Journal of Epidemiology. 2012 Jun 1;175(11):1110–9. PMID: 22582209. [PMC free article: PMC3888111] [PubMed: 22582209]
1051.: Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. Pharmacoepidemiology and Drug Safety. 2012. [PubMed: 22674821]
1052.: Yih WK, Lee GM, Lieu TA, et al. Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009–2010. American Journal of Epidemiology. 2012 Jun 1;175(11):1120–8. PMID: 22582207. [PubMed: 22582207]
1053.: Yu O, Bohlke K, Hanson CA, et al. Hepatitis B vaccine and risk of autoimmune thyroid disease: A Vaccine Safety Datalink study. Pharmacoepidemiology and Drug Safety. 2007 July;16(7):736–45. PMID: 2007375340 MEDLINE PMID 17192842 (http://www.ncbi.nlm.nih.gov/pubmed/17192842). [PubMed: 17192842]
1054.: Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009 25;27(9):1333–9. PMID: 2009067202 MEDLINE PMID 19162114 (http://www.ncbi.nlm.nih.gov/pubmed/19162114). [PubMed: 19162114]
1055.: Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012 Jul 4;308(1):43–9. PMID: 22760290. [PMC free article: PMC3683869] [PubMed: 22760290]
1056.: Christie CDC, Duncan ND, Thame KA, et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics. 2010 Dec;126(6):e1499–506. PMID: 21115586. [PubMed: 21115586]
1057.: EU/EEA EO. Study to evaluate the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001485-26-Outside-EU/EEA. 2015. PMID: CN-01820038.
1058.: EU/EEA EO. A phase III study to assess the efficacy, immunogenicity and safety of GSK Biologicals’ human rotavirus (HRV) vaccine given concomitantly with routine expanded program on immunisation (EPI) vaccinations including oral poliovirus vaccine (OPV) in healthy infants across 6 countries in Latin America. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001540-10-Outside-EU/EEA. 2015. PMID: CN-01839468.
1059.: Euctr Outside EU/EEA. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’ rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001484-39-Outside-EU/EEA. 2015. PMID: CN-01855362.
1060.: Euctr Outside EU/EEA. Study to evaluate the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. 2015. .
1061.: Euctr Outside EU/EEA. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001545-81-Outside-EU/EEA. 2015. PMID: CN-01871096.
1062.: Euctr Outside EU/EEA. Study to evaluate the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001541-92-Outside-EU/EEA. 2015. PMID: CN-01874019.
1063.: GlaxoSmithKline. A Study to Test 2 Doses of GSK Biologicals’ Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants. https://ClinicalTrials.gov/show/NCT00197210; 2003.
1064.: GlaxoSmithKline. Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants. 2003.
1065.: GlaxoSmithKline. Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210). https://ClinicalTrials.gov/show/NCT00329745; 2007.
1066.: GlaxoSmithKline Biologicals. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants 2015. PMID: 2015-001541-92
1067.: GlaxoSmithKline Biologicals. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001545-81-Outside-EU/EEA. 2015. PMID: CN-01871096.
1068.: Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal. 2007 Dec;26(12):1099–104. PMID: 18043445. [PubMed: 18043445]
1069.: Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal. 2012 Feb;31(2):184–8. PMID: 22252206. [PubMed: 22252206]
1070.: Guillermo M, al. e. RIX4414 (Rotarix™) has demonstrated efficacy during the first 2 years of life in infants from 11 Latin American countries. 10th International Rotavirus Symposium (IRS); 2012 September 19–21, 2012; Bangkok, Thailand.
1071.: Hemming-Harlo M, Lahdeaho M-L, Maki M, et al. Rotavirus Vaccination Does Not Increase Type 1 Diabetes and May Decrease Celiac Disease in Children and Adolescents. The Pediatric infectious disease journal. 2019;38(5):539–41. doi: 10.1097/INF.0000000000002281. [PubMed: 30986791] [CrossRef]
1072.: Laserson KF, Nyakundi D, Feikin DR, et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq([REGISTERED]), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine. 2012 Apr 27;30 Suppl 1:A61–70. PMID: 22520138. [PubMed: 22520138]
1073.: Lau YL, Nelson EA, Poon KH, et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine. 2013 Apr 26;31(18):2253–9. doi: 10.1016/j.vaccine.2013.03.001. PMID: 23499605. [PubMed: 23499605] [CrossRef]
1074.: Lee KJ, Carlin JB. Fractional polynomial adjustment for time-varying covariates in a self-controlled case series analysis. Statistics in medicine. 2014;33(1):105–16. doi: 10.1002/sim.5911. [PubMed: 23868284] [CrossRef]
1075.: Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271–84. doi: 10.1056/NEJMoa051016. PMID: 15930418. [PubMed: 15930418] [CrossRef]
1076.: Phua KB, al. e. Human rotavirus vaccine RIX4414 (Rotarix™) is highly efficacious in infants from Asia during the first two years of life. 13th International Congress on Infectious Diseases (ICID); 2008 June 9–13, 2008; Kuala Lumpur, Malaysia.
1077.: Phua KB, al. e. Human rotavirus vaccine RIX4414 (Rotarix™) is highly efficacious in Asian infants during the first three years of life. 13th Asian Pacific Congress of Pediatrics (APCP); 2009 October 14–18, 2009; Shanghai, China.
1078.: Phua KB, al. e. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2009 June 9–13, 2009; Brussels, Belgium.
1079.: Phua KB, al. e. Efficacy of rotavirus vaccine RIX4414 during the first 3 years of life: a randomised, double-blind, placebo-controlled study in infants from Hong Kong, Singapore and Taiwan. 10th International Rotavirus Symposium (IRS); 2012 September 19–21, 2012; Bangkok, Thailand.
1080.: Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009 Oct 9;27(43):5936–41. PMID: 19679216. [PubMed: 19679216]
1081.: Popmihajlov Z, Pang L, Brown E, et al. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL). Human Vaccines and Immunotherapeutics. 2018;14(12):2916–20. doi: 10.1080/21645515.2018.1502517. [PMC free article: PMC6343633] [PubMed: 30024827] [CrossRef]
1082.: Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal. 2007 Mar;26(3):221–7. PMID: 17484218. [PubMed: 17484218]
1083.: Sow SO, Tapia M, Haidara FC, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine. 2012 Apr 27;30 Suppl 1:A71–8. PMID: 22520140. [PubMed: 22520140]
1084.: Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal. 2011 June;30(6):e103–e8. PMID: 2011306258 MEDLINE PMID 21378594 (http://www.ncbi.nlm.nih.gov/pubmed/21378594). [PubMed: 21378594]
1085.: Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):615–23. PMID: 20692031. [PubMed: 20692031]
1086.: Zaman K, Yunus M, El Arifeen S, et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine. 2012 Apr 27;30 Suppl 1:A94–100. PMID: 22520143. [PubMed: 22520143]
1087.: Dynavax. Ongoing Studies Listing. https://www.dynavax.com/ongoing-studies/listing/. Accessed on September 30, 2020.
1088.: Dynavax. Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed. December 3, 2019. https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-heplisav-b-post-marketing-requirement-interim. Accessed on April 1, 2021.
1089.: In: Stratton K, Almario D, McCormick MC, eds. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington (DC); 2002. [PubMed: 25057609]
1090.: Centers for Disease Control and Prevention. Febrile Seizures and Childhood Vaccines. 2020. https://www.cdc.gov/vaccinesafety/concerns/febrile-seizures.html. Accessed on April 1, 2021.
1091.: U.S Food and Drug Administration. Statistical Review (STN 125508/0)-Gardasil 9. 2013.
1092.: Health Resources and Services Administration. Vaccine Injury Table. https://www.hrsa.gov/sites/default/files/vaccinecompensation/vaccineinjurytable.pdf.
1093.: Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine. 2019 Oct 16;37(44):6673–81. doi: 10.1016/j.vaccine.2019.09.035. PMID: 31540812. [PMC free article: PMC6906603] [PubMed: 31540812] [CrossRef]
1094.: Hartung DM, Zarin DA, Guise JM, et al. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014 Apr 1;160(7):477–83. doi: 10.7326/M13-0480. PMID: 24687070. [PMC free article: PMC4617780] [PubMed: 24687070] [CrossRef]
1095.: Tang E, Ravaud P, Riveros C, et al. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med. 2015 Aug 14;13:189. doi: 10.1186/s12916-015-0430-4. PMID: 26269118. [PMC free article: PMC4535304] [PubMed: 26269118] [CrossRef]
1096.: HealthIT.gov. Interoperability Proving Ground. https://www.healthit.gov/techlab/ipg/node/4/submission/2811. Accessed on December 22, 2020 2020.
1097.: Jackson S, Brashers SAJDE, Jackson SA, et al. Random Factors in ANOVA: SAGE Publications; 1994.
1098.: Malec DJ. Superpopulation. In: Lavrakas PJ, ed Encyclopedia of Survey Research Methods Thousand Oaks, CA: Sage Publications; 2011:856.
1099.: Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane; 2020.
1100.: Mooney CZ, Sage Publications i. Monte Carlo Simulation: SAGE Publications; 1997.
1101.: Atkins D, Chang S, Gartlehner G, et al. Assessing the Applicability of Studies When Comparing Medical Interventions. Agency for Healthcare Research and Quality; January 2011. Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication No. 11-EHC019-EF. January 2011. https://effectivehealthcare.ahrq.gov/products/methods-guidance-applicability/methods

Bookshelf ID: NBK572032

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Gidengil C, Goetz MB, Maglione M, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. (Comparative Effectiveness Review, No. 244.) References.
PDF version of this title (9.4M)

Other titles in this collection

AHRQ Comparative Effectiveness Reviews

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

References - Safety of Vaccines Used for Routine Immunization in the United Stat...
References - Safety of Vaccines Used for Routine Immunization in the United States: An Update
Technical Expert Panel - Interventions for the Prevention of Posttraumatic Stres...
Technical Expert Panel - Interventions for the Prevention of Posttraumatic Stress Disorder (PTSD) in Adults After Exposure to Psychological Trauma
Excluded Studies - Assessment and Management of Chronic Cough
Excluded Studies - Assessment and Management of Chronic Cough
Search Strategies - Improving Antibiotic Prescribing for Uncomplicated Acute Res...
Search Strategies - Improving Antibiotic Prescribing for Uncomplicated Acute Respiratory Tract Infections
Excluded Studies List - Cervical Ripening in the Outpatient Setting
Excluded Studies List - Cervical Ripening in the Outpatient Setting

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Safety of Vaccines Used for Routine Immunization in the United States: An Update [Internet].

References

Views

Other titles in this collection

Related information

Recent Activity